Quality of Life and Associated Factors Among Adult Cancer Patients Receiving Chemotherapy at Tigray, Ethiopia 2024/25: A Mixed Study

Quality of Life and Associated Factors Among Adult Cancer Patients Receiving Chemotherapy at Tigray, Ethiopia 2024/25: A Mixed Study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Quality of Life and Associated Factors Among Adult Cancer Patients Receiving Chemotherapy at Tigray, Ethiopia 2024/25: A Mixed Study Haileslasie Hailemariam, Solomon Gebremedhin, Abrha Hailay, Genet Tsehaye, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8010679/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Cancer is the main cause of morbidity and mortality in every part of the world, regardless of human development. Globally, there were 10.0 million recorded deaths and 19.3 million new cases of cancer in 2020. Objectives This study aimed to assess quality of life and associated factors among cancer patients receiving chemotherapy at the comprehensive specialized hospitals of Tigray, Ethiopia, 2024/25. Method and Materials: A hospital-based mixed study design was conducted from December-January 2024 GC for quantitative and from 1 April to 21 April for qualitative data on patients (492) at comprehensive specialized hospitals Tigray region, Ethiopia. A systematic sampling method was used to select study participants for the quantitative part, and a purposive sample method was used for the qualitative. For the Quantitative data, EpiData version 4.6 was used for entry, and Statistical Package for the Social Sciences version 27 was used for analysis.Bivariate and multivariable logistic regression analysis was done, and variables having a p-value of < 0.25 were considered candidates for multivariable logistic regression. P-value of < 0.05 was used as the criterion for statistical significance, and the qualitative data were analyzed by thematic analysis using the software Archive of Technology Life world and Language Text Interpretation (ATLAS.TI) version 7.5.8 software. Results From 478 patients included in this study, 74.9%,95% CI (70.8–79.9%) of cancer patients on chemotherapy had poor quality of life, College and above [AOR = 0.36,95%CI (0.16–0.83)] underweight(AOR = 3, 95% CI (1.28–7.47),anxiety[AOR = 2.7, 95% CI (1.29–5.7)],five and above chemotherapy cycle were 57% [AOR = 0.43,95%CI(0.19–0.95)] and stage 4 cancer (AOR = 2.5, 95% CI (1.06,-6.38) were significantly associated with quality of life. Conclusion and recommendation: Three-fourths of the patients with cancer had a poor quality of life. Healthcare providers should also focus on addressing the side effects of therapy and providing palliative care to improve quality of life. Cancer Chemotherapy quality of life Tigray Ethiopia Figures Figure 1 Figure 2 Figure 3 Background Cancer is a broad category of disorders that can originate in virtually any organ or tissue in the body when cells multiply and spread abnormally, uncontrollably to other parts of the body[ 1 ].Abnormal alterations called hyperplasia and dysplasia may lead normal cells to grow into cancerous[ 2 ]. Cancer and its treatment are known to reduce the quality of life. It has been proven that a decreased quality of life has negative effects not only on physiological but also on the psychological functioning of the individual[ 3 ].Chemotherapy is a type of systemic chemical therapy that is used to kill rapidly developing cells in the body [ 7 ]. It is one of the most popular and widely used cancer treatments. Unlike other therapies, chemotherapy exhibits systemic side effects that can negatively impact a person’s Quality of life [ 8 ]. Chemotherapy is a concentrated and repeated treatment regimen that has many adverse reactions, including hair loss, nausea, vomiting, and diarrhea, which can eventually affect the Quality of life of cancer patients [ 6 ]. Quality of life (QoL) is an individual’s perception of their position in life in the context of the culture and value systems in which they live and to their goals, expectations, standards and concerns [ 9 ]. Health related quality of life Is defined as an individual’s satisfaction with their physical, psychological, social relationships, environment, and spiritual aspects of life, and it is one of the significant variables in evaluating cancer patients' health and well-being In chronic illnesses, it is typically used to measure and often significantly impairs patients [ 10 ]. Cancer is the main cause of morbidity and mortality in every part of the world, regardless of human development [ 11 ]. Cancer is one of the most common chronic diseases in both industrialized and developing countries, and it has an impact on every part of the patient’s life [ 12 ].Globally, there were 10.0 million recorded deaths and 19.3 million new cases of cancer in 2020[ 13 ]. .it is the second leading global cause of death, with 70% of deaths in low- and middle-income countries (LMICs) [ 14 ].It is estimated that by 2040, there will be 27.5 million new instances of cancer and 16.3 million cancer-related deaths.[ 12 ]. It is an escalating public health issue in low-income nations, particularly in Ethiopia. Based on a systematic review, it was estimated that there were 53,560 new cancer cases and 39,480 cancer-related deaths in this country in 2019[ 15 ]. Cancer affects QOL through physical symptoms, emotional distress, and chemotherapy, treatment side effects, exacerbating these challenges through physical and psychological side effects[ 4 ]. Despite the critical importance of QoL in cancer care, there is limited research exploring the specific factors influencing QoL among adult cancer patients receiving chemotherapy in this region. This study aimed to address such a gap. Accordingly, I investigated QoL and associated factors among cancer patients receiving chemotherapy at the comprehensive specialized hospitals of Tigray. Additionally, using a mixed method, this study will also explore perceived barriers affecting quality of life among cancer patients receiving chemotherapy that were not studied in previously conducted studies. METHODS AND MATERIALS Study area Tigray is one of the twelve regions of Ethiopia. The state's capital and largest town is Mekelle. Tigray is framed by Eritrea to the north, the Amhara Region to the south and southwest, the Afar Region to the east, and Sudan to the west.In the Tigray region, there were 2 CSHs, 14 general hospitals, 24 primary hospitals, 230 health centers, and 741 health posts[ 5 ]. from those hospitals, only the two (Aku CSH and Ayder CSH) provideoncologyservices for the cancer patients.Aku CSH is located in Aksum town, and the distance from the capital city of Ethiopia is 1003 km. It hasprovidededucational and medical services since 2014 GC and provides services for cancer patients since November 2023.ACSH is found in Mekele town, which is the capital city of Tigray region, and the distance from AddisAbaba is 780 km. It hasprovidededucational and medical services since 2008[ 6 ]. Study period :The study was conductedfor the quantitative data from December-January 2024/25atthe comprehensive Specialized hospitals of Tigray, Ethiopia. For the qualitative part study was conducted from 1 April to -21 April,2025, at the Aksum Comprehensive Specialized Hospital of Tigray, Ethiopia. Study design Hospital-basedcross-sectional studysupported by the qualitative (sequential explanatory) method. Population: Source populations: All adult cancer patients who received chemotherapy treatment at Tigray, Ethiopia, 2024/2025. Study population : All sampled adult cancer patients receivingchemotherapy treatmentat oncology units during the data collection periodin Tigray, Ethiopia. Study unit: Individual patients who participated in the study at oncology units inTigray, Ethiopia. Eligibility Criteria Inclusion criteria All adult cancer patientswho had received at least tworounds of chemotherapy treatment Exclusion criteria Patients take less than two cycles of chemotherapy. patients newly diagnosed at the time of data collection. Sample size determination and Sampling technique Both the first and second objectives were utilized to calculate the sample size according to the single population proportion(sample size for the first objective) The sample size was determined using the single population proportion formula as follows: P = proportion of poor QoL of cancer patients Q = proportion of good QoL of cancer patients D = Margin of sampling error tolerated- 5% (0.05). α = Critical value at 95% confidence interval of certainty (1.96). (See Table 1 below). Table 1 Sample size calculation for quality of life and associated factors among adult cancer patients receiving chemotherapy at Tigray, Ethiopia, 2024/25 Proportion of poor QOL Calculated the final sample size by adding 5% References 52.7% 402 [ 7 ] 44.32% 398 [ 8 ] 31.7% 350 [ 9 ] Sample size determination for the second specific objective: To determine the required sample size for the second specific objectie (to identify factors affecting quality of life among cancer patients received chemotherapy treatment in CSH of tigray,Ethiopia, 2024/25).factors that have been taken into consideration and are significantly correlated with the outcome variables with a 95% confidence level, 80% power, and a 1:1 ratio. The Open Epi Info 7.2.6 StatCalc software application will determine the sample size.The double population proportion formula was used. (see Table 2 below). Table 2 Size determination for the second objective quality of life and associated factors among ca patients received chemotherapy in CSHs in Tigray, Ethiopia 2024/2025. Variables Power% CI % AOR % outcome of Unexposed Une Ratio of unexposed to exposed Sample size Add NR R 5% Final sample size Reference Underweight 80 95 0.45 49.7 1:1 230 12 242 [ 8 ] Anxiety 80 95[ 9 ] 0.32 52.7 1:1 120 6 132 [ 8 ] Depression 80 95 0.29 52.5 1:1 106 5 111 [ 8 ] Urban 80 95 1.74 55.3 1:1 468 24 492 [ 9 ] Civil servant 80 95 0,13 9.4 1:1 290 15 305 [ 9 ] Sample size computed for the associated factors by the double proportion using Epi Info v.7.2.5, and the maximum sample size was 492 [ 9 ].to increase the representativeness of the sample, the maximum sample size was 492determined using the second objective was chosen. . Sampling size determination and procedure for the qualitative part Purposive sampling was used to select hospitals and participants from all who participated in the quantitative part until data saturation was maintained. Sampling technique and procedure For the quantitative part The sample size was allocated to the study hospitals (AKUCSH and ACSH)proportionally based on the previous two months' patient load was taken from the patient registration book of each hospital. Systematic sampling was used by using the registration book (sampling frame) for ACSH, Kth interval = N/n = 460/354, approximately 1, and for AKUCSH, Kth interval = N/n = 180/138, approximately 1 so the participants were consecutively interviewed every day until the required sample size was obtained for two months. ( See Fig. 2 below ) For qualitative Data Purposive sampling with a maximum variation technique was used to select hospitals, and then, participants from all selected individuals who participated in the quantitative part. Data Collection Tool and Procedure For the quantitative part The data was collectedusing a validated interviewer-administered questionnaire and by reviewing the patient's chart. The validated Tigrigna from the structured questionnaire consisted of 30 items adapted from the Quality of Life Questionnaire (QLQ-30) version 3, which is currently the standard version.Cancer patients receiving chemotherapy were measured using a version of the European Organization for Research and Treatment of Cancer quality of life questionnaire core 30 (EORTC QLQ C-30). in addition to the socio-demographic, clinical,and chemotherapy-relatedcharacteristics adapted from different literature.questionnaire.There are nine scales and thirty items on the EORTC QLQ-C30. One of the most popular tools for assessing HRQOL in cancer patients is the EORTC QLQ-C30, which has been validated in multiple trials. includes both a single-item and multi-item scale: Physical Function (five items) Emotional Function (four items) Role Function (two items) Cognitive Function (two items), Social Function (two items) Global Health Status (two items), Three items: fatigue; two items: nausea/vomiting; and two items: pain. Six single items are used to quantify constipation, diarrhea, sleep difficulties, lack of appetite, dyspnea, and the disease's financial effect. The overall score is between 0 and 100. Higher scores indicate greater quality of life on functional assessments and global quality of life, but higher values indicate more severe symptoms on symptom-oriented scales. The raw scores were converted into scores ranging from 0 to 100. .There are various benefits to using these converted scores.Transformed scores may be difficult to interpret; however, there are several ways to ease the interpretation of QLQ-C30 results. It possible to report the raw scoresto the transformed scores.The following formula has been used to do a linear translation to 0-100 to obtain the score S[ 10 ]. Linear transformation- Apply the linear transformation to 0-100 to obtain the score S:[ 10 ] Range is the difference between the lowest and greatest values of RS that can exist. According to the QLQ-C30's design, every item on any scale falls within the same range of values. Since most items have scores between 1 and 4, the range of RS is equal to the range of the item values is 3.Therefore, in this study, after transformation of each domain is dichotomized into each scale and subscales into the > = 75 for the functional and global scale and the symptom scales < 25 ‘’Good QOL ” or for the functional and global scale = 25 “poor QOL” category “[ 11 , 12 ] The patient's anxiety and depression levels were evaluated using the Hospital Anxiety and Depression (HAD) Questionnaire. The questionnaire was created to assess mental health issues (including depression and anxiety) in general medical settings, and it is both valid and reliable. [41, 42]. The HAD consists of 14 items divided into two subscales (depression and anxiety), each with seven items. The items are evaluated on a four-point Likert scale, where 3 represents the least positive reaction and 0 represents the most pleasant response[ 13 ]. For the qualitative part Informationwas gathered to explore the perceived barriers affecting the quality of life of cancer patients receiving chemotherapy. Thesemi-structured interview guide was developed in English based on the literature review and study objectives; the semi-structured interview guide was developed in English, thenit was translated to Tigrigna by the principal investigator and an individual who has good ability in both languages. Data collection procedure For the quantitative part: Two MSc nurses were chosen for supervision, and four nurses with degrees were recruited from each hospital and assigned to each hospital. Data was collected through face-to-face interviews and reviewing of relevant records. Based on patients' willingness to participate in the study,the structured interview was coded for each participant.To collect the data,a total of 40 working days was required.Finally, face face-to-face interview questionnaire was distributed, and detailed clarification was provided on how to complete it, and specific clarification for any difficulty was provided accordingly. The collected data was checked for completeness, validity, and accuracy daily. For the qualitative part : The data was gathered through an in-depth, face-to-face interview. Once each subject had given their informed consent, the researcher used a semi-structured interview guide to conduct an in-depth interview. Using field notes and an audio tape recorder, the principal investigator conducted the interview. The Tigrigna language was used to conduct the interviews. Every interview was set up with the participants' permission and took place in a private space at the oncology head nurse's office. Time spent: 15 to 30 minutes each person. After conferring with the chief nurse and taking into account their medical profiles, the participants were chosen. RESULTS For Quantitative Data Out of the 492 participants initially targeted for the study, 478 patients undergoing chemotherapy took part, resulting in a response rate of 97.15%. The non-respondents were not participating due to various reasons, including a lack of time, transportation challenges. Socio-Demographic characteristics Among respondents, the majority,127(26.6%) were 50–59 age group, with 90(70.9%) had poor QOL.250(52.3%) were females, with72.8% having poor QOL. The median age and IQR were (53 and 19), 252(52.7%) lived in rural was, 75.4% had poor QOL, 194(40.6%) were unable to read and write, with 80.4 % having poor quality . (See Table 3 below). Table 3 Socio-Demographic of Adult Cancer Patients Under Chemotherapy Treatment at ACSH and AKCSH, Tigray, Ethiopia2024/25, n = 478 Variable Category Poor QOL (%) Good QOL (%) Total(N%) Age 18–40 78(72.9) 29(27.1) 107(22.4) 41–49 91(72.8) 34(27.2) 125(26.2) 50–59 90(70.9) 37(29.1) 127(26.6) >=60 99(83.2) 20(16.8) 119(24.9) Sex Male 176(77.2) 52(22.8) 228(47.7) Female 182(72.8) 68(27.2) 250(52.3) Ethnicity Tigray 324(75.2) 107(24.8) 431(90.2) Amhara 20(71.4) 8(28.6) 28(5.9) Afar 14(73.7) 5(26.3) 19(4) Religion Orthodox 282(77) 84(23) 366(76.5) Muslim 63(67.7) 30(32.3) 93(19.5) Others 13(68.4) 6(31.6) 19(4) Note:Others (Protestant, catholic) Marital status Single 30(73.2) 11(26.8) 41(8.6) Married 270(74.2) 94(25.8) 364(76.2) Divorced 14(77.8) 4(22.2) 18(3.8) Widowed 44(80) 11(20) 55(11.5) Occupation House wife 137(73.7) 49(26.3) 186(38.9) Private employ 35(70) 15(30) 50(10.3) Govt employ 56(83.6) 11(16.4) 67(14) Merchant 29(65.9) 15(34.1) 44(9.2) Farmer 75(77.3) 22(22.7) 97(20.3) Daily worker 9(75) 3(25) 12(2.5) Others 17(77.3) 5(22.7) 22(4.6) Educational status Un able to Read and write 156(80.4) 38(19.6) 194(40.6) Read and write 62(71,3) 25(28.7) 87(18.2) Primary school 65(73.9) 23(26.1) 87(18.2) Secondary school 20(66.7) 10(33.3) 30(6.3) College and above 55(69.6) 24(30.4) 79(16.5) Residence Rural 190(75.4) 62(24.6) 252(52.7) Urban 168(74.3) 58(25.7) 226(47.3) Cost covered My self 279(74) 98(26) 377(78.9) Family 50(80.6) 12(19.4) 62(13) Free 29(74) 10(26) 39(8.2) 5.1.2Clinical and chemotherapy factors Among the cancer patients receiving chemotherapy, breast cancer was the most prevalent, accounting for 170 (35.56%), with 70.6% having poor QOL,166 (34.7%) were at stage 4 with 86.7% having poor QOL. 195 (40.8%)were undergoing their fifth cycle of treatment or above with68.4% having poor QOL.257 patient53.8%) ha In terms of mental health, 223 patients (46.3%) did not experience anxiety, and 200 patients (41.8%) were free from depression. Furthermore, 333 patients (69.7%) had no co morbidity (See Table 4 below) Table 4 Clinical and chemotherapy-related factors of Adult Cancer Patients Under Chemotherapy Treatment at ACSH and AKuSH, Tigray, Ethiopia 2024/25, n = 478 Variable Category Poor QOL (%) Good QOL (%) Total(N%) Cancer type Breast 120(70.6) 50(29.4) 170(35.56) GI 70(70) 30(30) 100(20.9) Cervical 60(70.6) 25(29.4) 85(17.8) Lung 27(64.3) 13(35.7) 42(8.8) NHL 20(71.4) 8(28.6) 28(5.9) Liver 16(72.7) 6(27.3) 22(4.6) Other 22(70.9) 19(29.1) 31(6,5) Stage of cancer Stage 1 27(61.4) 17(38;6) 44(9.3) Stage 2 74(60.7) 48(39.3) 122(25.5) Stage 3 113(77.4) 33(22.6) 146(30.5) Stage 4 144(86.7) 22(13,3) 166(34.7) Cycle of chemotherapy 2nd cycle 73(83.5) 11(16.5) 84(17.6) 3rd cycle 101(80.7) 21(19.3) 121(25.5) 4th cycle 59(74) 18(26) 77 (16.1) 5th and above cycle 127(68.4) 70(31.6) 195(40.8) Chemotherapy line First line 239(78.9) 64(21.1) 303(63.4) Second line 91(65) 49(35) 140(29.3) Third line 28(80) 7(20) 35(7.3) Time since diagnosis Less than one year 198(77) 59(23) 257(53.8) 1–5 years 138(71.1) 56(28.9) 194(40.6) Above 5 years 22(81.5) 5(18.5) 27(5.6) BMI Underweight 198(84.6) 36(15.4) 234(49) Normal weight 140(67.3) 68(32.7) 208(43.5) Overweight 20(55.6) 16(44.4) 36(7.5) Duration of chemotherapy Less than 6 months 195(81.3) 45(18.7) 240(50.2) 6–12 months 120(67.8) 57(32.2) 177(37) Above 12 months 43(70.5) 18(29.5) 61(12.8) Anxiety No case 140(62.8) 83(37.8) 223(46.3) Border line 55(78.6) 15(21.4) 70(14.6) Anxiety 163(88.1) 22(11.9) 185(38.7) Depression No case 128(64) 72(36) 200(41.8) Border line 73(73) 27(27) 100(20.9) Depression 157(88.2) 21(11.8) 178(37.2) Comorbidity yes 126(90.7) 19(9,3) 145(30.3.) No 232(69.7) 101(30.3) 333(69.7) Side effect of chemotherapy Yes 214(78.7) 58(21.3) 272(56.9) No 144(69.9) 62(30.1) 206(43.1) 5.1.3Assessing the association between QOL and its domains Emotional functioning 254(83.8%)had poor QOL, and social functioning 215(81.1%) had poor QOL. fatigue 225(86.9%) had poor QOL and Financial difficulty 252(81.6%)had poor QOL. (See Table 5 below). Table 5 Functional and Symptom Scale Score among Adult Cancer Patients Undertaking Chemotherapy Treatment at ACSH and AKUCSH, Tigray, Ethiopia 2024/25, n = 478 Scales PoorQOL (%) GoodQOL (%) Total (N%) Functional scale Physical functioning Poor 243(79.9) 61(20.1) 304(63.6) Good 115(66) 59(34) 174(36.4) Emotional function Poor 254(83.8) 49(16.2) 303(63.4) Good 104(59.4) 71(40.6) 175(36.6) role function Poor 206(81.) 48(19) 254(53.1) Good 152(67.9) 72(30.1) 224(46.9) Social function Poor 215(81.1) 50(18.9) 265(55.4) Good 143(67.1) 70(32.9) 213(44.6) Cognitive function Poor 228(80) 57(20) 285(59.6) Good 130(67.4) 63(32.6) 193(40.4) Symptom scale Pain Poor 249(78) 70(22) 319(66.7) Good 109(68.5) 50(31.5) 159(33.3) Constipation Poor 223(78.5) 61(21.5) 284(59.4) Good 135(69.5) 58(31.5) 194(40.6) Diarrhea Poor 178(75.5) 58(24.5) 236(49.4) Good 180(74.4) 62(25.6) 242(50.6) Nausea and vomiting Poor 98(73.1) 36(26.9) 134(28) Good 260(75.6) 84(24.4) 344(72) Insomnia Poor 172(77) 51(23) 223(46.7) Good 186(72.9) 69(27.1) 255(53.3) Dyspnea Poor 202(77.7) 58(22.3) 260(54.4) Good 156(71.6) 62(28.4) 218(45.6) Appetite loss Poor 224(81.5) 51(18.5) 275(57.5) Good 134(66) 69(34) 203(42.5) Fatigue Poor 225(86.9) 34(13.1) 259(54.2) Good 133(60.7) 86(39.3) 219(45.8) Financial difficulty Poor 252(81.6) 57(18.4) 309(64.6) Good 106(62.7) 63(37.3) 169(35.4) Global scale Poor 240(80) 60(20) 300(62.8) Good 118(66.3) 60(33.7) 178(37.2) 5.1.4 QOL of cancer patients on chemotherapy The quality of life was calculated after transforming the domain (functional scale, symptoms scale, and global health) to linear, and the sum of all domains was divided by three and finally categorized as good QOL for greater than or equal to 75 and poor QOL for less than 75. Three-fourths of the patients receiving chemotherapy, 74.9% with 95% CI (70.99–78.8) had poor QOL. (See Fig. 3 below). 5.1.5 Factors associated with quality of life From the total variables, in bivariable analysis ten variables were significantly associated with QOL at P value less than 0.25 (Table 7). The bivariable logistic regression analysis shows, age, educational status, occupational status, BMI, cycles of chemotherapy, stage of cancer, co morbidity, side effects of chemotherapy, anxiety, and depression were associated with QOL at p < .0.25 and entered for multivariable analysis. In the multivariable analysis. After adjusting for potential confounders in the multivariable binary logistic regression analysis, only five variables showed an overall significant effect on quality of life at the 5% level of significance. College and above were 64%[AOR = 0.36,95%CI (0.16–0.83)]less likely to have poor QOL as compared with those who were unable to read and write. The odds of being under weight were about 3 times [(AOR = 3, 95% CI (1.28–7.47)] more likely to have poor quality of life than those who were overweight. The odds of having anxiety had about 2.7 times [AOR = 2.7, 95% CI (1.29–5.7)]more likely to have poor quality of life than those who had no anxiety. Cancer patients with five and above chemotherapy cycles were 57%[AOR = 0.43,95%CI(0.19–0.95)] less likely to have poor QOL as compared with those who had a second chemotherapy cycle. The odds of having stage four cancer patients were about 2.5 times [AOR = 2.5, 95% CI (1.06,-6.38)] more likely to have poor quality of life than those who had stage one cancer patients was statically significant at p value < 0.05. The enter method regression was used. (Table 6 below). Table 6 Association between associated factors of quality of life among cancer patients receiving chemotherapy at ACSH and AKUCSH Tigray, Ethiopia 2024/2025. Variables Poor QOL% Good QOL% COR AOR P-value Age 18–40 78(72.9) 29(27.1) 1 1 41–49 91(72.8) 34(27.20 0.99(0.55–1.78 1(0.54–2.28) 0.79 50–59 90(70.9) 37(29.1) 0.9(0.5–1.6) 0.84(0.4–1.77) 0.71 >=60 99(83.2) 20(16.8) 1.8(0.97–3.5) 1.3(0.53-3) 0.5 Occupation Housewife 128(73.6) 46(26.4) 1 1 Private empl 34(73.9) 12(26.1) 1(0.5–2.13) 1(0.4–2.58) 0.93 Govt employ 39(76.5) 12(23.5) 1.2(0.56–2.4) 1.5(0.5–3.8) 0.39 Merchant 32(64) 18(26) 0.64(0.33–1.25) 0.52(0.22–1.24) 0.14 Farmer 74(78.7) 20(21.3) 1.33(0.73–2.4) 0.92(0.48–1.96) 0.81 Daily worker 37(84.1) 7(15.9) 1.9(0.79–4.56) 2.7(0.95–7.4) 0.055 Others 14(73.7) 5(26.3) 1(0.34–2.94) 0.62(0.15–2.54) 0.51 Education Unable to read &write 155(80.3) 38(19.7) 1 1 Able to read &write 63(71.6) 25(28.4) 0.61(0.34–1.1) 0.88(0.43–1.7) 0.73 Primary school 65(73.9) 23(26.1) 0.69(0.38–1.25) 1(0.48–2.37) 0.82 Secondary school 20(66.7) 10(33.3) 0.49(0.2–1.1) 0.57(0.12–1.63) 0.29 College and above 55(69.6) 24(30.4) 0.56(0.3-1) 0.36(0.16–0.83) 0.017* BMI Underweight 198(84.6) 36(15.4) 4.4(2.08–9.28) 3(1.28–7.47) 0.012* Normal Overweight 140(67.3) 20(55.6) 68(32.7) 16(44.4) 1.65(0.8–3.38) 1 1.35(0.62–3.01) 1 0.46 Stage of cancer Stage 1 27(61.4) 17(38.6) 1 1 StageII 74(60.7) 48(39.3) 0.97(0.47–1.96) 1.58(0.7–3.87) 0.28 StageIII 113(77.4) 33(22.6) 2.15(1.04–4.43) 2.3(0.99–5.5) 0.052 Stage IV 144(86.7) 22(13.3) 4.12(1.93–8.78) 2.5(1.06–6.38) 0.047* Comorbidity Yes 126(86.9) 19(13.1) 2.88(1.68–4.93) 1.6(0.85–3.14) 0.13 No 232(69.7) 101(30.3) 1 1 Anxiety No anxiety 140(62.8) 83(37.2) 1 1 Border line 55(78.6) 15(21.4) 2.2(1.15-4) 1.75(0.79–3.85) 0.16 Anxiety 163(88.1) 22(11.9) 4.4(2.6–7.4) 2.7(1.29–5.7)* 0.008* Depression No depression 128(64) 72(36) 1 1 Border 73(73) 27(27) 1.5(0.89–2.57) 1(0.5–2.16) 0.69 Depression 157(88.2) 21(11.8) 4.2(2.4–7.2) 1.4(0.6–2.9) 0.28 Cycle of chemotherapy Second cycle 73(86.3) 11(13.7) 1 1 Third cycle 101(82.8) 21(17.2) 0.72(0.33–1.59) 0.82(0.3–1.87) 0.67 Fourth cycle 59(76.6) 18(23.4) 0.49(0.22–1.13) 0.81(0.32–2.25) 0.67 Five & above 125(64.1) 70(35.9) 0.27(0.13–0.54) 0.43(0.19–0.95) * 0.037* Side effects of chemotherapy Yes 214(78.7) 58(21.3) 1.58(1.04–2.4) 1.6(0.98–2.67) 0.072 No 144(69.2) 62(30.1) 1 1 Note:1.00 = Reference, *statistically significant, Hosmer and Lemeshow test (P-value = 0.82) 5.2 Qualitative study results 5.2.1 Demographic Characteristics of the In-depth Interview (IDI ) A total of 11 adult cancer patients receiving chemotherapy treatment participated in the in-depth interview. The age of patients ranged from 35 to 70 years, with a mean age of 53 years. The majority, 7 (66.34%), of the patients were diagnosed at cancer stage III and IV. (See Table 7 below). Table 7 Description of the Socio-demographic, clinical, and chemotherapy-related factors of adult cancer patients receiving chemotherapy treatment at AKUCSH(n = 11) code Sex Age Educational level Type of Ca Stage of Ca Occupation Cycle of chemo Hospital P1 Male 55 College Rectal II Teacher 3th AKUCSH P2 Female 40 Illiterate Cervical IV Housewife 5th AKUCSH P3 Female 60 Illiterate Breast IV Housewife 5th AKUCSH P4 Female 35 Illiterate Gastric III Widowed 7th AKUCSH P5 Female 57 Elementary Colonic IV Housewife 6th AKUCSH P6 Male 45 High school Colonic II Merchant 9th AKUCSH P7 Male 50 Illiterate Appendiceal III Farmer 4th AKUCSH P8 Male 65 Illiterate Lung IV Farmer 5th AKUCSH P9 Female 36 high school Breast II Housewife Second AKUCSH P10 Female 70 Illiterate Myeloma IV Widowed Second AKUCSH P11 Male 35 Degree Rectal II Gov’t employee 6th AKUCSH Thematic findings The findings that are found from the analysis of in-depth interviews were presented as themes and subthemes. The two main themes and subthemes were arranged by analysis through Atlas.ti version 7..5.8 The major themes were the experience of patients with the cancer and chemotherapy, and Barriers affect quality-of-life cancer patients receiving chemotherapy. 5.2.2. Theme 1. Experience of patients with cancer under chemotherapy positive experiences Seven participants reported that they were terrified of dying after heard about their illness; nevertheless, chemotherapy, despite having a positive effect, provides them hope for survival and positive health progress. The following participants expressed. ‘’After I begin chemotherapy treatment, after fourth round of the treatment I have seen a good progress thanks to God and chemotherapy treatment’’ (participant 5(F),57, stageII). This was supported by the following quote taken from in-depth interview: ‘’My pain began to subside after fourth chemotherapy rounds, and I was able to move a little more easily. I feel more at ease knowing that the treatment is having some effect’’ (participant 6(M),45, stage II). Negative experiences Every participant in this study had some level of chemo-related adverse symptoms, including nausea, vomiting, hair loss, and low appetite. The patient's quality of life is impacted by these side effects of chemotherapy. ’The following participant expressed; ‘Symptoms like nausea, vomiting, appetite loss, and hair loss are all present after received the treatment. Although I am bothered by the hair loss, the nurses told me that it will return once the treatment is complete’’ (participant 3 (F),60, stage IV) This was supported by the following quote taken from in-depth interview: ‘’I'm constantly exhausted and nauseous after chemotherapy. I'm unable to eat or sleep, and the treatment seems worse than the cancer itself. All I want is for it to stop’’ (participant 10 (F),70, stage IV). ‘’Chemotherapy made me fatigued and lose my hair. I look like a ghost and feel so weak. Being this ill makes it difficult for me’’ (participant 9 (F),36, stage II). 5.2.3 Theme2.Barriersand facilitators affect QOL in cancer patients receiving chemotherapy ( see Fig. 4 below) Socio-demographic related barriers Inadequate patient education Most of the participants six (6) had a lack of knowledge and experience about the disease and chemotherapy treatment. The following participant expressed; The quality of life for cancer patients receiving chemotherapy is greatly impacted by a lack of understanding and living in a remote area. The following participant expressed, "I didn't understand what the medications were doing or why I required so many chemotherapy sessions. Because I felt so ill, I thought I was getting worse, and I stopped my treatment’’ (participant 9 (F),36, stage II). "Most of the time, I have no idea what the physicians are saying. They speak in difficult words, and I'm too embarrassed to ask again. I'm feeling terrible about the treatment, and I'm not even sure whether it's helping" (participant 2 (F),40 stage IV). Poverty The majority of the patients' economic status was low, and they couldn’t afford the medical costs and the cost of transportation. The following participant expressed. ‘’ I had to sell my animals to cover the high cost of the chemotherapy medications. My family is now poor, and I feel bad every day. I find it difficult to concentrate on improving while I'm worried about money. ’ (participant 9 (F),36, stage II). “ Every time, I’m thinking about my poverty, and I skipped my treatment because I had to choose between feeding my kids’’ (participant 4 (F),40, stage III). Socio-demographic related facilitators Adequate patient education The health providers told me about hair loss and other side effects of the chemotherapy before I started the treatment, so I could prepare myself for that risk. I know it is hard, but I haven’t another opportunity. ’I have a bachelor's degree and am searching for information about my disease condition and the side effects of the chemotherapy beyond of the health professionals told me. I think this helps me manage my problems. Clinical and symptom-related Clinical and symptom-related barriers Severity of the disease Seven (7) participants discussed the disease's status as an incurable condition and stated that it is fatal. The primary grounds for categorizing the illness as serious were its symptoms and indicators, which they described. Additionally, the participants described the causes of the disease, including the combination of chemotherapy treatment and its adverse effects, which make it dangerous. The following participant expressed, ‘’Because of the effect of chemotherapy and metastasis of the disease to part of our body, food is always fed by my family. I am always in bed because I have severe fatigue due to those reasons and am abstaining from any daily and social activities’’ ( participant 5 (F),57, stage IV). Severe side effects Patients frequently reported debilitating side effects such as nausea, vomiting, fatigue, and pain, which severely disrupted their daily lives. The following participant expressed; ‘ ’Because of the effect of chemotherapy and metastasis of the disease to part of our body, food is always provided by my family. I am always in bed because I have severe fatigue due to those reasons,and I abstain from any daily and social activities (participant 4 (F),40, stage III). ‘’After treatment, I have severe weakness, and my appetite disappears for five to seven days. due to this, my weight decreased by 20 kilograms, nausea is persistent, and I'm exhausted. I feel as though my body is collapsing, and I am unable to eat or sleep normally. I don't know how to continue in this manner.’’ ( participant 1 (M),55, stage II mobility and self-care limitations Physical weakness and fatigue restricted patients’ ability to perform basic activities like walking or self-care.This was supported by the following quote taken from an in-depth interview: ‘’I used to work part-time, but now I can't even get out of bed most days because my body feels so weak from chemotherapy that I can't walk normally. I feel like I'm not just myself anymore ’’ ( participant 2 (F),40, stage IV). ‘’I'm too weak from chemotherapy to take a shower or put on clothes. I feel like a child because my husband cares for me. It deprives me of my dignity and is degrading. This demonstrates how restrictions in self-care affect quality of life (participant 9 (F),36, stage II). Weight loss The majority of the participants from the in-depth interview had impaired weight due to the severity of the disease and side effects of the chemotherapy.The following quote is taken from an in-depth interview. ‘’My weight has fallen as you can see because I have no hunger and can only gently attempt fluids like milk instead of solid things like injera. The drug has its side effects like general weakness, appetite loss, nausea, and vomiting, especially in the early phase of treatment ‘’ ( participant 11, (F),55, stage IV). Clinical and symptom-relatedfacilitators Early diagnosis Participants mentioned that early diagnosis and removal of the tumor by operation was it makes easier for the treatment and follow-ups.The following quote is taken from an in-depth interview follow-up for nurses. ‘’I was diagnosed earlier, and an operation was done for the tumor,and the disease did not metastasize to other parts of my body, and this helped me more.’’( participant 9(F),36, stage II). Early diagnosis of my illness allowed me to begin chemotherapy earlier and with less physical strain on my body. I still considered myself quite lucky.’’ (participant 6 (M),45 stage III) Late cycle of chemotherapy The majority of the respondents taken more cycles of chemotherapy expressedgood quality of life. The following quote is taken from an in-depth interview; ‘’I took the chemotherapy for nine rounds, and at the first three to four cycles,it was difficult; now, thanks to God and chemotherapy, my general health condition hasimproved. ‘’ (participant 5 (F),57, stage II) During my earlier chemotherapy treatment,it was difficult to remember the tough time. but after taking more than five rounds, the side effects of chemotherapy were decreased.’’ (participant 10, (F),70, stageIV). Psychological and care-related Psychological and care-related barriers Anxiety and fear of treatment Most of the participants experienced a wide range of psychological impacts as a result of the disease condition and the chemotherapy. They reported that negative feelings, fear, and anxiety were the most common psychological problems of cancer patients. The following participant stated the same thing as; ‘’Because I had heard that chemotherapy causes hair loss and has other side effects, I was afraid of it. I tremble during every session, and it's difficult for me to remain hopeful when I'm so terrified. This demonstrates how worry about adverse outcomes increases anxiety and lowers quality of life’’ ( participant 7(M),50, stage III). This was supported by the following quote taken from an in-depth interview: ‘’I always fear that the cancer may spread because the chemotherapy isn't working. because of this so nervous before every treatment. This illustrates how treatment efficacy anxiety affects quality of life’’ (participant 9(F),36, stage II). Depressive symptoms Some participants became emotionally unstable and started to suffer from loss of independence and autonomy, and this in turn increased their levels of depression. The following participant stated the same thing as; ‘’After being diagnosed with cancer and losing everything we had, I separated from my wife, and now I am at my parents’ house. I am not living a happy life with them because I feel like a dependent on them, and I have anxiety and depression when I remember those things ’’ (participant 1, male, age45). ‘’Due to my inability to work and dependence on my family, I have no hope for the future. makes me feel depressed at all .’’ (participant 11, (M),40, stageII). Fear of death The majority of respondents seven(7) had a fear of death, hopelessness due to the severity of the disease, and side effects of the treatment. The following participant stated the same thing as; ‘’’My nausea from chemotherapy makes me feel as though I will never recover. I consider passing away and leaving my kids behind, which makes me cry every day. This illustrates how the depression symptoms caused by chemotherapy worsen and lower quality of life (participant 10, (F),70, stageIV). ‘’I keep thinking about dying when I'm lying in bed after chemotherapy. I am afraid of what lies ahead as I watch my body deteriorate. Everyone urges me to keep strong, yet I want to talk about this fear. It's weighty, and death is always on my mind. " (participant 2 (F),40 stage IV). Psychological and care-related facilitators Hope Some of the respondents had hope and trust in the chemotherapy treatment,The following participant stated the same thing as; ’I believe that God will cure me of this illness, and I have faith in Him to do so.’’ (participant 4 (F),40, stage III). ‘’I no longer feel negatively about the illness. I am getting better, thank God.I'm hopeful that God will heal me.’’ (participant 5 (F),57, stage II) completelywell; therefore, I’m not concerned about today's Healthcare provides support ‘’The eighth follow-up is this one. and they reassured me when I questioned them about the illness. They gave me an injection and told me not to worry too much. and they have a great deal of compassion . ’’ ((participant 3, (F),60, stageIV). ‘’They gave me a warm welcome when I came back for a follow-up appointment. They take the time to inform me about the state of my health, offer suggestions for prescription drugs, and counsel us on healthy eating practices.’’ ((participant 10, (F),70, stage IV). Counseling ‘’I was terrified of the side effects of chemotherapy when I first started, including hair loss and constant nausea. the nurses' advice, which gave me courage to keep going, and that's made me stronger.’’ (participant 6 (M),45 stage III). ‘’I was discomfort during my chemotherapy treatment due to side effects and other financial issues, The health providers encouraged me to keep going, and that's made me stronger.’’ ((participant 3, (F),60, stage IV). Social related Social-related barriers Interrupt Social Life The disease condition and chemotherapy impacted the participant's social life, which affects the participant's involvement in daily activities. Due to this, some of the participants, especially at the early cycles of chemotherapy, don’t want to be seen by anyone while they get chemotherapy services because they think it will affect their family and social relationships. The following participant stated the same thing as; ‘’Our community has a lack of awareness about the cancer, because of how thin I was, people understood it spreads from person to person, I feel ashamed and don’t mix much with people’’ ((participant 10, (F),70, stage IV). ‘’I'm too weak from treatment to attend community events anymore. People's perceptions of me vary, and I feel quite isolated. This illustrates how the physical side effects and social stigma of chemotherapy cause social isolation and lower quality of life.’’ ( participant 7(M),50, stage III ) Interrupt family life The participants had participated in family activities, but they decreased their involvement once an illness issue affected their lives, which affected their family life. Furthermore, the community believes they are unable to engage in social activities. Such a condition impacts their social lives and makes living with the illness difficult. The following research participants support this: ‘ ’After being diagnosed with cancer and losing everything we had, I separated from my wife, and now I am at my parents’ house. I am not living a happy life with them because I feel like a dependent on them, and I have anxiety and depression when I remember those things’’ (participant 1, male, age45). ‘ ’My inability to work while undergoing treatment is causing hardship for my family. My husband is often upset. This demonstrates how family interactions are impacted by the financial disturbances caused by chemotherapy, which lowers quality of life ’’ (participant 9(F),36, stage II). Socially related facilitators Family and social support The relationship between family and society had positive impact on the quality of life the cancer patients on chemotherapy. The following research participants support this ‘’Since I was diagnosed with cancer, my family has not left my side. We have a wonderful bond, and I want to thank them. The good life I am living now would be unimaginable without them.’’ (participant 6 (M),40, stage II) ‘’I usually get support from my friends and family both during and after the chemotherapy treatment, which helps me feel strong and normal.’’ (participant 1, male, age45). Systemic and access-related Systemic and access-related barriers Limited access to medication and treatment All eleven(11) respondents stated that the unavailability of cancer medications in government hospitals and the high cost of private are the main challenges during chemotherapy treatment. The following research participants support this: most of the time, cancer patients’ medications are not easily available in governmental hospitals. Even when they are available, their high cost adds to our worries, as lack of access to these medications concern us more than the disease itself. Radiation Is not found completely in Tigray . (participant 2 (F),40 stage IV). ‘’I frequently have to wait weeks when the hospital runs out of chemotherapy medications. I am left with no choice except to lie in bed as my discomfort worsens. My inability to receive the medication on time makes me feel as though the illness is winning. Drug shortages have a direct influence on quality of life by delaying therapy and exacerbating physical symptoms’’ (participant 5 (F),57, stage II) Late diagnosis and treatment delays Late diagnosis was a significant issue including to advanced disease stages and weekend physical states. Majority respondents prolonged illness before diagnosis.The following research participants support this, “ When I was told I have cancer, it was difficult. I was shocked because it was already in a bad stage. If they had found it earlier, maybe I wouldn’t feel this weak and hopeless now.” (participant 8 (M),65, stage IV)). ‘’Although I had swelling, I didn't think it was dangerous. Nobody instructed me to check it. When I arrived at the hospital, they informed me that it was stage four, and as a result of the treatment, I'm constantly exhausted and in agony.’ (participant 2 (F),40 stage IV). Cost of treatment Most of the participants participated in this study stated cost of the treatment was so expensive. Some cancer drugs are not available in government hospitals. Most of the time, the treatment drugs came from private clinics, and some were also not widely available in the town. These produce psychological disturbance in the family and interrupt the treatment schedule. The following participant stated the same thing as; ‘’The cost of the chemotherapy and other laboratory investigations is expensive; it is not the illness the poor can afford. Until now, people they helped me because I am poor’’ ( participant 7(M),50, stage III ). This was supported by the following quote taken from an in-depth interview: ’’I was first unable to pay for the costly chemotherapy medications. By the time I received the medications, my condition had gotten worse, and I was too weak to even walk, so I had to borrow money. This demonstrates how financial limitations impair quality of life during treatment by delaying access to medication . ‘’(participant 6 (M),40,stage II). Cost of Transport The majority of nine (9) participants reported that the cost of the transport from the home to the treatment center was too expensive. The majority of the participants said ‘’Due to the absence of fuel, we paid double the normal tariff of transportation and it is difficult to follow our treatment, mostly every three weeks’ . The following participant expressed. ‘’I come from tselemti wereda and it is far away from the treatment center, Aksum and the Transport costs are very expensive due to fuel shortage” ( Participant 4, (F),35, stage III). I have to travel far for chemotherapy, and the cost of transportation is difficult due to the shortage of fuel. My discomfort worsens when I neglect my treatment due to the cost of transportation (participant 11, (M),40, stage II). Systemic and access-related facilitators Distance to the hospital Some of the respondents said their home is close to the hospital and benefits from different directions. The following research participants support this; ‘’My home is nearest to the hospital, and I don’t feel tired after chemotherapy, I can rest at home sooner ‘’ ’(participant 6 (M),40,stage II). ‘’The transport is cheap from the town to the treatment center. so I don’t stress about the expenses of transport, also going to the hospital without care caregiver . ’’ (participant 7(M),50, stage II) Discussion This explanatory sequential mixed-method study aimed to assess quality of life, associated factors, and explore perceived barriers among cancer patients receiving chemotherapy at Tigray,Ethiopia, 2024/25. This study showed that the poor quality of life among cancer patients receiving chemotherapy was 74.9% with 95% CI( 70.99–78.8). The finding of this study is higher than the results of the studies conducted in Amhara regional state on breast cancer, DessieComprehensive SpecializedHospital,Tikur AnbesaComprehensive SpecializedHospital,Amhara regional state 68.4,64.3,57.28,55.68[ 3 , 8 , 9 , 14 ].The possible explanation might be due to the tool used to measure the quality of life,and the current situation of Tigray, conflict and the related issues(war crisis),may be due to my study including various cancer types, which could encompass more advanced stages or cancers with greater symptom burdens[ 15 ]. Factors associated among cancer patients receiving chemotherapy treatment were: college and above educational status,stage four cancer,five or abovechemotherapy cycles,underweight, and anxiety.Statistically significant at p-value less than 0.05. This study showed that cancer patients with college and above were 64%{AOR = 0.36,95%CI(0.16–0.83)}less likely to have poor QOL as compared with those who had unable to read and write.This was similar to a cross-sectional study conducted cross sectional study in the Amhara regional state, Tikur Anbesacomprehensive specialized hospital,Ethiopia,in Gaza,Palestine, and in Nairobi,Kenya[ 8 , 16 – 18 ]Thiscould be due to lower education levels correlating with poorer self-reported health[ 19 ]. This is supported by qualitative data showing thatthe quality of life for cancer patients receiving chemotherapy is greatly impacted by a lack of understanding and Inadequate patient education. The odds of beingunderweightwere3 times (AOR = 3, 95% CI (1.28–7.47)} more likely to have poor quality of life than those who wereoverweight.This finding was supported bycross-sectionalstudies conducted in Amhara National Regional State,Ethiopia,Brazil, and Malawi [ 8 , 20 , 21 ].This could be due to malnutrition is linked to a decline in functional ability, an increase in the number and duration of hospital admissions, the experienceof worse symptoms, anxiety, and depression; all of which can lead to poor QOL[ 22 ]. This is supported by qualitative data showing that Loss of appetite,nausea, and vomiting lead to weight loss were the most frequently reported impairments affecting the quality of life by the interviewee participants. The odds of having anxiety were about 2.7times {AOR = 2.7, 95% CI (1.29–5.7)}more likely to have poor quality of life than those who had no anxiety.This was supported by studies conducted in selected comprehensive and specialized hospitals in the Amhara region, Ethiopia,Jordan, and Malawi.[ 8 , 21 , 23 ].This may be due to adverse drug reactions, prognostic uncertainty, the utilization of mostly disease-centered treatment modalities, and the significant compromise of patients' mental well-being[ 24 ]. The qualitative findings support this; the majority of the participants experienced a wide range of psychological impacts as a result of the disease condition and the chemotherapy. They reported that negative feelings, fear, anxiety, and depression were the most common psychological and emotional problems of cancer patients receiving chemotherapy as a result affected the quality of life.. Thisstudy also showed that cancer patients with five and above chemotherapy cycle were 57% {AOR = 0.43,95%CI(0.19–0.95)} less likely to have poor QoL as compared with those who hada second chemotherapy cycle.This was similar study conducted a cross sectional study in the Amhara region, Tikur AnbesaComprehensive SpecializedHospital, Ethiopia,Egypt,Iran[ 8 , 25 , 26 ].This could be due to This might be because chemotherapy frequently causes acute side effects that worsen patients' quality of life after they occur, usually at the end of the first cycle. Later, when their health improves and their symptoms lessen, their quality of life improves[ 27 ] . This qualitative study also strengthened this which stated that;majority of the respondents subside from the side effects of chemothrapy on the late cycle of chemothrapy and gave thanks for chemothrapy treatment . This implies that finishing more cycles—including late ones—is linked to improved quality of life, either as a result of adaptation or successful treatment results. The odds of having stage four cancer patients had about 2.5 times { AOR = 2.5, 95% CI (1.06,- 6.38)} more likely to have poor quality of life than those who had stage one cancer patients.This was similar to a cross-sectional study conducted cross sectional study in the Amhara region, Tikur Anbesacomprehensive specialized hospitals,Ethiopia,Dessie comprehensive specialized hospitals, Ethiopia. Kenya[ 8 , 9 , 18 ].This could be due toas the illness worsens, patients will have more excruciating symptoms, physical functioning impairment, and increased stress, anxiety, and depression, all of which are likely to have an impact on their quality of life[ 28 ].The qualitative findings support this:the majority of cancer patients,stage 4 patients, frequently report severe physical symptoms such as pain, fatigue, nausea, and loss of appetite,fear of death.The qualitativeinterviews reveal these symptoms significantly disrupt daily activities, emotional well-being, and social interactions, unlike stage 1 patients who often experience milder symptoms and less aggressive treatments. Limitation of the study The study was performed only once, and QOL may differ during different cycles of chemotherapy There was no comprehensive nutritional assessment because BMI is only used to determine nutritional status and has its limitations. Some drug-related variables (e.g., chemotherapy medication) were not assessed well in my study The study was performed only once, and QOL may differ during different cycles of chemotherapy. The information was gathered using a face-to-face interviewing method. Because of this, the respondents may respond in favor of those who are either overreporting or underreporting due to the severity of their condition. Conclusion and Recommendation According to this study overall quality of life cancer patients receiving chemotherapy at tigray Comprehensive SpecializedHospitals three-fourth of the patients was poor quality of life..college and above educational status,underweight,stage four of cancer,five and above cycle of chemotherapy and patients with anxiety was significant factors associated with the poor quality of life. Mobility and self-care limitations,side effects of the chemotherapy,anxiety, and fear of treatment.depression symptoms,interrupt social life,interrupt family life,expensive cost of the chemotherapy and transportation,late diagnosis and treatment delays,limited access to medication and treatment,were barriersaffectingthe quality of life of patients on chemotherapy. Based on the findings of this study, the following recommendations are forwarded: Health care providers should focus on addressing the side effects of therapy and on palliative care to improve quality of life. Promote healthcare and educational services, outreach initiatives, and mobile clinics to help cancer patients live better lives The administrators of hospitals and Tigray regional health bureaus advocate to nongovernmental organizations to cover the cost of treatment and other laboratory investigations. Cancer patients should be supported and encouraged to participate in economic activities and capacity development initiatives, either individually or in groups. Health advocates should also insist on financial assistance for cancer patients undergoing chemotherapy. A longitudinal study for future researchers to assess the quality of life of cancer patients receiving chemotherapy. Health care providers should focus on counseling services to minimize emotional challenges like anxiety and depression. The administrators of hospitals and Tigray regional health bureaus advocate to nongovernmental organizations to cover the cost of treatment and other laboratory investigations. ABREVIATIONS ACSH Ayder Comprehensive Specialized Hospital AKUCSH Aksum Comprehensive Specialized Hospital AOR Adjusted Odd Ratio BMI Body Mass Index BSc Bachelor of Science CA Cancer CI Confidence Interval COR Crude Odd Ratio CSH Comprehensive specialized hospital DC Data Collector EORTC QLQ C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 HADS Hospital Anxiety DepressionScale HRQOL Health Related Quality of Life MSc Master Of Science PI Principal Investigator QOL Quality of Life SPSS Statistical Package for Social Science Software Declarations Ethics approval and consent to participate An official IRC letter (082/2024) has been obtained from the ethical review board of Aksum University College of Health Sciences. The letter was handed over to the comprehensive specialty hospitals of Aksum and Ayder universities. in accordance with the ethical principles of the Declaration of Helsinki (1964) and its later amendments, as well as the National Research Ethics Review Guidelines of Ethiopia. After informing them, the respondents gave their verbal agreement. Every respondent's freedom to decline or discontinue participation in the interview was fully respected, and all information submitted was kept private by encoding each questionnaire and not disclosing any patient's personal information to outside parties.. Consent for publication Not applicable Competing interest The authors declare no competing interest. Author Contribution Hailseslasie Hailemariam designed this study, and all authors participated in the analysis. This manuscript is written by Hailseslasie Hailemariam, and the authors read and approved the manuscript. ACKNOWLEDGMENT First of all, I would like to thank my advisors, Tekleweyni Mariye and Abrha Hailay, for guiding and supervising my thesis. Also, I would like to thank to study participants and data collectors who helped me to collect my data.Finally, I would like to thank Aksum University, which gave me this opportunity to attend my MSc program. Data Availability All data supporting this finding are presented in the manuscript. References Ferlay J, et al. Global cancer observatory: cancer today. Lyon: International agency for research on cancer; 2020. p. 20182020. Islami F et al. American Cancer Society's report on the status of cancer disparities in the United States, 2021. CA: a cancer journal for clinicians, 2022. 72(2): pp. 112–43. Tadele N. Evaluation of quality of life of adult cancer patients attending Tikur Anbessa specialized referral hospital, Addis Ababa Ethiopia. Ethiop J health Sci. 2015;25(1):53–62. Lewandowska A, et al. Quality of life of cancer patients treated with chemotherapy. Int J Environ Res Public Health. 2020;17(19):6938. Gebregziabher M, et al. Geographical distribution of the health crisis of war in the Tigray region of Ethiopia. BMJ global health. 2022;7(4):e008475. Tuem KB, et al. Adequacy of Cancer-Related Pain Treatments and Factors Affecting Proper Management in Ayder Comprehensive Specialized Hospital, Mekelle, Ethiopia. J Oncol. 2020;2020(1):2903542. Abegaz TM, Ayele AA, Gebresillassie BM. Health Relat Qual life cancer patients Ethiopia J Oncol. 2018;2018(1):1467595. Muhamed AN, Bogale SK, Netere HB. Quality of life and associated factors among adult cancer patients undergoing chemotherapy treatment at Amhara National, Regional State, Ethiopia , 2021. SAGE Open Nursing, 2023. 9: p. 23779608231174866. Bayked EM, et al. Quality of life and associated factors among patients with cancer receiving chemotherapy at Dessie Comprehensive Specialized Hospital, North-East Ethiopia: a cross-sectional study. Front Oncol. 2024;13:1288166. Fayers P et al. The EORTC QLQ-C30 scoring manual, Brussels, Belgium: European Organization for Research and Treatment of Cancer 2001 . 2021. Hassen AM, et al. Quality of life and associated factors among patients with breast cancer under chemotherapy at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. PLoS ONE. 2019;14(9):e0222629. Araya LT, et al. Health-related quality of life and associated factors among cervical cancer patients at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. Volume 18. Health and quality of life outcomes; 2020. pp. 1–9. Rhee CK et al. COMPARISON OF WORLD HEALTH ORGANIZATION AND ASIA-PACIFIC BODY MASS INDEX CLASSIFICATIONS IN COPD PATIENT. Respirology, 2017. 22: pp. 4–4. Alem T, et al. Quality of life of breast cancer patients in Amhara region, Ethiopia: A cross-sectional study. PLoS ONE. 2024;19(6):e0305263. Teka H, et al. The impact of armed conflict on maternal morbidity and mortality at a teaching hospital in the Tigray region of Ethiopia: a pre-war and wartime comparative analysis. BMC Pregnancy Childbirth. 2025;25(1):1–12. Abraha A. Assessment of Breast Cancer Patients’ Quality of Life under Chemotherapy treatment at Tikur Anbessa Specialized Hospital, in Addis Ababa, Ethiopia , 2018. 2018. ElMokhallalati Y, et al. The symptom burden and quality of life in cancer patients in the Gaza strip, Palestine: a cross-sectional study. PLoS ONE. 2022;17(1):e0262512. Kung’u M, Onsongo L, Ogutu JO. Factors influencing quality of life among cancer survivors in Kenya. Afr Health Sci. 2022;22(4):87–95. OECD. An OECD learning framework 2030. Springer; 2019. Moreira DP, et al. Quality of life of patients with cancer undergoing chemotherapy in hospitals in Belo Horizonte, Minas Gerais State, Brazil: does individual characteristics matter? Volume 37. Cadernos de Saúde Pública; 2021. p. e00002220. 8. Banda JC, et al. Quality of life among cancer patients at Queen Elizabeth and Kamuzu Central Hospitals in Malawi: a cross-sectional double-center study. Afr Health Sci. 2022;22(3):222–32. Maia FdCP, et al. Malnutrition is associated with poor health-related quality of life in surgical patients with gastrointestinal cancer. Nutrition. 2020;75:110769. Mosleh SM. Health-related quality of life and associated factors in Jordanian cancer patients: A cross‐sectional study. Eur J Cancer Care. 2018;27(5):e12866. Amrein AC. Exploring the integration of evidence-based medicine, quality of life considerations and health economics for rare diseases. University of Southern Queensland; 2020. Bayumi H, Mohamed HS. Factors affecting quality of life among cancer patients with chemotherapy at Qena university hospital in upper Egypt. IOSR J Nurs Health Sci. 2016;5:168–73. Heydarnejad MS, Hassanpour DA, Solati DK. Factors affecting quality of life in cancer patients undergoing chemotherapy. Afr Health Sci, 2011. 11(2). Akhtari-Zavare M, et al. Determinants of quality of life among Malaysian cancer patients: a cross-sectional study. Health Qual Life Outcomes. 2018;16:1–17. Ramasubbu R, et al. Long versus short pulse width subcallosal cingulate stimulation for treatment-resistant depression: a randomised, double-blind, crossover trial. Lancet Psychiatry. 2020;7(1):29–40. Additional Declarations No competing interests reported. Supplementary Files Questionnaire.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8010679","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":571900990,"identity":"4c00277e-c444-421d-8abe-fe1809d2e75e","order_by":0,"name":"Haileslasie Hailemariam","email":"data:image/png;base64,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","orcid":"","institution":"Aksum University","correspondingAuthor":true,"prefix":"","firstName":"Haileslasie","middleName":"","lastName":"Hailemariam","suffix":""},{"id":571900991,"identity":"3ff00452-359b-457e-8617-666478341598","order_by":1,"name":"Solomon Gebremedhin","email":"","orcid":"","institution":"Aksum University","correspondingAuthor":false,"prefix":"","firstName":"Solomon","middleName":"","lastName":"Gebremedhin","suffix":""},{"id":571900992,"identity":"fc006b7c-1c94-4959-b6f0-46c1eaa5ef84","order_by":2,"name":"Abrha Hailay","email":"","orcid":"","institution":"Aksum University","correspondingAuthor":false,"prefix":"","firstName":"Abrha","middleName":"","lastName":"Hailay","suffix":""},{"id":571900993,"identity":"a8e202ce-9801-4c6c-8bd1-d0a5f4645d10","order_by":3,"name":"Genet Tsehaye","email":"","orcid":"","institution":"Aksum University","correspondingAuthor":false,"prefix":"","firstName":"Genet","middleName":"","lastName":"Tsehaye","suffix":""},{"id":571900994,"identity":"70c3a616-9555-442d-a99a-de85376a149b","order_by":4,"name":"Teklewoini mariye","email":"","orcid":"","institution":"Aksum University","correspondingAuthor":false,"prefix":"","firstName":"Teklewoini","middleName":"","lastName":"mariye","suffix":""},{"id":571900995,"identity":"8b16a5a4-f8df-47ff-84f9-a0e8ac80e33d","order_by":5,"name":"Abrham Hagos","email":"","orcid":"","institution":"Aksum University","correspondingAuthor":false,"prefix":"","firstName":"Abrham","middleName":"","lastName":"Hagos","suffix":""}],"badges":[],"createdAt":"2025-11-02 11:38:18","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8010679/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8010679/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":100388718,"identity":"540a8f47-8b81-4efd-a67d-1f4cb4c9de2a","added_by":"auto","created_at":"2026-01-16 11:17:55","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":327602,"visible":true,"origin":"","legend":"","description":"","filename":"hailishmanuscript1.docx","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/9a7ca146c6a0ca1a3b00ed7b.docx"},{"id":100388777,"identity":"219d4ba1-4a80-44bb-818e-a18b32e302b3","added_by":"auto","created_at":"2026-01-16 11:18:04","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":7814,"visible":true,"origin":"","legend":"","description":"","filename":"3ab2e8b1b35540648dd93d31568a22b6.json","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/262d6da9752d54fe21bcf79a.json"},{"id":100388728,"identity":"dab834fd-ad08-428f-8309-8f80d002983c","added_by":"auto","created_at":"2026-01-16 11:18:01","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":54991,"visible":true,"origin":"","legend":"","description":"","filename":"Questionnaire.docx","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/6ddb2ada8f52705b81ac27c1.docx"},{"id":100388798,"identity":"98522404-00c6-418a-b21c-1eff1e62f0e7","added_by":"auto","created_at":"2026-01-16 11:18:06","extension":"xml","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":190368,"visible":true,"origin":"","legend":"","description":"","filename":"3ab2e8b1b35540648dd93d31568a22b61enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/ccaa52c5f19a741dba16e847.xml"},{"id":100388610,"identity":"7440e5a6-5e60-4f99-a26f-8791222055cd","added_by":"auto","created_at":"2026-01-16 11:17:50","extension":"jpeg","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":2482,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/eea2123b040a986f734e5ec0.jpeg"},{"id":100388660,"identity":"f4794764-a1fc-4421-b7d0-7e93cb9da3db","added_by":"auto","created_at":"2026-01-16 11:17:52","extension":"jpeg","order_by":9,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":26488,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/463edc06197bf76b2dcab662.jpeg"},{"id":100388620,"identity":"e490d5c3-797f-43d3-887c-11703ab8ec4a","added_by":"auto","created_at":"2026-01-16 11:17:50","extension":"png","order_by":10,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":4355,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/bef735035bc1ee0e7db919a8.png"},{"id":100388698,"identity":"fb28c901-9dec-476c-93f8-5ade44de8a81","added_by":"auto","created_at":"2026-01-16 11:17:54","extension":"jpeg","order_by":11,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":10493,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage4.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/acc43def7b1d8522cbf01855.jpeg"},{"id":100388618,"identity":"2ff31524-56e1-46b1-acb6-2e2912916438","added_by":"auto","created_at":"2026-01-16 11:17:50","extension":"png","order_by":12,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":15756,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage5.png","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/fe42a716fe3250a59fdbc8dc.png"},{"id":100388343,"identity":"f5a7060b-15e4-4025-93a6-8de6f2a692e6","added_by":"auto","created_at":"2026-01-16 11:17:22","extension":"jpeg","order_by":13,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":943662,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage6.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/7208f4be45e942f39ab9f24e.jpeg"},{"id":100388541,"identity":"da3d1b83-fece-44a2-abe8-8204c46c67be","added_by":"auto","created_at":"2026-01-16 11:17:40","extension":"png","order_by":14,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1582,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/5bdd5d24e7b8cfe5ba5dd0ce.png"},{"id":100388627,"identity":"3a0fea84-e315-49eb-98cd-46fddf849110","added_by":"auto","created_at":"2026-01-16 11:17:51","extension":"png","order_by":15,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":5263,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/929db509646fd289f7f690d3.png"},{"id":100388545,"identity":"41f6b278-5721-44d9-bf0e-3a9721e06d87","added_by":"auto","created_at":"2026-01-16 11:17:41","extension":"png","order_by":16,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1806,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/bebe0f82e5e1ea766cac825e.png"},{"id":100388844,"identity":"380e5958-a718-467a-ab36-e67d9535267c","added_by":"auto","created_at":"2026-01-16 11:18:15","extension":"png","order_by":17,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":9923,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/434b84ed4a92c7eea4f0bea5.png"},{"id":100388919,"identity":"31aae96a-0f9d-405f-9f15-6f369b17accb","added_by":"auto","created_at":"2026-01-16 11:18:29","extension":"png","order_by":18,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":7587,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage5.png","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/d322cd42fa9d850620a3ceb4.png"},{"id":100388631,"identity":"03ce362d-34cd-4525-925f-4efae0203774","added_by":"auto","created_at":"2026-01-16 11:17:51","extension":"png","order_by":19,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":177196,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage6.png","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/c4c4c038791046cc80e7af1b.png"},{"id":100388651,"identity":"a3d34ffd-5538-4d0c-b54f-d14471dc64c4","added_by":"auto","created_at":"2026-01-16 11:17:51","extension":"xml","order_by":20,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":187934,"visible":true,"origin":"","legend":"","description":"","filename":"3ab2e8b1b35540648dd93d31568a22b61structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/c387d043c1f3e432b47a3c25.xml"},{"id":100388562,"identity":"529d3e81-c51c-43bd-9322-3de265aefa52","added_by":"auto","created_at":"2026-01-16 11:17:48","extension":"html","order_by":21,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":207379,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/329ae93f8e19fa1727b26da8.html"},{"id":100388784,"identity":"795e1b9f-5a02-45d4-b267-6e10853d327e","added_by":"auto","created_at":"2026-01-16 11:18:05","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":57340,"visible":true,"origin":"","legend":"\u003cp\u003eFigure 2: Schematic presentation of sampling quality of life and associated factors among adult cancer patients in CSHs of Tigray, Ethiopia,2024/25.\u003c/p\u003e","description":"","filename":"1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/57fc4cd6be4c5a92d48c46ac.jpg"},{"id":100388429,"identity":"ab77ffab-c4f6-4c45-b823-fafa60946f17","added_by":"auto","created_at":"2026-01-16 11:17:29","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":40841,"visible":true,"origin":"","legend":"\u003cp\u003eFigure 3.QOL among adult cancer patients receiving chemotherapy at ACSH and AKUCSH, Tigray, Ethiopia 2024/25, n=478\u003c/p\u003e","description":"","filename":"2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/bf4b68af3ea506f63a6115fb.jpg"},{"id":100388375,"identity":"8f500e3b-74ef-4b2d-aa74-26a7cbd2d195","added_by":"auto","created_at":"2026-01-16 11:17:24","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":217043,"visible":true,"origin":"","legend":"\u003cp\u003eFigure 4. Barriers and facilitators towards quality of life among Cancer patients receiving chemotherapy in Tigray, Ethiopia 2024/25,n=11\u003c/p\u003e","description":"","filename":"3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/868e23bbcb4aa7299167b36f.jpg"},{"id":107062311,"identity":"5e5341c2-7508-417c-b84c-f00f3b75e90d","added_by":"auto","created_at":"2026-04-16 10:28:08","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":3651442,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/06b8138a-2428-460a-a0bd-3d26380e768c.pdf"},{"id":100388693,"identity":"18ab9212-08b5-43c7-814b-01887be0221e","added_by":"auto","created_at":"2026-01-16 11:17:54","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":54991,"visible":true,"origin":"","legend":"","description":"","filename":"Questionnaire.docx","url":"https://assets-eu.researchsquare.com/files/rs-8010679/v1/d232ff53cbb0bce61fdca798.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"\u003cp\u003eQuality of Life and Associated Factors Among Adult Cancer Patients Receiving Chemotherapy at Tigray, Ethiopia 2024/25: A Mixed Study\u003c/p\u003e","fulltext":[{"header":"Background","content":"\u003cp\u003eCancer is a broad category of disorders that can originate in virtually any organ or tissue in the body when cells multiply and spread abnormally, uncontrollably to other parts of the body[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e].Abnormal alterations called hyperplasia and dysplasia may lead normal cells to grow into cancerous[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. Cancer and its treatment are known to reduce the quality of life. It has been proven that a decreased quality of life has negative effects not only on physiological but also on the psychological functioning of the individual[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e].Chemotherapy is a type of systemic chemical therapy that is used to kill rapidly developing cells in the body [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. It is one of the most popular and widely used cancer treatments. Unlike other therapies, chemotherapy exhibits systemic side effects that can negatively impact a person\u0026rsquo;s Quality of life [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Chemotherapy is a concentrated and repeated treatment regimen that has many adverse reactions, including hair loss, nausea, vomiting, and diarrhea, which can eventually affect the Quality of life of cancer patients [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eQuality of life (QoL) is an individual\u0026rsquo;s perception of their position in life in the context of the culture and value systems in which they live and to their goals, expectations, standards and concerns [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Health related quality of life Is defined as an individual\u0026rsquo;s satisfaction with their physical, psychological, social relationships, environment, and spiritual aspects of life, and it is one of the significant variables in evaluating cancer patients' health and well-being In chronic illnesses, it is typically used to measure and often significantly impairs patients [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eCancer is the main cause of morbidity and mortality in every part of the world, regardless of human development [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Cancer is one of the most common chronic diseases in both industrialized and developing countries, and it has an impact on every part of the patient\u0026rsquo;s life [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e].Globally, there were 10.0\u0026nbsp;million recorded deaths and 19.3\u0026nbsp;million new cases of cancer in 2020[\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. .it is the second leading global cause of death, with 70% of deaths in low- and middle-income countries (LMICs) [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e].It is estimated that by 2040, there will be 27.5\u0026nbsp;million new instances of cancer and 16.3\u0026nbsp;million cancer-related deaths.[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. It is an escalating public health issue in low-income nations, particularly in Ethiopia. Based on a systematic review, it was estimated that there were 53,560 new cancer cases and 39,480 cancer-related deaths in this country in 2019[\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eCancer affects QOL through physical symptoms, emotional distress, and chemotherapy, treatment side effects, exacerbating these challenges through physical and psychological side effects[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eDespite the critical importance of QoL in cancer care, there is limited research exploring the specific factors influencing QoL among adult cancer patients receiving chemotherapy in this region. This study aimed to address such a gap. Accordingly, I investigated QoL and associated factors among cancer patients receiving chemotherapy at the comprehensive specialized hospitals of Tigray. Additionally, using a mixed method, this study will also explore perceived barriers affecting quality of life among cancer patients receiving chemotherapy that were not studied in previously conducted studies.\u003c/p\u003e"},{"header":"METHODS AND MATERIALS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy area\u003c/h2\u003e \u003cp\u003eTigray is one of the twelve regions of Ethiopia. The state's capital and largest town is Mekelle. Tigray is framed by Eritrea to the north, the Amhara Region to the south and southwest, the Afar Region to the east, and Sudan to the west.In the Tigray region, there were 2 CSHs, 14 general hospitals, 24 primary hospitals, 230 health centers, and 741 health posts[\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. from those hospitals, only the two (Aku CSH and Ayder CSH) provideoncologyservices for the cancer patients.Aku CSH is located in Aksum town, and the distance from the capital city of Ethiopia is 1003 km. It hasprovidededucational and medical services since 2014 GC and provides services for cancer patients since November 2023.ACSH is found in Mekele town, which is the capital city of Tigray region, and the distance from AddisAbaba is 780 km. It hasprovidededucational and medical services since 2008[\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003cb\u003eStudy period\u003c/b\u003e:The study was conductedfor the quantitative data from December-January 2024/25atthe comprehensive Specialized hospitals of Tigray, Ethiopia. For the qualitative part study was conducted from 1 April to -21 April,2025, at the Aksum Comprehensive Specialized Hospital of Tigray, Ethiopia.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eStudy design\u003c/h3\u003e\n\u003cp\u003eHospital-basedcross-sectional studysupported by the qualitative (sequential explanatory) method.\u003c/p\u003e\n\u003ch3\u003ePopulation:\u003c/h3\u003e\n\u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eSource populations:\u003c/h2\u003e \u003cp\u003eAll adult cancer patients who received chemotherapy treatment at Tigray, Ethiopia, 2024/2025. \u003cb\u003eStudy population\u003c/b\u003e:\u003c/p\u003e \u003cp\u003eAll sampled adult cancer patients receivingchemotherapy treatmentat oncology units during the data collection periodin Tigray, Ethiopia.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eStudy unit:\u003c/h3\u003e\n\u003cp\u003e Individual patients who participated in the study at oncology units inTigray, Ethiopia.\u003c/p\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eEligibility Criteria\u003c/h2\u003e \u003cdiv id=\"Sec9\" class=\"Section3\"\u003e \u003ch2\u003eInclusion criteria\u003c/h2\u003e \u003cp\u003eAll adult cancer patientswho had received at least tworounds of chemotherapy treatment\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e\n\u003ch3\u003eExclusion criteria\u003c/h3\u003e\n\u003cp\u003ePatients take less than two cycles of chemotherapy.\u003c/p\u003e \u003cp\u003epatients newly diagnosed at the time of data collection.\u003c/p\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eSample size determination and Sampling technique\u003c/h2\u003e \u003cp\u003eBoth the first and second objectives were utilized to calculate the sample size according to the single population proportion(sample size for the first objective)\u003c/p\u003e \u003cp\u003eThe sample size was determined using the single population proportion formula as follows:\u003c/p\u003e \u003cp\u003e\u003cimg src=\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAWkAAABzCAYAAABaQfMHAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAFiUAABYlAUlSJPAAAIW3SURBVHhe7f1nlyVHmt8J/szdr743tI7MSC2RmRAFFFCiS3R1s6tLdJMcDjkzPDsfgOfMfoE906zPsLvvd87OcM8uySE55LBlaQAFjUykVpEqtI64cfV1d9sXj5m73xs3gExUFQqoin8ez4hwNzc3+bfHHnvsMaW11hzgt45PLGQNKgqkE1cIKpTbSgEOoEDLTw1o1St++z4oFEor1J5nOo7bhJSnDiEq+jv51N7pfPJ5RbIc7d/2p+RG2/LsgI5KohOdZZJ82h0DaNAhEABaYlQADgrH1KNJXTKZJlLHJkvt9yEtbYOwK48OaDeKP4Y279r3bHgVhQ1RUc57Q5sQ8r78xLzf65tfZCTLNInONvBZ4PepVL/Q2Lfa931wgKdHdyF2//1bgrL/2e/JT+n6vQjAwA66+/EEfMzDzyhvB/jMcEDSnxE+rutEz/YNpIwUnQhg/9z3nWSQj5ePYvTq9F9kJAtpv6sX9ru/D7RIw/YSmPiVA8pBKQeFYV+tCUO50FK1Kg4KQBhCEGrCMBHnxyYrmZ/9AiYj6sy/7nn3k5AMvd+gcYBfFwck/RmiV+OP7u3bv3oQtMHTdAt5a++7fzhIUk/3tR8+qVQ7YXg3QdAW9jtWRaVQKBNWI5pGGUAtUdtXtBaCDkPdI9798En56gVRmcV/PX0sVvkRiwBP0yIP8Kw4IOnPGMnGv29H2Len7LnRE/Kq/JPf9nl13wf73f2iI1mwyQK25KJ76HiT7/a+o0iQbAcS3zFrCB3fVHt1yrFUreLf98TbjeR3Ere7s9ABCb9fkO5S6ky5Jef4E/vF88VGMtfJ3z9bqIOFw88JOmrBriJ2iWdRb7UdLO5k9md3s9qL5Bvd3UzesItp3ctnnxz35xjJ8o0Sr9F7ykECSJBnz3FHdSUfRNBoQrQOQWkZSlWSwE2ZJ5LUQdIdaReSjx+LtC6Lh11fVx0r0x2I7yby26O85NbeMpO3YqGg49u9C+EAz4ADSfrzgj0d0XaY7lYu95J9qFfX635rf9iQ8c/uO7936CiwJOFYyTZp8fJsSJZZr3qJYAlTxWQbvWEMMT5ZilaAYxUm8b19P7w3sk6CjmFj7Iq5C/s92TcBB/gUOJCkP7ewHTaWWKQvSIdITjktok7VXaOmD8lt+X+vDJ6EMtJ059P9uuQXAj2zqRPkaIlZmxzulW6fJueRbtosCFrEk6CYlDVhnC7tmG/a7ya+mvxsoi5jiVZqTIGRYs1lsxLBfEzZdy325q+jDXV9M37XfptIjo6xN84DfDocSNKfWyQ6W8dlO0tv3ul5U4wIOm4ku3fvS9B9N37yewBNIkfdOUuW8n566gSSwU2wPeKP+YT8iGlNa6kRWUyMid6S/Z54Ishg2rGAF60+9siSrcGO+H6dmv24d+1H9k38AZ4SB5L05x09qkc2r3RL0fJX56aVGDohGllJSLpXr9B7u5Ylli8sujNkYXX/HUTcWbLxzx7SdRepWqk3uXygktFA9D2N1G9cxZ2Li1EUyXfjz3akNKp/pA18HJJtQdAZXtG7vKTdJWXwxDf3xGKfJH8e4NPggKR/F+jFAb37xV7Vhe2cCYEoVnwoE767U2izlpOUoBFZTsvPDkTE1XGz6+cXDN3ZsYiyk1R7dOqIY52vg+rYWSeVEARi1wxCqK7bKdD2RiJBe2Y6SO2oHuk2cdoa6vVY6rTrYVd6ut+ziIL0CKBJtjsbIC6dvdm1d/Y+OcDT40Dd8VmjR+Ono8l3dr59gkeICbpbtu5GpxYyRo8O1BEwmaJkyn7f0F0OOtYbd5D23jLorXuO7wGRXXQYqTSMFYTRIccDpalLO1BGjPvbx7N95tlCH+DT40CS/qzRXdqmrffq/ooefTQKL6QbE7R9OWECZRhDo9EqSdJyP2E01ZWupLlWrwTbFH2BOmp3NroRLSLaKzAEHQUA3IQkbVQTSf2xKfJuKVoDYRjGOwwRsztlVCGW2DUhGt2lMrGRdZZ1sr3YrEUhu9uMRVeautHxTkQLiYyZltb9bkcb7HrS+fMAnwYHkvRnjY9pr92Nv/vv7nc7Jejuaz/07vTdf3aiO86Pi/8Liq4sdU7ibeF0l7GwoXLAccUpUiRJm/g0MYmHCUl6T5Em4tS6W3L/ePSozd8QzLeV/V2uXiWzR2UWYb/7B3haHEjSnzW6S9u04WR3TAaJOkP3zUSn6XgjMYXulqTl97hrdXe0GNqQhP3dorNb9nrzc4vuco+QKMNIF68TUrR90ZZZ9+Kh6i3raHkUxRgi5BtJ0mYWExWjfNOuGkTSdJdZXjL6XllKRNd506DXO3QEMSGStNDx6Wet82cNf4BuHJD0Z43u0u7qQPZxkhpskE6ijrp/Z6RJO9nozU6Slt8Sqo49XWk/Ka77jS9QB+zOCiTyaFf94kC2tMyD6Pd4sp8sYzcqCx2ahURj6qGMdK2If9q35Rcbn1Vg2S8na8m6N+1Ezyx9TK18cvhEnScD7xdhhD25OsBvEAck/btAsp/3uN1dIR1dIHrXdqhEx7KhOohawtpOH2sO5Wfv7vWHRNKJvEbZSRq02VdleOv0oewAmiDwaTbaNJs+zWaLVitAa0UqkyWbzZFOp0inXVJetzokSczx9+VuVNE4uF1Daoye2XoGxDHamBIxxkl4CvRO3wF+fRyQ9OcIyYrQn9Dk9+qh4yedFwkysM9Bd2kRO7/1SXF3//4FQM9WrhMLhcnsqIT/EgmnDUHLpQHPXD7V6g7ra5tsb++yu1ulXm+hVIpiaZCBwRFKpRJ9fVkKeU+c+dtPa02oA6ODtq5KJfaQ0GgcFI5yEkTdGzZ7PbNp0Lu+n+ZNOtpSb3S2B/3Fah2faxyQ9OcEGum0sajV9WxPJ9NdJJoMlbzkWSdJ7/2GhTxJxpn8Rne8+8fzuUPPVq47zesUJk9OB0nLq5agA9A+Wof4fptarcb62gYrK2vsbFdoNNv4vgI8lJMjkynQ19/PxOQwE+ODFAs5XBHApV50QKhDlNLi+c5RaKOdDrUMpY5ycay6w1juSFI7y7+7tpJI1ljvt+T32EolDpWkCEVCZ5O4a392f3tP0AM8Mw5I+ncMaz+rTQdRgHIcHGUkKmMVAODYxaaO7hCby5l+H6k0kh0tCSuRabMduWORyLwXv2nVAciXrVf6L1j3kzIWKCy/WYJK7MG2JaxEzxyHsIeK+TSaFdbWVlhcWGB9bY2tzW0qlTo6VPQPDNM/MELbh4cPl3gyv0I6neX8+bNcunSeyYkxivks6ZRDylOgjC22MouFZlefLCEakjY6aW0OC0BLHTmOY+rY1Gfi6gVF57qG2GIjudMaHYZmYDBt0LHfDAiDMPqm02HGgpSTGTy0/Jl4koBpZ/u1y27sR0293g/DEK21tF1z8YxxYNtJIp6Pg9ZdA5gJnnwvtLuczP1PirMX9q5GHOAzg20QaNChdBL5O654bcy27BU/sFu/OnXQIcbUy/yMOq35pWPx0ZBTNFBEl4nXXDZJncZXXxzYMjBD4V59vi3XqLDM7WQkkVU5+H6bzY11Hsze5/atWzyYvc/K8iKVSpl02mN4ZIhiqcj65jrvv/8eb7z5Jh9dvcn8wjrb23XqdZ/Al7pRjoPjCvElO/DekjabYcKAIPAJQ6smiROdDN+Vw+hmnKdYao7uaE0YBEIsiYdhGBIEAUEQoEPjFCrxrvypCW072VN2ndiPOPdDsm32Qnf77Uav5/uFs2S/X1xJRHk1ZN39nv2ZjPPT4ICkfwewjVp6lUwfZZS1RyxptDY+h9E4SuNEFnWmAYB0SWWlW5G2XOXiOi6OObIpEdh04KRdmG04JjabhgQHay1SUq+tCl8MRJmVhT8VzTNM83dBeXI5KbmUR6gVQQhBuHcZ1XU9SqU+JicnOXbsKKfPnObsubOcOXuG48ePMTU1yeDAAI6jqNZrbO/sUKnWaDV9/ECjjVYrOmy2ByUnYe8qM5tyHCstdgU0M68g1PhBiB9o/FDLMVyGOOWVvYSCqf9osEhE7igH13VxHDduU8jHtDkGLAw1gY6/Q1eZJfGs0mS3dJyEzUPyeXfeks+6f2qtCYIA3/cJgqAjvA0ThpogkIGqUzLuKKY96E5v999PiwN1x2cMKex46m2RmHlG5KyRxheRuZXmTOtXqH2H2Q4lhZ3CRjfMQIBMb0Ebcu6U5iQt0vEAGSicT9fQfjeIaSJZ4r0X4KR8Ldo+BFpuOa7k3SFA4aPDNq1Wg2azTrvdFlFKOTiOR6HQj+tkePh4kf/wn/6a//o3P6HR8Hnt1a/yp9/5E06fOs7oSJFS0SOVTgyixoWp1HrCXhqMukPSF3dXSyLJC/xQ0w5CglCjDYs4CjxH4ZnfMRIj2A04Jt/azORAyDgiMpvIRNlpGWxkhicae40CRwYRxzbbRKn2KvVfB0kVB3SS4H73u+H7Pr7vE4YhruvieR6u60bPtSaeRWhwXQfPcxMknywfW3Z7B4zu+8+CA5L+jCFVubfIo8m0mdLqMABDisqRp7aboEVTqUNot30azTrNVpN2IItQOIpMJkMhnyeTzuCaxkKYkCKVkTYQG2qFSNHyTNKio0YYN7IvFEdHHceWuil5M61v1OrUyru06k28VJpcoUQmX8DxUmjloq2Ns/npEBiijqUpoR5rJx3g+y22tyo8eDjPz19/h3fe/4hQO7z80iv80de+xrGjhxjsz5HPOjieKUwtqQsJ0QTRLEtoz26fUXspTwuNx2SdIGmthTSNxO05ipRjrK0j1ZkW+o8G+ohxIqHA3teRhaD8r7VI0qJaMzYvSt7rRdI2pt8UuqXlpLroaYlRJ6RoS9KpVEp07gn4fidJy6wiUQ7yW8c3k0gOGL2efxIOSPozhiW+JFXLNNyQdKjRoS8kjUa5CuVKo9FaNks4jicLWxpWVja4PzvL3Pw81XoVHMjnc0xNTXHyxAkmx8dNx4TA96XD2KmyuTQyXdWhpEk5bsfiUNRBEx3vi4FOkg4JCMKAoB1QrVRZeDLP3Zu3WF1aoVjs5/iJUxw+cpT+oUFypSLpjEhUvlEjOAR4ylh4dMxV0oBL0K5w//5Dbt2+x/zCCqsbZWrNkP6BIS5eOM+li+eZGBshk1I4InxHCLXG1z6BljpyHAfXMUOzmQkREbID2nje08gMyOjDQk2n2iGaiClc8ztIpdrflZKZVafNuNS0jvS0IRhLE1HLSTANaCXDlqwdykcSzetTt5luauomt09aLOwmzW4ST5I5CaLv/o6UgQ1r+o75acm6M6z4aVEJ1ZR91iu9n4R9JssH+O3DVlAs3UlHiVYi4g4TmYnJFQQ+ftunXK6xtLzC7bv3uXL1Oh9du8HtO3d5/OQJ6+vrNBqNji9GjdJGa74vRBAS6kBW8nXYqYdN+GySN76o0Ggt5ddsNNja2uTJ4yfcunWbWzducufWHR7ef8DK0jLVym6HvGwLIsp7qMH3CZoNwtYuzdomS4tL3L9/jxs3rvPo8UOUAydOHOPixfMcPzHD0Egf+YzCteNfspB1Qr8bfSSmt25/Hp1NRRaKbV25jsJzFSlX4TkK10i2tiVJOCtl2wXoOB3ytw0diplgEKCTC4fIFENZYkvoyZ+Oep4dvUi7F9H1IuVuJAnTqjm6F28tJIyoORwnPu1d4ukOLfesnl4bSxyJtvfg8Ek4kKQ/Q0R9wfaDqIfKaGmlJtENiiSNEhtaWWVKAVCp1FhZ2WRxaY25+SUePnrCxtYWuXyG6alxDh2aYPrQFIcPHWJ4cAjXSEQ6CI1aQ3V1QtGBivSlUI6Lcjy0kgYZGknaEZXjF2hkt+UredVWkvZD6tUay4vLPLr/gIUn82xvlWnUW6TSGaaPHOHspQscOXGMQqmI6zjiRIkQpQO57KpfUGd1ZYX5+QWWV9dYXV1np1xBeRnGJg4zPXOc4ZFR+vr7KBayZNMeKRBJOskHH1uocTvpGVB3yvXSboj1x2ZMCQ0pefsSqQbb7sxlCSUMtWjHHQ+lxGG25Xe7WGnjV063uaig9zf34mkoqZuAk6SbJO9kXEkCtlK4vZ98JwnR3YtEDPGgaBETcPwsScK/CUn6gKQ/I9hCTna3WFomOk402UHQAYQ+EBhP8lkAlpeW+PDyDW7enmVrp0KgFflCkSMz01x47jTHjx2mWMxHvcJFyYktumO+K2qVoA2IDax15aaVG1kFB2Hs0N5z5OpBE59TxGUZ+4XWMhyGIX6rjV9vsbW+xbWr13j99Td48OgJE9OHefmrX+PC8y8wNj5KqS9PLpPCBcKwDTrAcVOi4mhuc+XKZd597z1WV9colvqYnDrE8NgkoxOHGBqdJJsrobUm8H1SrkMh45HPpES/H5p24ChRbfdEstUkaS9GYAZTG1ahjYWPSP+BsfIAhecpvO4IondtOYWiW4seKzNAuGhlEmpIOgg1vm+m+I7C80RVY4axGL9hqkmSn7W8UEYy7tYr94IMPmK1AZBKpTqIU/Jk43R6qDY6fxcClr+T/JscDJI/nxYHJP0ZwRZysrvFJG27QPw3GJLWvhC1UuCl0a02t+4+5Ke/fJsrV2+jnRSHZmY4fuIEJ47NcPrkUcYGStF3W2EbRyk8tadbSvxBS346Drh2q3PcwANz6aiL7kcTn0fEZRmTNAlnRcY3dLPG1Ssf8Q//8GNu3LhFOlfi6OlzHDt5hiNHZ5g5cojRkX5SJtNBu0Hgt6jVdllaWODtd97mrbfeYm19nbGJCU6eOsPo+BTF/hFyxQGyuSKpVIZ0KkVfMc/oYB9DfQVcB5r1BvVanUarRdP3aZrFX1n20yh8nNAuWALKwfVSZDIFsvkimWwe10vhuAnTSR2AkdgcJcN/qMEPNK22T7VapVqrEvoBKc8lk06TSafIZtJkMh6uq0yth4ZtbM1L7duhLvppTNRkvcQsrtlFyqitRNPH3zgs2VopdT/dsg2TVGu0220ajQbNZpNGo0Gr1UJrTTabo1Aoks1mjSokVud0wxJ0aIpLwtpnnbrs7jQ9DQ5I+jNCkqTtTy21C4gddETSOjTTTnOFog8Mg5ByucpH1+/w1z9+g8s37zE6Psk3//ibvPaVV5maGKMvlyZjvuGHPmEQ4LourtODpAFom+8oo07ZXwKxlCcEQMd0+vMJS9Cii9ZolLLnoGPy6oFusPDoCdevXWP2/kNW1nco1wNSmSKnz57l5Vde5tSpIxTS8pbfbrIw95i7t29x585NLl/+kGvXr7G5tc3A4BBThw5TKA3QCh187dLXN8jMzFFOHD/G0cOHOHF0mqmxYRxCtjY2WFpaYWVtnYXlNVY3t2m1W3iuS8pzUWEbggZO6KMUuJ5LNl9kZHyKqUPHGZuYpq+/n0IxSzqS9ESFJXygzOUQaNjcrnDv3n3u3btPrVqlr1RifGyEkeFBxkaGGB4cIJNLgxOadmHKKCF7a7OY2iG9m8mAwthyd6hUpNV3bqSK8WmIy5KfNSXsRcrJe2EY7rHiAKjX65TLZTY2Nnj8+DGPHz+m1Wpx9OgxnnvuAlNTU2Qy0qO6k5n82+qgMSqOpNQdU2xvkv8kuD/60Y9+1H3zAL9ddLdVZSo8NnwLzFQzNJwZ0m422N3eZnV5hdkHj7l57yHLG2WGx8d56eWXeOHFiwynXOPyB2PGZ3aOGZOrIAhpNFvUqzXq1Rp+swpBE4K2GQTa+EGbWqtJpdGi0mxRa/s0/YBWKIuJIp2JSeCnaG+fC0hZ21oIQYlZXSaTIpvNUK01eTy3xMLyKl4qy+TUIUZHx8gZkg4DzerKCg8fzvL48WNWVlbY3a2gdUg6kyWdTtNq+2xsbbO+sUmj1SKfzzM0OMDgQInhwRJ9xSyKgGp1l43NdebmF7h+8zZXr93k4aM5Nje22C3vsruzTbVcplYpUy5vs7W5wfb2DpVqg1ojoN4KCLUmlfJIZTO4SiHqq7iVhaFPrd5kc3uXpaUV7s8+5MHDx2xubgOabDZDNpuhkM+Rz+dIpTwjHLQJgxaBX6fVrFKr1dgqN9jaaVJrBARa4bguKlqcVLhG2rRtI2E4ui+6yfVpkVQj2O3qybi6STopSbuui9aadrsdEfXi4iKPHj1ifX3dSNNZHLM1HjCbeSQ++xml4nRos84gYaQc5FH896fBgST9GSFBCcKbpgFL9VnJ1Ko4pIOgQnAVaJ/d9XXmHj7i4YMnzD5e5ubjNdZrIUdPn+Q7f/ptXn3leQZM/EEILhrXgTDwqdbqlHcrbG5us7CwwOL8PI1ahdGhPo5MTzA02Ec6kyXUinK1zoP5ZWbnlqg2WuTyRUZGRhgfG+PYzDQzhyYoGsniiwHTgcw/IQ3ryc4MhGEbv9mkXq2xurLBO+9f48e/eIcnC+ucPX+RP/vun/Pyy19iZMglpSBoh2ysrzA//4TV1WU2NtbY2d6m2WqSSqfI5PJox6XWCGj4mkw2z8T4BFOTE4yNDDI+3MdAKYuDplGvs7a2wbVrt/n7n77Bex9cww80h6YPcezIYSbHh5gcH6BUTNOoVVhdXmZjc4udSotKyyGd7+PEyZO88OLznDxxlIG+PNmUwnOJFprbjV1u33vAtZv3WV7dxPc16UyOYrHI2OgwkxMjjAwNMNjfR6mYF61X2CRs7LK9tcnCwiJLy2ts7NTYrmoClWVkfIJT505x9NhhCmlx/yRt2TRwWYJOELb5P8k2huCelqRj1YGYy/26sCTdaDQol8usrKywsLDAxoYMhM1mk3y+wKlTpzh//jwTExNkMqmIjLW2C4uC3vmIybnn46fAgST9GcHWj9VwaFOpTofkoaUVW3WHg9hDq4Dy5gb379zh7q3brG7sEKYKDE4e4tDRoxw6coiBoUFcx2yzCCDlKtmooGB3t8Li0ioPHjzkw8uXeeutt7h+/SrVnW0yroMKAmqVXdZXV5mdfcDPX3+Lv/77n/H2u5d5+GSRcqVOEGj6+6RT59JGpPxCIKKOhHSnpKx1AGELjN4+k8ngOi6ra5vcm33M6sY2ff0DzMwcYWRkhLSXwdGyMaRQKDA2Ps7RY8c5d+48Lzz/Ii+9/DIvvvgSFy9d5MKFS1x64UVefOklnn/+eU6fOsX09CRDg/3kcx6uI5uOvHSe/lKenXKVm7fvc/feI8IQpqamOXXyJOfOn+XlV17k+RcuMDk1QTrl0Wy0mFtc4fK1W1y/dZdqo0Vf/yClvj4y6RTplBLnTThAm92tdT744Ao/++Ub3L0/Sy5f5My585w9d44Tx48yNTXByPAQhVxGyC9ooxsVajubLD55zPWrH/HBex/w4eWrfPjRTW7ff0yt1WJ4bJTpQ9MUPbGbtoKHlK0IHtIGY0uP6JeIuJK7KPcjuqS0GhP1fmGT+LjwVqpOp9Pk83lGRkaYmpqiv3+AlZUVPvjgQ+7cuYPWmpGREfr7+/C8VIfFRhDEunDXNQu1xgTPZqtb+n5W/PrD0QGeCrYZmia8B6E1gg+M45xEQ4aQVrPO1sY6K0uL7Gxv4aVSDI+OMTQySi6fl5HdvJLUByqtCfxAnNH7Pl46zeDQEJOTk0xNTzMxOcHAwACB77OyvMSjhw+Yn5tjfX2TWr1JJptjbGKciekJ+gb6O7bMflGgTYe0GxJMl42fai1mK+kshUKeXC6Ll3LRBDSadXbK22xtbbK7u0u73ZZB1XPw0mnS2RzZfIlcaYBCaUiuwhClwgCDhRIjhQIj+SyD2RTFlEvGdXCVRotWVxbjvDTpdBrPTeEoWaBzlIvrpsiksxQKBTK5AUYnJzh54jinTp5geHiYZrvN8uoa84tLLK2ssbaxRaVaJQxksVm3ttheecKTxw9ZWV6iWqkAUCwVGJ8YZWp6nJHRQQqFDJ4j84pGo8Hm+gaPHz7gzo1r3L99k+X5Ocrbm5S3t1ldW2NxeYW1jU3qjYaZnZiStEssZiBUvwYxWViS1VrsyC3hVatVnjx5wvXr17l8+TJXr17l1q1bzM7Osri4yMrKCo8ePeLy5cu8+eabvPXWW1y5coV79+6xvLxMrVYTIcmoSVKpFNlslsHBQSYmxhkbG2NoaIhcLkelUuXx48fcu3efpeXlaP+BMqoNGYRiR2Sdz+K/Py0OJOnfBZStRPlTAzoMCAPxU4zSOI42Q6iCsMX28jJ3btzk/r1Z6m1NaewQYzPHGZ2YYHhkkFIxR0bJWdaukgtAt32q1RrlSpV2GNLf18fRo0e48Nx5Xv7Si1y4cI7h4SG2tza5f+8ejx49YW1rF53KMjVzhK9+/av8yZ9+m5deep5Dk+Nk0ynROybz83mHIehQh2aqajuPmbUQIvqBNCoMWFha5t7sQ9Y3NsnmcgwNDVEsFMhmPYr5LNlsSjjebjzsGFA7YZd/fXx8WoQ00bRQZiFQLCYCVlc2uHP3EQuL63huipHhEUZGhhkc6GNooEh/XwZUmkJ/kWI2y/pWmTsPnrC0vk2h1M/U1CFGhocY7C8w1Jcl7QSsryxy9/YtZmfvs7y6ga9dhkfHOXvuDGfPnWZ8fIiMbF6kHWga9QaVnR1WF+eYvXWN2zeusDD3iHqjjuul8LVLuR7S0h6jExOcO3+G4ydmKLiOKI60WTRE4TjimGnfgnkGyAArC79Wl7y+vs7Vq1d5++23uXr1Kvdn7zM3N8fqyiqVSoVyuczDBw947/33ee/d97h9+zZzc3Osr6/j+z6FQoG+vr490rVFEIR4nkehUAAF29vbbG9v4zgOAwODFAp5MIuE1jGaHf7j+3bHYSLiT4EDSfozQlRPHaveAhmBbRWLrK1F/DM60wC/1aJW2WV3Z4dGo46b8ij191HoK5Ey6gfbRKJGYfQqnutRKOQZGR7i2LGjPP/8JV586UVOnDxBX38/odZsbm+zsLjE2vo6qXSaEydO8uKLL/LCi89z7vxpjo30M5jx8IxKpdds4PMMW5xi6RFPRWVObk3MHJTnksqkyeWzZHMZNAG75R021tfYLe/Q9ltxrwnNKq01kAkxqiofTRvfXAFNAlqEtEWC1jawuUxiXNcl5aXMlNoVU8FQE0bG6i6oHKVSiXyhgJdKg5le2/w5ZsdhGPiRO9WHs7NUq1UGhwY5PHOYickJ+vqLZEyuQRaaxZGQLztaQ59ABzieQ7GYZ2RwgKGBfnK5PMrxCHFMluP2YC8VLYI/HSJp9CkuG77dbrOzs8PS0hL379/n6kdXef+997ly5Qqzs7MsLy+zsbnJ9vY2m9ubLCwscPPmTS5fvsy1a9d4+Oghq6urNJvNyE7aIp1OMzY6yqlTJzlx/DjpVIrF+Xnu3LnDwsIC9Xq9I7wyO3KtJB2ntyPYp8azk/QXrXd+5kg2171QUSOWIMbhXbTi7Lqu6PHCAHxfWKDtE7ZatOp16rUa7VYLz3PIF3Lk8lnclGekNcMVdh+CBuU6FAp5xsdGOXJomuNHZzh65DBjoyOEvs+Th4+5+tFVrly+xs3b91he22JweJTXXvsq3/rWtzl39iyFfC6ilBjJfD7N1flmgqJ6hLCh9t7dg6cIgp3WuuJ3QiQza4+McfBvLtclnc1Q7CvS318i5bnUalW2Njcp75Tx234cr5O4TIe0Ul8Q+btIbgMRHa2sQyReNr052lihwXNTZDM58oUixWIfeCWJIaiyurHB+qZRv7TEXK+/WGR4cIC+vj7SmQyh1uxs77A4N8fS/AJ+q8XwyCjTh2cYGB5BpVKY1kVoFuIy6RSlYoHJqUnOP3+J1775DV77o69z8eJFZg4fYmRoiEK+gOOmCHBoh4pWIGNUiBFAfkPElIQyG1Ssqk0ZB2Kjo6McOnSIgf4Bdstl7t29x907d5ifn6daq1LqK3Hx+Ut8/etf59TpU7Tbbe7cucMHH3wQEfqDBw/Y3d3d871CscD46CijI8O4CjY21llcWGBzc1NsqU3YQGupa2TmKz5UOqKLm7Lpl7ZvPlXbfWaStpE+ZeS9YNPWfe0b6AuFj0+4Sl7KBhUxSHX47FVmH69xaBwE6HabdqNJs9HA99t4nkM2lyaTy+CkXEJL0OY1cZgEKIdcPsfI0ACT4yMMDwyQS2fxXMX62irXr13nvfc+5Oade6xtlsFNMz1zlC+9/CVeeeVLHJmZIOUqWkZgtPkQdNfifpeE1V2kbK+9bbY7RI9bnS/sCxtE2U0Ojlijh1rctGoc2WlpN7YoBy+VplAoUCwV8DyXZrPBbnmHWq2G7/cg6ahAjO2uDqMDHKybWBeFG51UaE3F7ItSClblFfpi3x4EAX47oNn2IWwStHZYXFjkweMnrK1voLWmr1RibHiIibERxkeGGewr4bopgiBkd6fM2vIKG6trhEHI4PAwY1OTFAf60Y5DE2hFJK1Ipz2KxQKjE2OceO48L37lNV569cucPnOGqfFxBvv6yGZyOF6aEAdfK1phTPSR5GHy89SV9BRIxqRRZHNZxsbGODpzhLHRUcIgZH1tjdXVNSrVKq7nMTE5yUsvvcQ3vvlNLl66RKFQYGtriwcPHnD16lU++ugjHjx4QLlc7voa5DIZBvr7Gejrw1WKSrnM5uYGu7tl2u12tAvXDwN8Lf4LxTVsV/NM/CGz4z2Z+US4//pHP/pRkvhl2h27MrTYd/oS+WeR/ztCJb3yJH6N05nU4nS/a0LYuZzpaL9bfFKJdpZZb3SWpNLEJnhJp9L2pwO0WqwvLHL96jUePHyEm8szc/Y5jp47T//QEOlMCs91ZMuBMnsGtZK4tSipxQGONp2nydb6KlevXuONt97l2q27lOs+Q+OHOHn+Ii+89DLnL5xncqxEzgh6MY3tPf0vmudFOoSu+jbSRmCJUSm59pSW3LG2AFprmvUGuzu7VMoVGtU67WaLwPelaBzj/e0T0NHGzKksyhJ3NI32jMlayOr6Bk/mFtnY2MJvy2agbCbL6PAQ05MT9Cd2dEbe5qL+YhZ9jZ9mpSQ3SaE73lmKlKr2WV1e497dBzx5skiz0cRR4rWwWt2lXN5meWWZe7Oz3Lh1m/sPHrG6sY3jZTh86DAvvvA8Lz1/kWMzU4z0FVBOiL+1xZ3r17l6+QprG9sMThzi2PlLTMwcpdjfj5sWl5y29GQzVYijQnC1pNRRpHSbVqVKbbvM6nqZR8s7rFfa9A2PcOLsSY4cO0wh5Zi9iEZ9ogMa9RqLiwvcvHmLj65c5caNG9y5fYc7d+5w5/Zd7tyV32/fus3Nm7e4desWd27d4e6du9y5fYdbN25y6+ZtHj54yOraGru1Kq12Gzfl4XkeQSD+V8rbO6yvrTP3ZI7trW0Ghwa5cOkil55/gaNHjzExMUk+X6Ber7O6usbu7q64BPB9/HZAsVhkanqakZGRqE7RonrylEO9WuP+fZHQ6/Uah2dmOHP2LEOjw+A4tLWPVmKT13EgQqILiGltZ8/vGKMl0L5w/+pf/+hHyQAhdoulmQom0IuoNUgio44rUMnjncxrEtZ2Rduk7bsmmDYN3gwW0vbjTtUjCU+F7rzw8eXyMegVk4V9tn8Yyaf9ss2XlJ0Uo/FmZGvRAVpN1hcWuHb1GrMPH+EVihw7f5Gj556jb3BQfOAqoZgUkFLSz1RoFGVKg+MDDVqNMlvrKzx++IBfvfMeP3vjbe7PLTM0fphXvvYtXv3aNzhz/ixjo4Pk0l4kKFpycbSxNbaVpTFzOFujycoUhDoUiSOQhTvMYouFvCW6n6ieUWgdsL25zfLiCuurG9R2q/gtHx2I6ZTnpXC8j58MJtsaEmtEzjFBq8R2eM3q2gaPn8yxtrZBu+3juSkK+TzjYyMcmp6kv78vijwIieYIOtqWbNQrdhEtKkNZXpLUBOanQgdtVlbXeXD/MfNPFqiUK9RqNbZ3tlhZW2F+cYGHjx9x6+49bt+bZWl1jVQmx4kTJ/nSSy/xpRef58zJY0wMD+CmPGg3aa2vc/vada5+dJ2tcpWRw8c4fvEFxg4fIVMsiAtcI/SY0kbpAEf7KN0GpwV+ndZumdrmFuWNbZbXdniwtM161advZISTZ4SkiykRECSPmjD0KZe3uX3rFr/8xS/5xc9/wXvvvsfVq1e5+tE1Prp2lavXrnP16lU+vHyFDz/8kCuXr3Dt6lVuXLvOtY+u8eEHH3L5w8vM3p9lc3ubVrsNjkM+nyefy0OoKe+U2VhbZ31tndXlFVqtJocOz/DaV7/KK6++yuGpSdKpFE4qRaPeoFFvoIDAD9gt71Kv1xkYGOT4iRNMToxHbUZhDi/Aob5b5f69u9y9e5dmq8nhozOcOnuGweFBSDkE2kcnFg87OFKLdZVKCC+KhK46ETRCj3tOtwAUY2/oSKpNtvrk88Q70nDNlejA8d1Yiu6MqjNyG6M2huM6CNGR+PJ0eIagH4OnjSWZq/3fsdRgr84nRuZSyjgdllCRmV4opWcfJ8cubcoqqlct5AcBQbPG6tICt65d5cqHHzL78CHlepNUocT44RlOP3eecxee4/CRw5SKWVKJDcFukqDREMp2dVkEQxbfHFeuSN8qqVKWtBxHfGOrWJaM9dJ7W0Pgt9na3OTRw0fM3p9laXGZWqVO4IcoLSRICH6zTWWnzPbmFpubW2xtb7Ozu0u12cQPk8KG/CYdxR4v1pnWuNziDhcTa1d9dlWezIbo7LDJV6PXO+OxgzQ6QGtZWXCUSHOu64lvjnSGdK5Aoa+foZExZo4c5cKF87z0/EXOnDzG2NAAXtosA2oZPUI/JAxCmZorFzeVwUlnUJ7MZOKyNymKZlqyWI1xT0oQ4mgtnvs05kg1+475ZPJKbNm2TvX9tk+77dNut2m35Gq12rRaLbnabdptOSXFb/u0Wy1azSatVtOoF2SAl2+aujJbsRWKVCpNPpenVOpjcGCQoaEhW7y4jkM2n2d4ZITx8QlKpT6CIGB3d5dKpUKr2Uq4h03Ac0h7KdJeipTr4ig537Jer1Ft1Gi1WyJkWqGioxzkMI2e2Of2fthD0o5Sckae64iLRjNdw9gp9iJJ2yAlZKLBi+Ik0RTkdzkeqPNddGIQQFq7ODO3esTOs8h075HlmfDsMTzrG8lq2/soJgE7S0icwmzLQilwHXClHDDG/4Ef4Lfb+L4v278NwgDabZD1J/NtJfG1q3Ue3rnHT3/8U/7+H37M/MIS0zMzvPqVr/Diyy9y7Phhxsb7GUhDNsE/jum/ER/pEB348qEwMMRsDiLomNiLksQhRdpNk0ulybkeKSXSZdQiTBsUgovLzG82WV1Z4c7t29y4cZPFpWX8ICSbzZHP51EpsR+rlMssLiwwe/8+N2/e5Nr1G9y9f5+19XWRwGyyIwsabKnL/cT/fhifY6eUI07uzSEIySOlbBTiUEiJgyPXEr/ptGZtIAyMCaAdYKNEKLNY6aEUtNtNWs06Kc9lcnKCSxcv8rWvf40//e6f8Rf/+C/5b/75P+Of/4t/wT/9p/+UP/nOH/PCpYscPjTFQKlAysHUhy/tKJXGzWRIZ7JkMhm8dBrleuDI+oW9kilRUfc1daDFd7Rs95ZzMyVfUmGO0nL8VqKVh6YtZ3NZDh8+zKtf/jLf/bPv8sMf/oAffP/7fO973+fPv/c9vvvd7/Ld736X733ve/zgBz/ghz/4IT/8wQ/44fcl3A++/32+9+ff44//+Du88sqXOXPmDFNTk5RKJRyl8IOQtu8T+D5aa1KeRyabJZvJ4HpyIIZFyxe+SKdT5HL5yGkSKIIgoNVu0WrF7SSCAs91SKdS5DJZ0l4K3/cpV8rslHeoNxqgHVxSyJ5L6XPCb+YyqhCwJiC96eDjEJF0suHIdFAanJCHjdzqiOMvJZpsD8Qdzl5JCTqidm3CGhWHfWpFEzstk5Ez9n/8tNgvjfvd7424U388usPYdCbSm7gloU3cXWUdBVQOypHNDSkvjet4hKF4NGu3xWlMFLXpWyB6RgjQ9RrNjU2W5pa4d2eWq1dvcOfuLEGoOX36DK995VUuXjwX2c22gUo7oNr0abZFErMDCtocwxUG6KBN2GoS1Gv4zRrtdgO/3cD3G/h+nbZfo+3Xafl1mn6Lhu9TD0IaYUgz1PjGQY8GqWcw8kgAukmjVmVrc4OlpUWWlpeo1Kq4KY90NkMQBDS2q2wur7CytMzK8jKLS4vMzc/z6MkTHj1+wuMnT5hfWGB1fZ1qrUpg/GnbUo9rJC5rreV8wCDQiGWWg+uk8Lw0juvtqV7Hjq1WhZPokHHfijfRRAMnmHTIgKaMlNZut/E8j5GREY4dP86Fixd55cuv8LWvv8Y3XnmZb33lNb7+2mu8cOE5jhyaYmigRDaTkim134bAl6bkuripFF46jZdK4zguWkNgDsJNorNlJx/aviezH7AL2uJbRqE7TnuJ3nQcMpksExOTXLx0ia//0df51re/zTe/9S2+9a1v8s1vfIM/+sYf8Y1vfINvfvObfOvb3+bbf/xtvv3tb/PNb32Tb37rm3zrWxL+K1/9CpcuXeTo0WOMjo6Rz+VQxOcORmtnZmEYheicg3iB1w98gjAwDpA0riubV9LplCHrzu3dEUzbtAfxuq6LDkNa7RbNVktmdLIMHLUoS86dDGVLOMGdXXXwcZB8KTvS211ZySAmAfasvY7ZYaKZm62QcqquIXPDOVFYJbEZ2TlGlP6O0SJ+pqyJWpcFxDOgO3T330+PKEM9YO/bMD3CdvYBQ8wyyAaYxTVix0jGWzuOcsimMxRzBXKZHI6Twg9kE4JvT4BAhO6Up0llgLSClGJjfZ0PPviIX77+DjdvP6TRdhkZO8S5cxf4yquv8NXXvsRz504yXCrR1gH3Hz7ml6+/xc9+/ia3b9+nUmmYtIrdLmhIpVDpFM1GndkH93nzrTf58U9+zD/87Kf8/I3XeeeD97lz9y5zc3M8eviIGzeu8+GHl7l27Qazs3MsL2+xs1PDbwW4CjzT2NEa3W7SqJTZLW9Rr1cJdICbdsmXCpQG+8BV3Ju9x9/+3d/wn//Lf+b9995ldXmZZr1B6Af4rTbra+t88P6H/PVf/w0//cnPuHdvlkazGZG0zMYC5IQ+HdWT40geWy2fRrONH2g8L00mk8PzUsZyJlGHe3qbVQUIe1tJXClps3G7NeVo3nEdB9dx8VzPEEhGZgy5HPl8FvEkbuo42QURUoxHC4lbBpuAtt+m5RtVQlssR8x+qcRisHRgHfiEvp0deZDNk84VSGXzOF4a5dhBKsRVmkwqRS7tkgMyZj3ExcFVsl6Qz+cZGhpmYmKCqalJpqYnmZyaZHJqgsnJCSYmx5mammR6eorp6SkmpyYZn5hgfGKcyUNTHJo5FC3qlUpFspl0ZNetCVHGLSoKfL9FoyFnfYY6lPsG+UwGz3VptRpUqxUajQbKgUxGHEtl0mnjVKoLvqbVatNstWg2W7TbPko5ZDM5crkc6XRaDkAwNRnLzwa2HUR/R6ZXPdrN/nCsnxJtvKRFW2dNHAohEqWMGwlXmVmtKKi0GRVikrbSbiKCLq7aQ9SajnFHS6D4Dy1TKNfz8FJymu+zkjS9k/KMeJq3k1/pvgw6+6fRD5pDPSOpy4phQtiu45LP5ugrFMnn8ijl0mwFNFsBfiDhlXHMn/ISLOI3mZub441fvcs//OxN7swukMkPcuL0BS5deoHnL5zj7MwRRtI5QtqsLi9z5fJVfvzjX/DTn77OzZv3qFQSxvu2kWkNgc/W9ha379zm9Tfe4Mc/+yk//eUveP2tt3jvww+5cesWd+/d58bNm7z77nu8+eabvP/+Ze7fe8zK8jaVcoPADyLFCDhoHVKvV9naWGNzc41Wu0GumGdgZIjh8RH6h/vRnubB41l+8vOf8A8//jtu3LxOtVrBc13yuRyZVIZqpcpHV67y1//1b/iHf/gx9+7O0my0oloIIq9oduIvFeI5DqEOaTRa1GoNfB9SqSz5fIl0OodGJczw7HtGMookZ4XWQprKcXFcT9QhkZ9jom5t9yTaU3McR4arIAhotppCPPV6ZP4YAE1jDpkkA5RjyNox6goZhAId4gcB7XaLVqNJu9EkbAc4WkckHbXOIED7bWOfD5ijd1uBpuGHNH0f32+jgxY68NF+0KEziVu6DDgpLy0DTaFAoVikWCxSLBUolszPYoFSqUhfX5FSqUihWCBXyJMrFCj2legfHKB/oI98IU86nRL1q60preWYME8UZ81Wg91KmUqlTK1WpdVqRulyAT9oUy7vsLGxQb1eI51OMzDQx8BAH8VCnpR4pBJoDYFGt1o0mg3q9QaNZhPfD0il0hRLJfr6ZGOP06U+sl1by6m8cZxd/bmTYD8eDhhpN2INwZ53oxpIMox9187UDZlHL0dJjsMnyFnSbKRu7HS/092gtj4XosHDPOtM7meM7grYD1GhJf4GsGojmw+hWLGzjMshWowzU9dMLksun8fzxMnOzvYu5Z1dWi0hH9vpdNgmqG9RWX3MvZvXuXLlMh98eIWPrt1kfnGFliEe3w9YX1vlweM7fHTnCm/88uf88hc/4/LlD3ny+AkbG1vU6o3OqaCjaDcabC0tisOnu3dZXFqiUq8RKkWuUKLUP4hy06ytb3Ln7j2uXrsmvhVu3mJ+boFatYHrpEh7GVzldjblQFPe3mFhfp75uTnq9Rp9A31MTk8yODJIKpvGS3sUSgXGxkaYmp5kanqKialJxifGGR0Zpb+/n5SXplqpsrS4wvLyKuXdKkEgbc9B2qrWobhn9a3FMIBsdGk0GtRqDUINuXyR/oEhiqU+0ql0Z/vu6g/d7TI6nHWPrt6RRVe/wu76Oqura2xtbbGzs8P6xgZz8/M8ePCAJ2Yrc7Vai+2RbUsKpbyiVS9lzjdzHVTKI5XLki8VyRXygKJWrbK7U6ZVq0MYdkjkCo3ryUJlq92mvLzC/O07XL9ylStXrnLl2nVu3b3LwtI8W5vrrC4vcvf2HS6/f4NrT1Z4sLzOyvom5WqFtu/LvMisbSUv2VXpkU6lyaTlIATPFcHLcR0cz8FJObgpVy7PxXMdXLOOEeXd0oDWcmZls0mlUmF1dY2HDx9w48YNHs7Psbi+yuzcYx7MzvLgwQMWF+Zpt1tMjI9x+vRpjswcoVQqmpgFYRAQtts0mnIYQBD4KKXwUiky2SyFfIF8vkDKkbUEaQFWZjYnIO2HqH+bv5+Cx9x/bX13mJUhZfzCOnbBMIIZBSyU+SDxFM6JHJZIpUvSJRUSJnFpzMqzjCyOMguV0bTNLJAFsi02UsNEmTLp+5jy+O3Cfjg58exOTFeeMQOomanEekoJa6fDYrolhChlEbC7vcn848esrq7SVh6qMIjK95HKZOgrFhgo5ckrRRpot6osL8xx46MrvPvOO/zqrXd4//I15uaX0MplYHCQfCFPq11naWmeGzeu8frrv+BnP/kJH7z/IUuLKzhOivGxcU6dPM6xY4cpFnOSJUezu7nOjRvXeO/dd7n/4AG1Vpvi0AgzR09w4dILnD17nkK+wNLSErdv3eL+vVnm5ubZ3a3S1zfAyVNnOHHiFMNDBTLGzaX1NRK2myw8ecytmzd4/OQJ7VAzNDrO9OEZpqamGRgcIJvN0FfMc/jQFBeeO8/FS5c4duKEcTZVQCmXarXOwuIym1vb9PcPcf78c5w+c4ZS3njwU4AO8Nt12u0GngdKpYGAJ3PzXL16i/n5ZQr5Po4dP8mxY8cYnxhlcLBEPp82rc/WXly/YLqK/UbXWpHckrCtZpOtjS3mnsxz88YdPvjgKjdv3WN1bZ2d8i7Veg2Upn+gn4HBftKZjKhFbPsIEM/7CY6WLe6KIGiwvLLCyuoafqgoDIxQGBglncmRy6YpFbLkPFcGdUIcpfGUh3IV1fI2s7ducuWtt/ngV2/z3jvv8cHlq1y9dY/Z+SXWdnapNVpUKjXW1zZYW15ld3ubdlNM3LLpNFnjzlaErOTZmoJ45tzNMwZRPxd9c2f5QbPVZGd7m/W1NRYXFnjw4CGLi4s0mg00UKnVWFpaYn5uXtRtxmZ8YX6evlIfFy9c4Etf+hKnTp1idHQ0cuyPJrI+adTqbG1s8ODRQ+YXFnA8j1Nnz/Dc85cYHxkXCd28pIy6zuqn7UJ7xA6W/8ziv/TtHjnvccsOTpEU3PvduCFIoXU+QouNrzK84piRwjxCd0wo7XtG5E9aikREboKYcNHCS4+Fy98tkgXRXWideYnv2QYq6Zc82stWqyM6QWst4Sq8bIriQInBkUHyhRytVpOttQ12NrZoNxo4xlROAaHWNBpNtnZ22NrepuX7FEtFxicnOHT4ENPTU4yODJPyXMo7OywvLrEwN8/S4iLbm5ukPJepyXFmjhxiZHSIdFr8ElvU61UeP3rAlSuXuX37NtV6g6HhUY4eP8m58xc4e/Y8k1PT6FCxurbByuoau+UKgR+Q8jyKhRwD/XmKOUh7Rhg1CNoBO9tllhZXWFpaoe0HjIyOcOjwIQaGBuQMPaUYHZvgwgsv8MKXX+HY6bMMj41TLBbQGpqNFkGgGegf4sjMcWYOH2VwYAjPjfWOjnKNFBSidZvAbwEN/KBOo1GjVqsa3aVDqdTH0PAI/f0DZDKZTlqxjTxqj/HiUXIQ1lEfUNGcJwwUzWZAvd4m1IpSX7/Ry45R6i/iphQaWQRrt30CPxBPcLbjRuqVODkChUqlKA0OMHlomsnpSdKZNDtbW6wsLrKztU3Q9hOStE2hC6QIUdRqjcikcXu3Qq3dRqU9BocHmJ4cZ3ighPbbbK2vs74q/rRrtTqtVstskxZYkhbnVsk2n+jTidKLC8vstDWCXHcWrfV5xAnmW+1Wm3J5l/X1dZaXl8Uj3vIy5Z0yCkVfqY/pqSlOnTrNmTNnOHToEPlCIRkxWmuqtSrr6+usb2wQBAH9A/2MjY8xODRILpeLrOptS5A66STqGCZTVop2enHD/lC+LHnKH1hJ3EQQFYBM6xQmQBQaCLVMuUwilFLG0kSbqZ4ZMxWGhKwpipbpmt1ckNg9FlWaWTRDm7jN96M0RnlNVKGdanTf74mnLyiLT4qxM4TE3/GVqLFqQKHNEbRWzYtZ/HMcjVJtmYYHZTbmn3DroyvcuXWPpa06G36BoDjG4eMneOXLz/Pc2RMMGqJu+w12NtZYWZxndXWZtdUtNjZ3abRCiqU+RsdGKJSKsjPNb9JsidPz8m6FUCsKxUGGhscYGR5lcmKCybER8jlL1HWe3LrB//F//Ad++rOfE+By4Utf4Utf/SbHT53h2PFjFFIus0+e8Pd/87e8/eav2N7cIu2lGB0Z5bmLl/jaH32T5y6cxwq1QSh5BqhvbvH222/yi1/8nNW1VU6cPcuXv/4Njp86TamvRDrlkXG8RDcQva7fqLGwsMKVj25x8+Ys5UqdTK7I8MgoU9OTnD59nKPHpinlYqLWukkQVAmDGo6r8LwU29sVfvaLd/l3//5vuXHrMWfPXeIHP/xLvvLaq4yNFshlEHM3NNqYdsmCuqTH2rJrRKrVjtV1ykxUEZLCOM1qNqlWa+yUd1lb3WBufpmVtU0azTbKcckVC4yOjXHk6AxTUxMUiwXSKQ9XyexDjjK0G6K0lIUXAj7t6g6PHj3gzp17PJlfYX5tl62apjgwwksvv8RXvvIKhwbyOEYaVPjmiICARnWTlbknLM3Nsb25RXm3SrXRpu5DM0wRuBmcdJZMLk++WKS/r8TwYB/DA30M9JUY6CtRyGWly2stJqLGYgzLDYaclVIiZUe1YotK1j40oB2FjjYHCXZ2K8w/fsyDe/e4fu0a77zzDrOzswwMD/Hlr7zG8y++SKmvhO/7tJot/FabVrNJyvWYnJzkxIkTTE5NkcvljGVOIgWhZvbuPW5dv8H84yesra9TbzYoDfZz8cUXePHVV5gYHUcBTdPfRZJO9HXrEkDL/gJIWv90k0ICPe6rVhhohT2TLFFYGjF1s05i7Mp0UtrVGm1GO+wJC2aksAUrdCTbgTEqPEebKQFxnNosoGmJVhIXy5UfA6sXRN6I9EHJ+/shkZenwCfF9nGIv2KXGIjG4jBUBLJ3AIUcDO66GJKuQXuHyuYKi0+eMD+3yMPFLe4u1thsekwfO8ZXv/4qL77wHIPGVSlolPYJwzah9gl9TRhI2SjHFXte14lVUlrH42GkGxcTTNeRKbFnp0rhLo9uXOXf/tv/H3/34x+Dl+O1b/wjvv7H3+PE6TNMTY+TcuDBo0f87Mc/5cP3PqTVbDI0MMCh6WlOnjrJhUsXOXrsCJ5tRoAKNbR9NtbWeOedd3jjzTfY3Nniwgsv8M0/+Q4nT58m46YI8HEQfSoEhEGDeqXK5voWs7NPePNXl7l2Y5ZMro8vv/pVXvvq15g+NEGx6JFOi0dSWxeKNtAA6vjtBvV6nZWVDV5/8zL/5a9f58GjVS49/zL/5L/5Z3ztK19mqN+0Ry2SXtCWAddxwUlJJYfGzlqj0I5rSFqJqKJDVBjihhrXSMSgCJUsNMrisZRHCJHQ47hmI1BCeov0nrZRmg1LqABoETSqbO9ss7y2zpOFFS5fu8eNu3OoVI5XX/sKf/ydb3Ps8DBpIws5+DhKDrxFG7e5Zj+C1iJMhLiEeHKZrf04QrQucnSWnUkLn0gf74Y2i+QkOcD2EWmSsl5g1kK0I2oC+Y5gZ3eX+cdPeDg7y+2bt/jgww9YmF/g8JEZ/tGf/xlf/frXKRQK7JTL1KpVctkcA339lIpF0umMHC5rnfQbfrPw2z4fvvseb73xJgvz8+RyOSamJpmcnmLmxHFmjh+jf2AwGuAsLJvYC61RkQdDFe356FEkMXo8c8CuNstTO/KFoXE+j1RCJKqjTElaYxPrd8LUStSK4uQm3RlKfGYEjYhfvm/qJ7psWJMwmfoE4rwmDmB+RjBv77n/+UTHgGTVTdj1KDPjUJDOZRmZGOPQkcOMjA6jQ5+N1VXWFpfZWt+mWm7QNGpKmWWkcNw8ntdHOttPttBHtlgik8+TzmRJeWk8L4PnZUmlcmTSOXKZHPlMlkI6QyGVIu+5ZIyJrMg9IagQrX3afotms0G7Jbu1XNfDdVIo2QRIs6kp79TY2tyhUWuSSYtD9YGBfgr5TETQthBq1RrLK2ssLK5S3q3hpbP09Q/T1z8opza7qWhqHug2IS10WKe6u8P83GPu3rnNwvw8mUyGM2fO8PzzL3Dy5GnGxsYplTy8lBRlEBo1rsY0VtlX2Wg0RLc5O8vm5gb5Ql5UQ4cmGRoqkssn1EkhhFr6g7KVJhmRtm3MWm1blH+mlpVjzKQ8YXY3jZPK4GbSpDIZMua8wXw2Qz6TJpdOkXFdUonzAwUJl2p2rUjZvgmO51HsH2By+hCHZ44wNT3F0OAAKUexsbbK7Zs3uXHzIYsrWzQbYpqotCIMNODgeBncTAkvO0gqN0I6N0Q2108+V6CYy9CXTdOfSdGfStHneRQ8l6zrkDI68/0Q92sRCTV2k48R5Ij5Q0jN8kRnlw4DWdytVCrsVnapVms0Wk2CMMTzUhTyBQb6BxgdGWFiYoLJyUkmJico9feRyWVwU3I2I4aL2u02lUqFleUVbt+6xYOHD1nfWKfdblPq62NmZobjx08wPj5ONpOJWDBKk3GsFZ/0bvuhtI9oENBWR5XIzCfAcQyZRs1Ma2P4LQ7opdElvXbJR+x0RNjFSGbWzMiJd17ppNbCVI6jHHGGHSnAYwk6FC1IROo2LzqUXXZByyfwEyZ+pjhMKKOxT775MbDBniLor4vuz9j82mw4jkh5nmv6fPSCAtcjXSgwND7G5MwhBkeEpLfXV1ldXGZtYY31lR3KuwHNDquoAB35r+vyYWydm5rjozoWhU0I68pSkmHK2FSZa1yrKschDAKarRaNZotGA+p1KO80WV3ZYnlpha3NLXzfJ51Ok8mkce0qoYHWIds7ZR4+nuPeg0ds7dYolIaYnJ5hZGScbCaf6KABod+i1ahSLW+ztrzI3Vs3ufLhhyzMzzE9PcX3vv99vv+D73Py9Cn8MGS7HFKpQcsH3zTbMMqvaBcrO7vM3n/AzRu32NzcYmxsjEvPX+TMuRMMj5Swavm4zuQQVseT3Yi2HUufNM7ezeCmTQ9TysVRntgbu2bNQSOJaofotiZod9thx7AtXWESYfS2hLZuTT05DiqVIVPoY2hknOnpwxw/doKTJ48zPjZCeXuLD959j1+9/jr37tylVq1K+nBkt387NBtjGqDrQD3hLy9GaFpW27QT640Em99ErcVdLSoNMPrfIAwM58T9WkUqUJlFiK43RttvU6lW2NjcZH1jk63tLcrlcrTVu1Gvg9YUC0WGh4bpK/XF9sbd0NBqNFmYm+eDDz7g7bfe5v79+zSbLYp9JSanJjly9CgzR2YYGR4hkxaSTkYQahFswzCIOrVMABzZ1+HIhqXIBO8ZSMf9K+MFL/qoFpeJ2qgvYoI2j7WWTQBGXy2jnDUXi1cekwYz2ozwykyJXGV6urIjWUcLjC5HZlNI3owZnm2H1kHM0xJyTyRy3lnqvzUk5SqbeenA3VI00g2cwFwueFky6TSVaovllS3KO3XSqQyFQkl2IQY+ruvgZTwcVxFq8WsMGqXsfCY0ykypZyLzRqmhKJRZ+LUQzTlyZt72Bg8fPmRpaQUcj2L/CJlciVZbU6v5bG1VmXsyx4P7s2yur5PyPErFArlclnTaJZNx8TzIZFyU8giCNkvLK9y794C5hWVa7YC+gSEmJieZPjTN6OgI+Zw9/LZNs1Flc22FuUcPmb1zh+vXrnPv3n0q1QaDw+NMTh3BS2dZ39pmfmGRnfIOmpBMJk3Kc40qSaPwUbpOtbxlLABu8ejxPCEek9NHOXH6DMeOH2ViYoRiLodrBA4tKlZZqHcSbdD8VJHqTi4hJePPQ4nE2kFhdo9BKBtQIlVAh+RsAtoOHklkdtaopW5tk3Ycs8UkQzrjEYSitnBdDx2EtJpNlNb0l4oM9svZiPZTjpUSEs6BNNIwJdWOCFNWiNdRU+5Mqmnp8m78SH41JZAwBrACXDS7VqYMbITm6xqo7O6ysrzCysoK29tbVCtVHNdlfHycEyeOMzU1RaFQIJvNipMlO9tJdD2MeW+73aJaqbKyssz83DwbGxuEYUBfXx+Tk5McO3GcI8eOMjwygme8Byb7Bkhckod4AZGo/kzhWIksyX/d6HHL/asf/esuko4bmvgukMhEbymO0sMw4S/XELlpsQl9h2krSKJl9xVmytbxxY6wosHrvOxzpRTK+kmIdPBRM/gEmJiSn+3+SMeDp8fTfN1Co2MPg7ZRyq82QDyL1SGoQIoVJVKf64J2SHl5+ksDZNJptjY3mHvymPLONl7KI5cv4KQ8MGaNVp8pElgUueTS7IiTOpYZDZjBM052RDfg06jvsr6xSXm3QqsdsrPbYG5hhfv3HzL74CEPHz5keWmZoN2mr1gkk0mLu82lBbY216hXy7QaVbQOyOVSaK2ZX1jm+q17zC+skM6XmDl6gqPHjzM2PkahkCXlGYIjpLqzwfUrl/nFT37Cm2+8wY3rN1hYWGJjq8zmTpW5xVWu3rjFm2+9zfsffMDSyhKptMvQUD/FYp6sJ4JCo15laWGe2bv3uXXrDnduz7K+ucPA4CjnLz7PhUvPc+jQNIVCHseubCasmOI+Zq0Xwo61lVCcf5oeYP5pUDpEhYEhQBORmVlGC+hdfST+LUHUSEIiwcluRo68DEpfFKnUI5svMDgwwNDQIKPDQ4wMDVEs5EGLHtZxHDLZLF46ZfzliMZNeNgKSObEGNM+rFxmVa0KGXBCbYUqSW9M11KAHW3LzDwcq9ZIPkQWY7VRJWC2z1eqFba3Nqns7uIoRV9fH1PTkxw5Kqqdvr4SqXSKdCpFKhUfnBzaY8uUAjTNVpNKZZfd8g67uxXabZ9cPsf0oUOcPnOGU2fOcGhmhoGBAbyMOQHJdniTj6hunei3qHqU7hpokxlMPuis7g64f/Wjv+ogaWX+U6ZylZkiiEmRvbQpaxNGKVQYErbbBO0mgd/C1yGB0vgoQhufBsc0UPGeJhUYhNAKoBlAW5sTr20BmE4habGNWP6OKt2WyL5I5HCfgtiLpwtov/xJKbCQbiRNVmzR7aBlYHnUDpZOiHLEusUOeV4qy0DfIMMDwyitWVpYYH7uCa12i0J/H8X+flKpNJ7nkfI85KwXIxXpUMRBdLQjTikjJycsYyRdNk0apcSPNAT4QZN6vYHvh/gBbG7LaeQrK2tsbm5RreyigMnxcWYOTZPJpNncXGdlZZFWs4bnQTqlyGbTFIsFUIonc0vcuHWP5fVtBofHOHPuHMeOH2egv0jKFalX1CSa2s4m169e5d233uLu3buUyxVwPALtUK37rGxs8ejJPHdnZ1lYWkATMjU5yuHDUwwMlMi44rBrZ3uLJw8f8+D+I+bnl9jY3EE5KQ4fOc6lF1/i7LkzDGTSKNchMBKjMlUhbdIWj5SrNmUHoG2ZdpA0Ug+hIWlMJFb36iiZITomZKJpy7es9GzUDnbqZWZHop4Ugo4dPUlbS6XTlEolBgf6GR4aNOch9uO6Du1WiyAIyWYzFIpFXFcGeK3CDoKWVmF8+tj8GM5JlkW8Qa2boBPhJbj5O8Ej9oGBxi5sx9wTBD7NRoNavUYYBHLy0MQ4R47MMD09xcCgmEqmzeaTTDol5aFFpSLfdNCEtJoNqtUq9XqdMAzJpNMMDg1z5OhRTp0+xfThaYqlEl4qFRe/TbtNP5IHsT4xfGm7mMmfvJAorGRGu/LcDdUO2toWjowAsd2hIjYtikYy0xit4YTrOKA1jWqN1ZUVVtdWqdTqNEONSqUp9vUxMTHJ2NgY2VQK2k2atSrlnR1W19bY3Nqm3vLxtYubztI/MMj4xBjDQ0PkMmlSYiYsebKlIynquj4Oykj5n1Aav0UYRYORjs0gZwc6+xMZgSOSVgE4bXB9o64wdRFC0ILqboMnjxe4fuM2TxYWcTJZhqemGJueZnxijMnxEYb6i8ajnY8KzGbiSBQwi1jGlb9Mz01jcqxULcEdFeIilgON+g4rS8ssLCyysLDK47k1VtbKtANFLl+iv19IYGpinL5inq3NdWZn77G2tkxfKcvMkXGmp8cZGxthcHiYtg8fXrnLz17/kJW1HZ67eJHv/PG3OH/uGPkU6CDACdu4KQcIqWyucu3qR1y9cpnl5RXCEFLpHLgZtJsjdLK0Q6jU6mitmZya4IXnL/DcuTMMDvThuZpmvcr6ygoP7z9gaX6RWq2GVpArFjl05AhnnnuO6fEJlNW5Jvxd2JZkO6gIMEGs9nBk3iGqIynXiNS0xglDnFB8Z0dtM8Fe2nZyA/staRiiqkIZkgaRoq0u1JGBV+o1ejsyEAuRzRrNZotWo0WtVqPZlCO4+gb66O/vi7ZaB7qNxnwPbQjaw1HWSjjuerE7g26YO0pm50koJL+2XffuncZdgpHKFRCGIfV6na3NLcrlnWgW4KVS4qzf80in0+RyOYrFopjZKXE5oMMwXjPTIY1mk3qtRqPZpNVsEQQBnuvR19/PwOBgR0oia+VERmx+k3mz6kNbb3bfSAeiF7vu94BqthvacZxYF5Qk6Ug1AUTjqdVLKeMNSxM0GqyurnDz5i1u3r7N8uoaO/UGyksxMTXNyy+/wqVLF+kvFfHrVbbX1njy5DE3btzg/uwDtspVWqFDttDPkWPHef6FFzlz+jQjg33kMx5pz4ywER8n9XDRzY9BvLDzu4C2BN1x00gcYSgzDGXrIPleiFYtNG1QOpK8pexdgramVm2ws11mp7zL+s4ua7sVmmHIyNgIx48fYXJshBygdBsV+ELDUZVa6dkQheOIBKikliUNFiEuPoo2OhQXkc12m2q1yfZ2nd1KC3DJ5ork83my2QzZjIfrQL1WZXNzi1q1Qj6fYmi4QKGYJgwDarUaaxs7XL3+gPeu3GNnt8WFS8/x7W9/jXOnjpAzLY/ARzlhtHBYr9eo1+q02z5oB6VcNB4+HoFyjdskYdZ0Ok2xkCeXzhAGber1CpXyDlsbm6wur1HbrVEslpg6NM3o+Bi5YgEvk8LxLCVLOShD1HZ2ZwTe2JLD/LR00knSptMirifFdtaIZVoDCh3r8CTeqOxtM0+QtD1N3vYD02c1ona0unAbmW052ui/xaIiXo9QSplt4a5Z8LTWW3LJkC1kL4RvPq6Nn/NArDOUI86iVIKYROCI+6moZ+T3JMfYNHYjJn9bkkLUvi/+p3W0NhZfjkmD/Rl/g1ji0xJ35Kc9sG5qlZmFpmXADcXXCxi9uVkEtFs4bJQJqjSlFT/7daBafkOL7jleIJTpW5zxGLagJZOteo2drU02VldZWlzk4aPHPHz8hMWVFRZX16k220xOTfNHf/RHvPrlL9NXzFPZ3mJtaYGV5SVxJbm4xPLaJmubFQLlceTYCb785dd4/vnnmZmeZHykn75iLtrsQEgsxkfpsX93QUn4UIsv6mZD9vdXKhVabfHVoIydpGTZNkT5F38lURPYKZkpK/Nca/kOaJTjiG+CTIZsNksulyOXy5LyvKjitEb0+mZ0FtvSBEkrm8/Eyn3U8WwniRE026xubjG3ssZ2TfxdHDo0zVhfkYRGruOdznJ72pmGtQzt9BrWavso5dHLmRgIt7TbbdJpZc4U9Gk115mfX2B+cYUHT9Z5vFjGJ8WZs6f48pdf4MT4cGQXKxCSlnTu86FPQEhIrVahWtmlsltld7tC0A4ZGBxiZuYwqWjTjiDZ2T4/0IlhP5nCZPv4TcO2lc9faXyeYEmbZEn9mkWm/LApa80Jk7nIPhrRs8Qwc3EF+G3WV9e4cf0a169dZXV1zZjieWxsbnPr7j3m5pfoHxzk1Vdf40tfeom057KyOMfq0gKgKRRLOG6KJ4vLXL52m/nldYZHxsQ726VLnD97mnNnTnB4apxUYuNWB0mLbiBOYiSJSEMNA3HRWKtWWVpa5MaNm9y+dYuNTTnI0/U8GZWtHxEUjiMOzoV4zWp7NIK6Yl5lCDUMNUHkgzggCDWZTIbhoWGxTpia4sjRGY7MHGaoT87GkzK26TfJRQaMDnyKym1qaLR9cULU/fBzhtrOY27evs384grVtotKD5LvH2H68CGOH59i+LfBNV3QfkAYgmtPNTnAAX4N6FCmWZ0Cr/TlPf37KaFC3bLaE0PSXTrphM4ItKg4lIJ2k6XFRd555y3effddtra2GBkbY3Rsgs2tHd5570OuXruJl0pz6dLzXLz4HJm0x/bGKpXyFoODA5w8dZqB4RHuPXjC3//0dT66fodcvsiZs+e4eOECLz5/iS+//AKnTxwh6kOR4GCkiI6FsMScw5K0L0f07O7s8ODBA9761a945913WVpaIgxDOdQyFHeOMqVROEp8VmtzgGqoRY/lOHLfTqEAIWdjiN/2fcJQk8vlmJyc5tjx45w8cYLz589y7txpxodEx2VJWsp2f8ipEQ3a7aaoRRLWIERxqEido5VDqOwONrOrS2scZKdWPAzbnaRB1zYjo5tWLhpXpsy2OLU2Nrky9ZWFLnNiTmTZYFxtKheM03vChGkVIZ4T4NKmUSvz8NEDrt+6xdLqBl5ugKHJYwyNTTMwNMTgUD+lQpasq0jrAFeHKGs2qCWtaJMrheRMgXYgVJowskoAdCjHfxGatTb7L566S18yetVocT45zZaGl5yS21LrrkPTGqPntgfZHpaUguN3pR61UhCKmwA78YktSUx7JyTEJyRAK9MujHWV1rKDFS2ChOO4IlcredfqdcG4U7WpSjgxitNt/5JviqbdvhGHJ/JWISfl2DLbUzCRIiiG6vrefmX6WcBSh7ia1WJiiNk9aSw3tDYbOSSglL05RMBLedEansV+qp1ngdK6raXp2JelIKW0jNJFYyRHY+vnKAh8djY3uH/vDrP371CtVhkYHKLQ18f84go/+enrvPnWu1RrDQ4dOsypkyeYmhhlcmyI8dFBJibGmJyawkll+Oj6Hf7jf/l73n7/I9xUlhMnT/Hc+fO8+PwFXn35BU6fPELaSFV2jFAqbnhizG9zZB4aktaBj99uU61UWFxc5Mb169y8dYv19TUCPxCiSSx4iPRsfscUqhJCcpQ1VYvJW4pHmq1dWMjmsuIzYmqa6elpjh45zJGZQwz1iUvE/RqiJW6LlZVVrnz0ITduXGd7axNHyVluEthcdkVcGRNIxxX/1NaHhFmgMl0orlNEa+pgF7AS+TBbgMW+3bZcjOmY6awq3qwRogmNotba1WutxIAnNN1XKfG05oR4KiBoN1jbWGd+aYXt3RpepkhxcIxC3yCZfIFMNks65comZO3jhAEOsnCttMLBRZk9gJIbSUOoNKEjbThJtkrbU86FYMTcy42GL61FzynmkaYPRHpU08mi/7trrhOmT9pGGoVWyj40sz+zmGbjjdqSjgcPZSK0uZT35GCIUAlJo6R/okR/qkOJy7GWGCoupThx5ptd57+b2wY277LTlATvJksgJuj4bvwVyWfyq3SXoJYbtq6SiMvcQJv/Ppbsogroug9EA29cL53flLtS4nEIFV0y+OkwpNlsAprxsTFeePFFnn/hBYqlzvmrcIvJmfmM1IfhlY7QvaG0eEfqLFRzyfZwI42p+HQJWTEJCVpNartbVMtbtFpNvHSKdqC5fe8B/+W//gM//unrrK1v0d8/wNGjM1x87izf/qNXee3l55mYGINMllp5l7ff/4j/7//+17zxzmVw0hw/cYrz585x6cJZXn7xPCeOTpMy40PgG5tMS9R2IcW2IEPOthK1WRBoN5vslsusrK6yurpKpVLBb7dllFPKnPjiEGqN7wf4YYhSDq7n4bpeNEhpDe3Ap9Vu4wcBGAfnjrE1dhxFKp2mUCxR6uunv08ciw/0F8ln0jj7NCHpoNGCPQDXb9zk3/yb/43/+B/+PY8ePcRxHPK5XLKK5F3MGqDtbLYMoqfyMz61OCYta5eeDB0ocfbeITdFQ3nSDkSI0JK0NuOE1ItCB4aoJVU4QMrVpF1wlabth9RbAa1Ao5UHbgrcFMpNRUdVqcCHoIkK/cgGxcHBxcNBHC2FaAJCQhVGP+VsuUTmEmUW5VcLEdo5hg0nncoQky2/SMVmCjsBZSNN2plrs4gVSfomDm0kWmvWmFgrlJ2QoBC/zo7dkWgWmO23tNJoFaKdUMpdSRu2/B9PIWIJ3qTKEL4grs2uhUYJaArLRmbFx86iwHwlohttWwnxe10k3VF69kFc/B0Bkt/arwoSlqNxfDZ8RP4xuj4ZI3pgzSKl7rRxIqdAfNmYY7TKOzuEOuTCc8/xf/kf/0f+h3/5LxmfGOuIT/qlmaGZS2aWRmUah94XSuswsXaaGLFJ2DtqzJZW06UVRhfsQ9AiDOr47SZhGFDerXL1xh3+9//jb/m7n7zB1k6V6elDXHjuPC8+f55vf/0VXnnxPCozKHG1tnj9rQ/4X//t/8kv37qMk8pz5txzXLx4gYvnT/HChZMcPyy+W3UIvq+N8bxK+EdIdqZktmMLijAIaLVaVGs1arUarVYL35xCrJSs5jquqDgi1YdyxCeF65lZhEiofhDQCuRAXJlqStnIACbbpb1UOjoENJdNk82mSLvWitImz5R71JhU5FcZ4IMPr/D//H/83/lf/pf/V3zzAAc4wOcKpVye/+l/+r/yr/7Vv2L6yOH4gSFp+bXTjFCMNeThJxG1Y4/6ie0chfgUZqe344iPguSQH2i0H4r3O1fhZFI4KQe/3aS2u83u1ibbW9uUq3WcVJbDx07ypVe/wvMvfonxyQkzOleBCs16hXqtQrVapVpr0A40qWyBQt8guWIfqXQ6yoTWwtTRphqbi2iqb6QWhdh1G5UESD4ymQyDg4NMTk8zc+QIR48d49ixYxw9epSZI0eYOXKEI0ePcezECU6cPMXJkyc5fvw4R44cYWbmCIdnZpiZmeHo0aOcPHGCU6dOyXXyOCdOHOXY8aMcPTLD9KFDjI2NMzAwQD6fJ5VOyUJkPJSAlsEjCGS/fzxUxlAJW+UDHOAAn094ysExmocORKos+UM51oIrXtMiEokT3NAFFYRWIysSqUKbjRNREHPJQo1MqUJ0EKAIUOkQlE+7vsP26irzj+e4fPUW//FvX+f1D26R7xvmz//8e/zFD77H2dNHmBzKUMoEKFdDu83m6iY//9WH/L///d/x5ge3GRid5uvf/GO+8pWvcPbEIU4cGmJ8KI8HhIEm9ANRdVjvWImZqkDyoq1XLR0fSGBLTSvRnegwYRlipGAZiGyEZrEgijo5z5BRUkZFeWz9GViHUqFRnclZbCIlOxD7Q7Dn7Cm7LVg0rfbrN+/c5d/8b/8r//Hf/3seP3pEKpWiWCjILALRRWsg0Mro0W2r6CgQM++zsw0tz+3GDGNua2FbQWDnVEZvplB42qRPi4ojMGoFO+WO25HkW5nkOFZdopHyTmqnFKJGUi6h4xEql9DY+WpTRyr0pb5M2hXgqristDm8V0JImhJrYoLEZCuu0G7YF7pUIFG+rArEWDjtgag3pHaMfa4JKFulJRHiK1wSEWot2jro0oIKYp2xDPIRrNG2yZjR2hnHV9I3tJZpurWFNhGa+XL8pSjerrYvD2znsZUW13EMc2RUR6GrqNx09B7xu91RkPh0FxS9w3dpnSLY8Mnc2FR3R9MdRUdZJLOB0ShYzVYYUqtUcZXi/Pnz/It/8d/xz/7b/5bxw9M94+v+djJtSfS852utpfwkBWKCH2/ZlpgdNK4sJkUdLsRRAbgh0KSxu8bc7H3u3rzD1Rv3+ck717n2YIXhicP8xV/8JX/5w+9z6vg0AzkfL9yFVp36bpmlxVV+8dYV/j//+We8f+Mx08fO8L0f/mO++a1vcXR6jOGiS19GkXZNAekwauBYvXTUuOKqkBVVU7AAWuO3fer1OrVGA9/3xSm3bcyANn6V7aREorbG8EZaN+QVhkILCrt13pCalvQ4roeXklOIM+kUmbRLKqHuUNrYZpuq00pW2JXREwOsbmxw/epH3L55k/LODp7nyskgJr8K0UParQbm0x1VbYlTG92ifaK0MmcJx0RiYYwD4tDKhA/lwsSrHSFnCa8JEZ2wbE82umOV2PqgZSTTgYxkyXKVViftS3csOlg/I5aiBQ4q8ksu9Wf8VtjRwOpBbRYiEknClhomYOLSHYopCWcJ2uhZ7bvRwbNY08zYV4eN3rYv6WNEqjptCFYWRG1/kwVYWbi1KwA9ZlU2DrOTTlpCcoC0dWvzZH/vrFsbbxx/dzlhnoaoqAwSNK8dabV6j8Rkys387LodwbySrI3E7Z6vg22jnYjesZ9NoEOPbX52hyGRDht/d5xKiwTmt9ooFCMjI5w/f56z585RGBAzWws7Q9ZIRMm+1pG/Hr9H93wdHe1qAgQoe+Sl3VKjHQJcQuXJso2yW7VDs7mgyu7GAreuXOGjD65w485jLt9fZm7bZ+roSX74w7/gh9//M45PluRoer1Ba3eTrZUVnjya5/X3rvEf/uFdrj9c49RzL/DP/rt/yZ/+yZ8wMaJIh5AKIePJiRiyqUU6rnTKpFlLdzXbP0UCr1YqrK6usr6+Tq1WA6MGsRKbtYgIDFkLiYh5k5jeiU8DuzkmNHprZVUtBq4nTo4KxRLFQoFSqUBfKU825cVSa1crsU0/CR2GBO0WYSADSuz8XQExMXQ2gjjOuDSExDAdK7q0WZHvJq8kR9lHofEnbwUqJ+6T4gBeFu987RNoH2WmgeII3mxK1uK3Qlt/oUrszrVyCLUiCM2MwLGub02jNoNyR2M2XAzEsyG08XMS59qETpBVEsn2omLpOY7OPFIm07a9x0QFQtJhKFYiYvZmvqVVYqZm4pI3zD37fVlMjFcOzYYfsxgdRguSnamV/3W0LVy8U8YWPY5jFrWVawSMHiTalV37eyfkO2KuafnBkrQyBO3Gy9DJPHcXuUXyQyaMTvSB5KvKPuxCt6dG7Hs9CBo609Lj8xFsOmwN27TYuJ0okF2vMxzhGk+gifwEWoQ5iAU+uvPW42cSyheRM1EophLkbJ5o9E2StGsMPKTpBECFneVHfPjWW7z71jvcebDI/dUGO7rA4ZNn+N73/pzv/um3OTKQNlLiBpW1JRYePmD23ixvX77L3719m9nVKs+9+DL/4l/+9/yjP/0jxnKm2gNIKTM9TzRsK4WYLERTZykHaZBaB4S+T6MmvkXu3r3Lvfv32drclIU/Q67KRCCSqZGoRcQBIyE5bqrTfjoUEzzrAF5r+Ww2m2VwaISx8QnGx8eYnppgcmKEvnzCL3IY5QCwkrR5ZPIjuq4DHOAAXxiEHWRKoEN8a5ljfIYkCbmbnHuSdNtI0vJQizZS+8asDXmi7NE5MrKraEquzTbhXTbnZnnr5z/nzV++weyTVVZbWYLSJEdOneU73/kW3/rGlzlczEYkvbnwiHvXr3Lz+i0+vPWEt24us1JTXHj5Jf75f/9P+c53vsZ4wkQsHr3Ei5UkOPbBa0c065rTOpgJwzbNRoPy1hYPHz7kvffe44MPPmBhYYFWs2mkJEh5Hl4qhVKi8LFEHEnMODiuJ6Z2ZvItliB2tyJm04sSPxDThzh+4gTHjx/nzOmTnDp5jNGBfilSLWY9ojIx5Wx00ihlpu4ypRcPdl8c2GGNqBEmZZJ40BNY6e7ZhqJkDJ89kkch2JR45oSXp0QQQOjLgoBrJdD9y0DvU4K2X8RvJkvfIu7dvzkkU2RT8Zv+xu8eNpcWEQ9ZJIvBIlkcGnwt5rwy4zcHoiRqxZZa988kIu6LvmP1Yhp5xTJiJKHGwaJtUTpEt9pUd3fZ3Nhkd7eC63oMDQ0xMjJCoZiPnW4btFut6Ej2yu4urufS199PqU8sOkIt50Fst302dnbZrdRot9smOVbpZtJlstb5BcmEtiobY2aXy+Xo6+uTo5wGBxkYGGBgYID+gQH6+/sZGBhgaHCQoaGh6BocHGRwaJDBQQk7OGjDmGtwkKHBgegaGOinr69IIZ8jm0njecY8rxdiNaSk1+pWjYMbUVMYWP869opMJC0RSouxbSeIJuc23s5w0ce7rvhXqyYxsWlzCkgoOw8xevVQy5FUQbwmaNIQRP9C7aN1O5l4CHy030L7TTGAl9VPKQlTbaGJM0jQo4+mrQPaYRs/bBFq44TKqiJsAYSYhTPjpS6KIaG3iRPbcdmNrPb7EsxPnEWSPJPE/K7NQnSyyHxz2Wz7suiugwDd9gmbDYJWlVZjm1plg92dVXa2VtneWmd7e4typUqt7Ufn67SAtoZWCO0A2j74gag8OlUxkgCNL+m2aUtqVkI7W7QlbH1SyxTdxmhLLEAn7iaf2vj3tqWe6A5jLq3jWG0O9D7hbTF3pzHEcFOPS3eUTCJ8V9JCE5+UuaZNSFuHhnDNQq8P+Bp84T6/Vqe5u0tta5vd9U121jbY2d6iWW8ARoru4sCnRSRJ25wrHRhft1ZLLgs7WrnGoxemV4a4uo1KB+BXWL93i//8n/4T//Wv/46lzRqlw+eZufAqJ849xwsvXeTCueNMZNPGLc4Wc3ev89bPfsoH773Po5VdVtsF6J/izKWX+PZ3/phLF8/IwaRzj2iWNxnp7+Pw1ARDQwMdGYjM8ZKesExFRWZ4YYBvzjBbW1uLdNJBEJg4pOUqDRiTQ+W4UrfRkT6JxUOro8Su2sdqFw14qRSFQoFSXx+lUon+vn5KpRK5bFrsoI3a1ErjmngRzqo/MHpUFyfyURs1tqTrRmuUkmgApi92jFrxRhYz6Ea/74W2CYRI4x2F7IjYLGiFRPsWZQutDSzDgzKsF2lWTRnoQPTTOgTlejheyuhh4+WQSE4wkNQYPWy0VdlsDkCJnh3Znhy/Y/ITqcqsMtNYJUR/J77Ruc6GhBYvgLKwHkZ30UYnG21T318qBhunHFHlt5s0GzV2d8tsbm1S3t0l1JDO5skWShT7B+kbGiWfz+IkCEaFGhVIDbgKXFcbVWAMbV0DmLZrLU7kYRQqkRd727gW6GofdvlSRXVpI1FgNt5D1+2OX82DzmRG2Gd5BKyOOVlHpsrsTwuFTFC6iuJjwyer2eYqHpRMnIjBhItdcDcvhOA3muyWdyjv7FCrV8UwIQzIFQqMTIwzPDZKyvOiAYKEsG2/2/0zCdWOdNKGpMNQiFrbBQwzBVdmZ5I2xOX7OGEL1wugXWbx9g3+3b/9d/yn//Nv2Kj4HLn0Ghe/+iecfO4iZ86c5NiRSUYznpkUbvPo1kf84u//jnfffpeFzToVbwhvaIYjpy/w0iuvceL4CfzaLuvzs/jVbQ5PjnL+9Akmkzt6IFGsyVuxzhitZQHFTZrXJYtEC5n4PmEge85d15xB17PIPhnJFGkzpoVmyHajRddkeE2ogsiMDIhMuRydIGkToU66hlRylJgT7YKJza2SDT5utJ1l0FVyBklCi+0K5I1kwo2NfSg/FcJPdg1VzIZMHMb8LIpCa3Fu1PbRoZZdhqk0yjWN2Qw0Klr/iD4q5WXM7sAMzlJaYvGRtMxQ5p2OAdBmz8zCunquFvcZHaQhJRbg4MfWT/al0KyiRlsujZKuu/nYbxi2bdWr7G5vsbO5zvb2Bhub65QrZXytcdNZsoU++kfGGZ2cYXB0gkzWjcw4nRBUIDtHXUfM+hJr14Csbchgjvij6bLPBcwsLM58VGORu9MYQtC2PSTtTVRkJggd0XWUQSwo9EYvksbU1R7STdRTEupjSDo0P5OQeo1h8x+gEyQtp6GLRVEiflOP9Z1dFufnWZifY2Nzk/JuGV+HDI6McOa5cxw/dYpcOk1oJHP5pllM7/p+j+zj/t/+57/6kRS43apoGm7C5EwanLEqULLjTxFA0MZp1wnKOzx59Ii33n6P9y9fZbfeYvLoSc5cep6ZI0eYGBtmoJin4Br9alBhe2WVJw8eMje3yMrGLktbVVa2Kmzu7LK9XWZ9bYOdrQ2csM1AMcfY8BAjQ4Pk89ko8eIQiYTKw6bV3IZYunZUQveXLBol46QjkpzjGmmuZ3E9HRIpkaab+Jyy0qZKNmYhEGMLGeVFzMYSJrHJNFttj51GdXQ+ET3idNjnySv+/J4+1fFuJ2wjhk71l8Kkx75jJOHYdsgSROKyeXIccF206xI6TkKKESJwECkxlu1M/uxHpftEvVx4Jy6jrsKOy1clxKskklJ09CjuXPJ+wsGTDeQgOmbldGQzeQV+QND0qZerLM8vcev6Da5/dJXFhQVC7ZPLZwnCgPXNdRaWl1jd2GajXGV7t0696aMcl3R0GIZ4HnEVOJY5onK3xRtvnrCLVlqbGZxRLyXrJepHKqZgi84QyYzFFkeJgNGf9lZnG+2B7maciKLnm13fsLeSPyMkmlvX7e5bENU2YHImv8ldm1scaVaVjU1uXr/Oe+++y9WPrnDr9i3m5uaoNxsMDA8xPjlBLpMxahThLGk1HaVmvrEXThAEIsnYl5QDjmemnaYR6th3g4PxOeAqlAppN1tsl6tsblcpVxo0WgHacckXcgwP9jEyWKKUz5J2ZOQAH1oBrnbI5UrkS4PgpNjc3Obh/Xtcfu9dfvbTf+BnP/077ty5AYRMTk4yPj5OLpeLEm5PGA60MZ2LuqH837lTEsIgRIdttG6BbhtFYVtOyg7N3x26NjOx1D469I3OL262lqy6G7J5a09MKDEftJsi5WWrL5UepUQWjCoPRClqfQfowIYz5lWuK+c9Gu9nlmzkkNXkFdetSjJpNxl1STKSjrgphTLniC6bd0cJiVqL3jjNVn1tnd87xlxLPqSUi5NK4aTTkEoROk6kc461o6aUtVEUG3tikdtseVn/E06ka7UqKItkSWDbefR3Al3lIe/af8qoNVKg0+anOaVEISJWVOu9EfghjWqD8vo2i48WuPbhNd7+1bvcunmHdstnbHyE/oESu9Uyd+/f4cMrH/DW2+/w1jvvc/3WXVY3t2kH8jnXQTauWAnazrKsBK2VkLQ5Is0EkUXrIDR9QptKlxJNDjq2/ewtPRsusehp1qy6x+GOe7A3QOKy7ay73X2qy344kYBIAO1xdf9Lti0pN23WZ7p6vta0ahUW555w7aMrvPfuu7z/3nt8dPUj7t2/y9raKo1mI1J1WJO8bt74OLj/81/91Y86JWhJdpzZOLDWWrqqncaGPoHfptVsUas3KdcaOOksh4+f5PmXv8z5S5eYnJygr1ggl/JIKSUk7bdoN5s0Wz5aeah0HlI5UrkSA8PDjI+PMTU5zokjhzhz4ghHD00xNNBHNpMStYVJC4gUIOSTSGqid0a/mYdxdmQn4v6wemYh0TiolIuWIPEtq9YwV/JZ1BTs7ya8BDOBbcIS5a3ADJBG6jP1FEcoP5LZiHeLJhOXvD4ZynTBbiSzhW3uiliv2wFTRiaQCPsy2Ef2wMgzu3FDvO9Fr6OslGjJQtsUaNNWe+VNfspnrae+RKSJ7g9dhUccVeSgKZFr23mVBLABDa+FBO0muzubrK0usrw8x8LiHAtLC2xsbuIHIa6bFvcAvgg39VqNnZ0d2n6bkdFhTp87xczRw7R1wPziAnMLi+xUGjQDBU6KYqnExNgoIyOD5BxTR0Z4Sta3tmVjCNpmy4rYGhnopHyMnX+i+iwPCISczd3u0ovR4xb73e55My77bvS4hZKuQUdSzf14mOlCj5v2k92P4hK1dR/HHcXvyOJJs1JlbWON8u4ujudSLBUZGRtl5ugRTp89y8zRI+RyebQRcmTfgG1Le9PfDdUOgogh7P+2gyr7nzYLNcY0T7ZkA2FA2G7RbjRko8jaBhvbO2jXo290nMGxSfLFEpmUOBcSK+s2+A1a1Qrl7R02N3dYWNvmwco2q7sNnHSOweFhhkeGGBsaYGK4n+G+Avl0ipQrmyMw+jaRbQx5QaRfs9M5C+G3ZNOKG3R0JyIAIikrSdLSoDslEnRnqVorB23V+ZZHDGy/l7TaaadJsxM/jFJnCdpcUYVEkZjGZKa2IkEHCcdTJnyXhGSfJEMls2JnTMlQ2qggLIkmY1ShVTXI2yYx0Z/2UghBa98XU0pHgeeCa3ccxt6tNaLDdAnxIgndWCggKhJtNsIk80Fix3YkRHXlNUqSNuJN9LJJvtnmHppytI8dHBztxIO7jdQLgRa1rXXu3LvD9Zs3eTy/wNLqBpV6m+GRcV798lf4ype/wuTYOK6GZrVOvVpla2ODym6ZXDHN1OExCgN5Hjx6wM9ef533L3/E1m4LNzvI4Mg0Z86c5ssvP8/Z08cp2eJuhdFMRiR5I/+adSQLHYovbkVygV2GnajEbMFBtEM1mkGYh7LLMxHQItFuu27HSJZbL3TN5CL00jETTciivzHfs10piSh8V1i6BBL73LZ1m3uroe/QSStHSLpaZX1tjbXVVXZ3y1QbdUIdUuzvZ3rmCBOHpslmsmaWbePrKPk9P5NQodYy2zbTQ0VMaDHBaHToE4YJknYsMRpWchxwUh3HGvmmD6joClHax8FulAECTaXWYnmnRrkR4GVz9A8O0FdKkVYSWwchRLH3gCFUOojaHBcfraokqym+J2oHSa1I5oaMEyRt9Xu9oD+GpKWcJFwyD9rqBZVc2km2RNOJLEF359z8qW0VYEnabt1N4pNJOgkhaRIhhKjslE2bRisxyupNp5VEYiDpyDAQBBFJ4zgoS9LGPj2ZcgXiqN9IfrEELjvytNmRl8xHR1kny6grjGMeJL2R2odahdFl3wezDT3y9WwfGCcotNhdX+LDyx/y1jvvcv32XW7de8jKZpmJycP85Q/+kn/yl/+EMyePyilDQVe5uCZf1Lh7/z5vvvUWV2/cotIIyZVGGBmf5sTxY1y8cIbjM9Pk7YSkHeIq6w8Es3IbKyokek0YBOjAB2JVmbLTjE4dlykYO70nUnZIezR13oWe5JrIInSVc/J3i31IukPmSMAu7iahTPjuaGw2u6NRXWm0n7LqNp3oPY6J27Edzn5cGWsAAK0Jm02a7RYohZvO4KbFB3wyG/a73d/vTjfYNS0jaUZT0qQEqMx/5pQH5crJGwqziq1c8QPspPecO+eZq3O5TskdxwM3A+m8nCg+NsLM9BiHxgcZ7UtRUpADbKwxxezNYJRRKyEYMo1PUUlSfMcb5qcsktr3OsLbKaPV534MlJmeRzsyk1xlf098Wng/ocqIJtNd0kp3srsfJQeD6APdV+c70bs9r70h5J9YmlizQAkXp1/+3IegbXSOg3Jd8Dz5acra5ti2lXhYSUSk5FADa3Fkq6P7cx3lAWAsfwMC413E6AWt3jo5+hjrBat8EYsOuUTWN3bBjiFn1341Q2lgkKlDRzh15jynTp1nZHQax83Tajs02w7twMG3vTSZURegzc7mMjdv3uXO7QcsL23RbioG+4Y5d+oMr770IhfOnmZ0cADXJFUZyx6chPVVwnQu2eplNmyEkSRVJQtKAkZ/R/UbxdVNcQZxQX88kuG634m+2fN2zwc2b8nLPtvzrX3C22DJnwoidURk1dHRL6WBaQXaSRA0gFI42Sy5Uh+5QpF0WnzIx/F21UsC3X9bONiXFUbi7OrnJoAy5xc6rodyvHhR0RKa1p0O+E1TSEZlOzpYkyVE+lWKXCZFfz5DMeOSMjH0EHL2zQg2/g6Clmt/kk6kzC6wOJ1hFd3E3RsK02nMAqE1lbJv2OfdL9hjqJSyzaC7Sdi0dCGRfPvduL/ZppBsEvu+vufaL4SkzhJ0l1bNMuPHtUJMQ/M8VCoFnmfs9URCs68mlqOiLwtBG+ctriFq83W6Ptf9adsarQOokNi2PRJvooamjU23ELIlaCFps9isWxA2E5tZTGt1PYZGxzl56jxnz11i5shphoamyOUHcVN5tJNObPiJtqYANXbWl7l79y5Xrlzn9u2HbGxUcJ08YyNTnD99hpcuXeTs8UMMlwoRSWNIWnaqmpPeuwo9WYMmd52dykIhD7pUZd2tsCP2PTeeAr0qqiuOfW7vffAJxJv8I/HKnnC9fko7jEm6oySUEersMXrd7UjLtFpjtHOJOLt7ZXdaekGJsuNZkKjEuC4Tf9tS2e+zZmcSNkzvcMlE9Q7xabFfzF33u/P2KfDsUXTIOOa9feZo+6I7sMX+L3W/0Rlyb4p63t8v2Cfhqd7rTiF7Aus9d+L7snvO7qMTXb8DxqufI6pcMPNkcb2LahuPUomYlZkX+j675V22traoVqsEQZuQkGazRb3RZHunxpOFVd589yof3XxIoTTA9/78u/zlX3yPM6fGKCgMuddp16vslsssL69x78ECcwtrNJohXjpHX98gE5OTHD9xjOnpSXLG+jRKkdENKbq6m8mP3BP9m2zqkuEhctRlVXdR/pN/7IeEjiHxzf3e6lUnEbpf+rjA3WExSdl762PxNOFtmI5i6Q6bjKhXJF1ItKLob57u1U9D0ha9XnuaT/KMSTzAAT49tLnEnA8ZBo2PcUfbzULJ0EG8AVsZKdkKE04GSKMbNe7fn+XG9evMz89RrezQ9ptypJpWtAKHrd0mt2eXmVveZWxymh/84M/5x3/5Z5w9NiKeIAloNTZYWnjC4vw8K6tbrKxXqDY0AwNjHD95hpnDR8lkswR+W2yocykKxSy5rGwJk3OBZd+C64q6kuT6qsmxLCQbOdBMeD591+v9ci82oGfIAzwr4vb5zLCVlbyeFs8a/gAH+HUhbS5W0Qhha8yCsbaK6VhdJ/vVzSJaGNCs7rK1ssTs7CNm7z/k0cMnzM8tsLa6xu7ONrVqmd3yJltbq2xtrVOpVWkHgbgadRxCFZsYBrrB5sYGs/fuc/nDy3z00RUezD5gbW2dcqVCs9Wi7fvsViosLCzyYPYBC/ML1CoVMOogZUjZZEaSbEcle2EWsonXaw763hcLv4YkfYADfP4RSdJGF4wht8haJAggkNN+RL+rjZrDOGxyRDsZNurcn53j2rV7PHmyxG65Qhi0yaRdxicGmJwawvVgbW2dx3OLPJpf59q9FZ6s1BmeOMwPf/h9/uKH3+XkkUEyOmR3/Qmzt6/zy5/9mLfffouNzTJuuo9C/xil/mGGRicYGBjCdV38dotsJs2pU8d4+eUXOH3qeCRd+ZGTpHgYUpbAzUAk7G1/l7v2uTXHe3r0FrD2I5G9IQ/wrPg1JOkDHOCLA20kSgtLTDoMCMM2oW6Ltzi7B7/LAUSr2eLRwyf88vV3+PFP3+DmnQcEpJk6fIwXvvQK3/z2t/jjP/k2r772Jc6cOsbU5Ah9fXm8tENIiB9q/BCabajWmuxsV1hf22RhfpHHDx8z93iOtbU1tra2mF+Y4/KVD/j5L3/G62/8kisfXeHhowesra1Rr9c7CFH8zIty1nq1syoNWWs15qdKnlndtOxITIjbB/jcwv3Rj370o+6bBzjA7xNEaDY7SBFSi3SzRqp0HHFSpRxtVB6BcZ8aQLvF5voWH129zVvvXOHxkyVKpQHOnj3HmTOnOXpsmqGxQRzPRQd1arUq1WqdpbUyK1s1UtkCJ0+d4syZkwwN5EgpBxW0cHSAqxQDAwMcO3GS8xee5+xzFzl2/AQzRw4zM3OYI0dnOHb0CMePHeX4iWMcOjRNf19/ZPVl3ddg9M0mx9GI1C0lS75l74CVorvDfDx6S9L74elDHmA/HKg7DvB7DVF1aPxAE5hzFV1X4TpK7KGNLlrcHRhy1m0IW9BqErR96vUWCwur/M3fv8F//C8/ZWFpky996RX+8T/+C1555XmmporkiwGEVbY31ph/Ms/Nu0/429ev8auPnuDlh/ju9/6cf/wX3+PM8WGKClSzSdioUtvdolbZJdCg0nmcVA7tuMaOW1hOIZtPMukMuVyOTDqNY6xerWoj8jwYhuJ4TMvA47qd9v1J6dkuKD4bepP0fiSyN+QBnhUH6o4D/EEgUgGYvyPRxEqSSWky4iFN229Tr9WolCtUKzVq9SYtX+Ols/T1DzI4OEQ+XwAgDHxcR5PNpMjn0mTSKSOxykBhDyV1gWwmQ75/iJFDJ5g5+zzHzr3A0ROnRXo+NMWxQ9McPzzN8UPTHDs0yczkGOPD/eRyabSGIDAkbpObzEJiB3E3OqXnAwr9IuCApA/wew87vfdcx/jdlr1z4gwrJNTWQM9adijZEet5BBqazTaNRpN2OwBlToFPZ0lnsqTTaSPGhmAOhE26J1DGljcMwffl6vSRZyXbTkbVidNGkoglZxV7VbRStJYQkt+9O2SFuC15q303On0aWMrvvg7w6+OApA/wew9l9NCyiCaSrdbGSZdxcmV9tEQkjSsHPyg5oSc0PkPiU+OVnCwfWnIXlgyDkHa7TbvdJgh8tDnFJCIsoxeXfSWhuMkNmhA20donAFoaaoGm5ofUg5CGloO7/KRfGEPQ0Q7hRGatpBydWt5B0D3E6wN8rnFA0gf4vUWSjqzcaGVHhRhv6MS15yUc3FSKTDZHNp/H9Vx836feqFOr1ajVazSaTRNrDidTQLkuzVabRr1Bq9VChyGuA7mMQ6mQopgWfzQ61OAHscvWhNypFLiOwnPkIA6tIQg1QXQuYbfcHcOSc7ww2PkMQ9jWuuOAtD//OCDpA/xhwVjWyTFQnfflSk7WFalUmkKxRKmvj1xeDlT2/RaVSpnNzXU2NtapVirmZYdmK6RSrbNbqdKoNwh9H0eHpDxNNq3JGJ20DgM5ri20HiFjslTGb5MlabQx5w51zOk9iNrqpbtnDLF6I0nUYop3QNKffxyY4B3gDxDCyFrLlulouzREuxFRsvvFcVw8x6Pd8llcWWduYZlavUEulyGT9mjUdynvrFMpr7GxssTC3BxPnizyZH6Zuw8WmVvcIEQxOTHB9MQYuULRHHsV4FkvXFaHgfEsaQV6q94wqXaUUdtYMu5a77Swt4SgE+QfhbUmiHul7Y+HDfjULxzgN4ADkj7AHwSsbKwRHXRoJGkhvfh8z06GA9wUKp3B0Yrybo2d3V1arRb1epXlpQXu37vNw9k7zD28x8PZ+zx5PMfi0ioLSxvce7jA4/kVGo02+VyBXCaH0pD1XErFDF46LZtmQl9I2Xhb1Cij2pA0yCKhvQw5d+uik4hUOMmFwiQpy4vJ3/fCllhycdHeO8BniQOSPsAfHLQWrx0qIugubbVVfaDNqfFpPEfRaLVp+4E5wi2kUa9Sr1fQfhOlfQLfl6MQnDQhHvVWSKBd+gYGmJyYZHRklP5SkaGBAkMDRTw3FVmFACjjn11rFR3DppQcOOsYcu50SdsDSTVIQpJ+NoKmByF/XNgD/DZxsJnlAL/XsHyrjXJWR5YWxsdFx049Y6mhg9g3uuuKi9LAZ2Njm8WlNdbWNtna2qJcLtNuNcimFYV8imwmTSqTwfHSNNua1e1dNnZq4KQZGhllcnyCsdEhJkcHGBss4LmeGNqFbXPOTQqtUmjjZyQ0JwK5e2ygYzK291XymMJIDy1SdOQFz6g4Ytiu34sCukn6AL8rHJD0AX6vYQk6tMegYawfkr6UrdSM7iRq7JY+0S3o0J5+HpO+9Z5njyxTjpw6FKJoh9AOZT8jxnbZcyDtQMoR0zxrm621QuOhtTndKMGR9lfd4YY0hjImeUkiTz6z6NXVlc3jHhyQ9OcFByR9gN9rCPXKWZKaUEhaqU6H90miVgmiNgSmsRKoPcjt0yM0xCjHcNnNMwCKUMuhAtrSY5daIxoXepG04VSVzEoXx/bs6h+nOvmYJwf47HBA0gf4vUWyYWvEn0WkHoD4uOmOHmClZ+MNz97bAytpJq/9EY0DYI7mCuJNMAA4aHtwWPfnOpg68XsC3YTcC/u8+kx4is8c4DeMA5I+wO814sYd02RENDpB1EkojDG1DWQl3oSEjX1PGbM5FzpO6N4P2pC0jcfEFZ2/LiZ4HREkkvfrkOT+aXp6/DrfP8Cnw683dzvAAT7neCpSSQYyv9szw4VGe52TnbjT9bA7rKHy6BIy775syK6XkAijMeMAf3A4IOkD/N5jX3JLEmH37xHim2IX0km3vWK38jE9ok++ud/dDiR1xt3sf4A/CByQ9AH+ILAPBe6LzvBJIrU21YlNHl0K4W7K3fvtZIi9T/cgGeR3TNS/48//QeKApA/wB4Nu8vwkdIbvJmjjI9RaiSRg3zNn2HaK1t1housTUpZMTI/4Pksks/Q7TsofBPa2sAMc4A8F3QuGPZFkR/t7tzQdh0nG2CFg7/lU8r1kPAc4QCcOrDsO8AeCLk2xNj+7gyT5uAOf1E32vPAx6LSPtu92+eWLoNjn872D74teUfym8IxJOcAz4ECSPsAfHnoR9D63Ylgy3e96FnS/+wlx/DbZ9QCfexxI0gf4/Ycm3pjSi6A/hh87BN6uW5237d3u7mRDdH9kb8Tdb1ookl6Tkg/Mu3uj6oleUbDP/U+Iag+eNfwBnh4HJH2A3188Tcvej132ebe3GtsqKnTiwkRuL/v3viy/3ycja+3uu3KrR4J63KJHDPZer/vJVD8NniXsAZ4NB+qOAxxgX6r6ddFN2j2+kbi1l+i63z/AHyIOSPoAf+D4BBJ9KlgfIEn5Mxln97U/Ytm7cy9ib+yl9QP8/uGApA/wB4wkAX4cGT4tkiqIJIF2k3TiW78Wz/4m0nyAzzsOdNIH+P1FR8v+hGauov8E+wTvrZM2b+roP/m5ZydLLCd/snyUTEBXYqI/9/Mz2vNmdyzRvV73u4eZT8KzhD3As+GTWsoBDvB7hCRpdpHnfuz7LIiI3lwdcXZ/85OQpMlEPMnXOwaBZ4n7AF8kHJD0Af4A8VmQmSHWX/tTv4HB4xPQPRz89r94gGfBAUkf4A8Qv0Ua6hW1Zp8HTyMDdz1JCOq/CSSj27vJ/QCfB/z/AXR+j3SVlqseAAAAAElFTkSuQmCC\" style=\"width: 246px; height: 78.3657px;\" width=\"246\" height=\"78.3657\"\u003e\u003c/p\u003e\u003cp\u003eP\u0026thinsp;=\u0026thinsp;proportion of poor QoL of cancer patients\u003c/p\u003e \u003cp\u003eQ\u0026thinsp;=\u0026thinsp;proportion of good QoL of cancer patients\u003c/p\u003e \u003cp\u003eD\u0026thinsp;=\u0026thinsp;Margin of sampling error tolerated- 5% (0.05).\u003c/p\u003e \u003cp\u003eα\u0026thinsp;=\u0026thinsp;Critical value at 95% confidence interval of certainty (1.96). \u003cb\u003e(See Table\u0026nbsp;1 below).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSample size calculation for quality of life and associated factors among adult cancer patients receiving chemotherapy at Tigray, Ethiopia, 2024/25\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eProportion of poor QOL\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCalculated the final sample size by adding 5%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eReferences\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e52.7%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e402\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e44.32%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e398\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e31.7%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e350\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eSample size determination for the second specific objective:\u003c/h2\u003e \u003cp\u003eTo determine the required sample size for the second specific objectie (to identify factors affecting quality of life among cancer patients received chemotherapy treatment in CSH of tigray,Ethiopia, 2024/25).factors that have been taken into consideration and are significantly correlated with the outcome variables with a 95% confidence level, 80% power, and a 1:1 ratio. The Open Epi Info 7.2.6 StatCalc software application will determine the sample size.The double population proportion formula was used. \u003cb\u003e(see Table\u0026nbsp;2 below).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSize determination for the second objective quality of life and associated factors among ca patients received chemotherapy in CSHs in Tigray, Ethiopia 2024/2025.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"10\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVariables\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePower%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCI\u003c/p\u003e \u003cp\u003e%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAOR\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003e% outcome of Unexposed Une\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eRatio of unexposed to exposed\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eSample size\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003eAdd NR R 5%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c9\"\u003e \u003cp\u003eFinal sample size\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eUnderweight\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e49.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1:1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e230\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c9\"\u003e \u003cp\u003e242\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAnxiety\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e95[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.32\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e52.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1:1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e120\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c9\"\u003e \u003cp\u003e132\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDepression\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e52.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1:1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e106\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c9\"\u003e \u003cp\u003e111\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eUrban\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.74\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e55.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1:1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e468\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c9\"\u003e \u003cp\u003e492\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCivil servant\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0,13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e9.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1:1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e290\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c9\"\u003e \u003cp\u003e305\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eSample size computed for the associated factors by the double proportion using Epi Info v.7.2.5, and the maximum sample size was \u003cb\u003e492\u003c/b\u003e[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e].to increase the representativeness of the sample, the maximum sample size was 492determined using the second objective was chosen.\u003c/p\u003e \u003cp\u003e.\u003cb\u003eSampling size determination and procedure for the qualitative part\u003c/b\u003e\u003c/p\u003e \u003cp\u003e Purposive sampling was used to select hospitals and participants from all who participated in the quantitative part until data saturation was maintained.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eSampling technique and procedure\u003c/h2\u003e \u003cdiv id=\"Sec14\" class=\"Section3\"\u003e \u003ch2\u003eFor the quantitative part\u003c/h2\u003e \u003cp\u003eThe sample size was allocated to the study hospitals (AKUCSH and ACSH)proportionally based on the previous two months' patient load was taken from the patient registration book of each hospital. Systematic sampling was used by using the registration book (sampling frame) for ACSH, Kth interval\u0026thinsp;=\u0026thinsp;N/n\u0026thinsp;=\u0026thinsp;460/354, approximately 1, and for AKUCSH, Kth interval\u0026thinsp;=\u0026thinsp;N/n\u0026thinsp;=\u0026thinsp;180/138, approximately 1 so the participants were consecutively interviewed every day until the required sample size was obtained for two months. (\u003cb\u003eSee Fig.\u0026nbsp;2 below\u003c/b\u003e)\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eFor qualitative Data\u003c/h2\u003e \u003cp\u003ePurposive sampling with a maximum variation technique was used to select hospitals, and then, participants from all selected individuals who participated in the quantitative part.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003eData Collection Tool and Procedure\u003c/h2\u003e \u003cdiv id=\"Sec17\" class=\"Section3\"\u003e \u003ch2\u003eFor the quantitative part\u003c/h2\u003e \u003cp\u003eThe data was collectedusing a validated interviewer-administered questionnaire and by reviewing the patient's chart. The validated Tigrigna from the structured questionnaire consisted of 30 items adapted from the Quality of Life Questionnaire (QLQ-30) version 3, which is currently the standard version.Cancer patients receiving chemotherapy were measured using a version of the European Organization for Research and Treatment of Cancer quality of life questionnaire core 30 (EORTC QLQ C-30). in addition to the socio-demographic, clinical,and chemotherapy-relatedcharacteristics adapted from different literature.questionnaire.There are nine scales and thirty items on the EORTC QLQ-C30. One of the most popular tools for assessing HRQOL in cancer patients is the EORTC QLQ-C30, which has been validated in multiple trials. includes both a single-item and multi-item scale:\u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003ePhysical Function (five items)\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eEmotional Function (four items)\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eRole Function (two items)\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eCognitive Function (two items),\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eSocial Function (two items)\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eGlobal Health Status (two items),\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eThree items: fatigue; two items: nausea/vomiting; and two items: pain.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eSix single items are used to quantify constipation, diarrhea, sleep difficulties, lack of appetite, dyspnea, and the disease's financial effect.\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003cp\u003eThe overall score is between 0 and 100. Higher scores indicate greater quality of life on functional assessments and global quality of life, but higher values indicate more severe symptoms on symptom-oriented scales.\u003c/p\u003e \u003cp\u003e \u003cb\u003eThe raw scores were converted into scores ranging from 0 to 100.\u003c/b\u003e \u003c/p\u003e \u003cp\u003e.There are various benefits to using these converted scores.Transformed scores may be difficult to interpret; however, there are several ways to ease the interpretation of QLQ-C30 results. It possible to report the raw scoresto the transformed scores.The following formula has been used to do a linear translation to 0-100 to obtain the score S[\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" width=\"313\" height=\"79\"\u003e\u003c/p\u003e\u003cp\u003eLinear transformation- Apply the linear transformation to 0-100 to obtain the score S:[\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]\u003c/p\u003e \u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" style=\"width: 439px; height: 123.876px;\" width=\"439\" height=\"123.876\"\u003e\u003c/p\u003e \u003cp\u003eRange is the difference between the lowest and greatest values of RS that can exist. According to the QLQ-C30's design, every item on any scale falls within the same range of values. Since most items have scores between 1 and 4, the range of RS is equal to the range of the item values is 3.Therefore, in this study, after transformation of each domain is dichotomized into each scale and subscales into the \u003cb\u003e\u0026gt;\u0026thinsp;=\u0026thinsp;75\u003c/b\u003e for the functional and global scale and the symptom scales\u0026thinsp;\u003cb\u003e\u0026lt;\u0026thinsp;25 \u0026lsquo;\u0026rsquo;Good QOL\u003c/b\u003e\u0026rdquo; or for the functional and global scale\u0026thinsp;\u003cb\u003e\u0026lt;\u0026thinsp;75\u003c/b\u003e and for the symptom scales\u0026thinsp;\u003cb\u003e\u0026gt;\u0026thinsp;=\u0026thinsp;25 \u0026ldquo;poor QOL\u0026rdquo;\u003c/b\u003e category \u0026ldquo;[\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eThe patient's anxiety and depression levels were evaluated using the Hospital Anxiety and Depression (HAD) Questionnaire. The questionnaire was created to assess mental health issues (including depression and anxiety) in general medical settings, and it is both valid and reliable. \u003cb\u003e[41, 42].\u003c/b\u003e The HAD consists of 14 items divided into two subscales (depression and anxiety), each with seven items. The items are evaluated on a four-point Likert scale, where 3 represents the least positive reaction and 0 represents the most pleasant response[\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eFor the qualitative part\u003c/h2\u003e \u003cp\u003eInformationwas gathered to explore the perceived barriers affecting the quality of life of cancer patients receiving chemotherapy. Thesemi-structured interview guide was developed in English based on the literature review and study objectives; the semi-structured interview guide was developed in English, thenit was translated to Tigrigna by the principal investigator and an individual who has good ability in both languages.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003eData collection procedure\u003c/h2\u003e \u003cdiv id=\"Sec20\" class=\"Section3\"\u003e \u003ch2\u003eFor the quantitative part:\u003c/h2\u003e \u003cp\u003eTwo MSc nurses were chosen for supervision, and four nurses with degrees were recruited from each hospital and assigned to each hospital. Data was collected through face-to-face interviews and reviewing of relevant records. Based on patients' willingness to participate in the study,the structured interview was coded for each participant.To collect the data,a total of 40 working days was required.Finally, face face-to-face interview questionnaire was distributed, and detailed clarification was provided on how to complete it, and specific clarification for any difficulty was provided accordingly. The collected data was checked for completeness, validity, and accuracy daily.\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec21\" class=\"Section2\"\u003e \u003ch2\u003eFor the qualitative part :\u003c/h2\u003e \u003cp\u003eThe data was gathered through an in-depth, face-to-face interview. Once each subject had given their informed consent, the researcher used a semi-structured interview guide to conduct an in-depth interview. Using field notes and an audio tape recorder, the principal investigator conducted the interview. The Tigrigna language was used to conduct the interviews. Every interview was set up with the participants' permission and took place in a private space at the oncology head nurse's office. Time spent: 15 to 30 minutes each person. After conferring with the chief nurse and taking into account their medical profiles, the participants were chosen.\u003c/p\u003e \u003c/div\u003e"},{"header":"RESULTS","content":"\u003cdiv id=\"Sec23\" class=\"Section2\"\u003e \u003ch2\u003eFor Quantitative Data\u003c/h2\u003e \u003cp\u003eOut of the 492 participants initially targeted for the study, 478 patients undergoing chemotherapy took part, resulting in a response rate of 97.15%. The non-respondents were not participating due to various reasons, including a lack of time, transportation challenges.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec24\" class=\"Section2\"\u003e \u003ch2\u003eSocio-Demographic characteristics\u003c/h2\u003e \u003cp\u003eAmong respondents, the majority,127(26.6%) were 50\u0026ndash;59 age group, with 90(70.9%) had poor QOL.250(52.3%) were females, with72.8% having poor QOL. The median age and IQR were (53 and 19), 252(52.7%) lived in rural was,\u003cem\u003e75.4% had\u003c/em\u003e poor QOL, 194(40.6%) were unable to read and write, with 80.4\u003cem\u003e% having poor quality\u003c/em\u003e. (See \u003cb\u003eTable\u0026nbsp;3 below).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSocio-Demographic of Adult Cancer Patients Under Chemotherapy Treatment at ACSH and AKCSH, Tigray, Ethiopia2024/25, n\u0026thinsp;=\u0026thinsp;478\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVariable\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCategory\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePoor QOL (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eGood QOL (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eTotal(N%)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e18\u0026ndash;40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e78(72.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e29(27.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e107(22.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e41\u0026ndash;49\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e91(72.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e34(27.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e125(26.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e50\u0026ndash;59\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e90(70.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e37(29.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e127(26.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026gt;=60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e99(83.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e20(16.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e119(24.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eSex\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e176(77.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e52(22.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e228(47.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e182(72.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e68(27.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e250(52.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eEthnicity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTigray\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e324(75.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e107(24.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e431(90.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAmhara\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e20(71.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8(28.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e28(5.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAfar\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14(73.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5(26.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e19(4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eReligion\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOrthodox\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e282(77)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e84(23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e366(76.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMuslim\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e63(67.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e30(32.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e93(19.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOthers\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e13(68.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6(31.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e19(4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNote:Others (Protestant, catholic)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eMarital status\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSingle\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30(73.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11(26.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e41(8.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMarried\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e270(74.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e94(25.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e364(76.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eDivorced\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14(77.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4(22.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e18(3.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWidowed\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e44(80)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11(20)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e55(11.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"6\" rowspan=\"7\"\u003e \u003cp\u003eOccupation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHouse wife\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e137(73.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e49(26.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e186(38.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePrivate employ\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e35(70)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e15(30)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e50(10.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGovt employ\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e56(83.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11(16.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e67(14)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMerchant\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29(65.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e15(34.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e44(9.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFarmer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e75(77.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e22(22.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e97(20.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eDaily worker\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9(75)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3(25)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e12(2.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOthers\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e17(77.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5(22.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e22(4.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eEducational status\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eUn able to Read and write\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e156(80.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e38(19.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e194(40.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRead and write\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e62(71,3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e25(28.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e87(18.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePrimary school\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e65(73.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e23(26.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e87(18.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSecondary school\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e20(66.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10(33.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e30(6.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCollege and above\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e55(69.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e24(30.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e79(16.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eResidence\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRural\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e190(75.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e62(24.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e252(52.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eUrban\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e168(74.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e58(25.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e226(47.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eCost covered\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMy self\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e279(74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e98(26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e377(78.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFamily\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e50(80.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e12(19.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e62(13)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFree\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29(74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10(26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e39(8.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003e5.1.2Clinical and chemotherapy factors\u003c/b\u003e \u003c/p\u003e \u003cp\u003eAmong the cancer patients receiving chemotherapy, breast cancer was the most prevalent, accounting for 170 (35.56%), with 70.6% having poor QOL,166 (34.7%) were at stage 4 with 86.7% having poor QOL.\u003c/p\u003e \u003cp\u003e195 (40.8%)were undergoing their fifth cycle of treatment or above with68.4% having poor QOL.257 patient53.8%) ha In terms of mental health, 223 patients (46.3%) did not experience anxiety, and 200 patients (41.8%) were free from depression. Furthermore, 333 patients (69.7%) had no co morbidity \u003cb\u003e(See Table\u0026nbsp;4 below)\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eClinical and chemotherapy-related factors of Adult Cancer Patients Under Chemotherapy Treatment at ACSH and AKuSH, Tigray, Ethiopia 2024/25, n\u0026thinsp;=\u0026thinsp;478\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVariable\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCategory\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePoor QOL (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eGood QOL (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eTotal(N%)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"6\" rowspan=\"7\"\u003e \u003cp\u003eCancer type\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBreast\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e120(70.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e50(29.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e170(35.56)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e70(70)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e30(30)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e100(20.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCervical\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e60(70.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e25(29.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e85(17.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLung\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e27(64.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e13(35.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e42(8.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNHL\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e20(71.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8(28.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e28(5.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLiver\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16(72.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6(27.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e22(4.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOther\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e22(70.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e19(29.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e31(6,5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eStage of cancer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eStage 1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e27(61.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e17(38;6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e44(9.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eStage 2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e74(60.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e48(39.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e122(25.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eStage 3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e113(77.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e33(22.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e146(30.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eStage 4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e144(86.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e22(13,3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e166(34.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eCycle of chemotherapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2nd cycle\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e73(83.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11(16.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e84(17.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3rd cycle\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e101(80.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e21(19.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e121(25.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4th cycle\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e59(74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e18(26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e77 (16.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5th and above cycle\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e127(68.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e70(31.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e195(40.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eChemotherapy line\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFirst line\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e239(78.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e64(21.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e303(63.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSecond line\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e91(65)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e49(35)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e140(29.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThird line\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e28(80)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7(20)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e35(7.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eTime since diagnosis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLess than one year\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e198(77)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e59(23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e257(53.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u0026ndash;5 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e138(71.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e56(28.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e194(40.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAbove 5 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e22(81.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5(18.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e27(5.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eBMI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eUnderweight\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e198(84.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e36(15.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e234(49)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNormal weight\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e140(67.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e68(32.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e208(43.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOverweight\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e20(55.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e16(44.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e36(7.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eDuration of chemotherapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLess than 6 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e195(81.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e45(18.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e240(50.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6\u0026ndash;12 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e120(67.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e57(32.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e177(37)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAbove 12 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e43(70.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e18(29.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e61(12.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eAnxiety\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo case\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e140(62.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e83(37.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e223(46.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBorder line\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e55(78.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e15(21.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e70(14.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAnxiety\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e163(88.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e22(11.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e185(38.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eDepression\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo case\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e128(64)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e72(36)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e200(41.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBorder line\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e73(73)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e27(27)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e100(20.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eDepression\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e157(88.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e21(11.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e178(37.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eComorbidity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eyes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e126(90.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e19(9,3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e145(30.3.)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e232(69.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e101(30.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e333(69.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eSide effect of chemotherapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e214(78.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e58(21.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e272(56.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e144(69.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e62(30.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e206(43.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003e5.1.3Assessing the association between QOL and its domains\u003c/b\u003e \u003c/p\u003e \u003cp\u003eEmotional functioning 254(83.8%)had poor QOL, and social functioning 215(81.1%) had poor QOL. fatigue 225(86.9%) had poor QOL and Financial difficulty 252(81.6%)had poor QOL. \u003cb\u003e(See Table\u0026nbsp;5 below).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab5\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 5\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eFunctional and Symptom Scale Score among Adult Cancer Patients Undertaking Chemotherapy Treatment at ACSH and AKUCSH, Tigray, Ethiopia 2024/25, n\u0026thinsp;=\u0026thinsp;478\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eScales\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePoorQOL (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eGoodQOL (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eTotal (N%)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFunctional scale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003ePhysical functioning\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e243(79.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e61(20.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e304(63.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e115(66)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e59(34)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e174(36.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eEmotional function\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e254(83.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e49(16.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e303(63.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e104(59.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e71(40.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e175(36.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003erole function\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e206(81.)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e48(19)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e254(53.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e152(67.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e72(30.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e224(46.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eSocial function\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e215(81.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e50(18.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e265(55.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e143(67.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e70(32.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e213(44.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eCognitive function\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e228(80)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e57(20)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e285(59.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e130(67.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e63(32.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e193(40.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSymptom scale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePain\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e249(78)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e70(22)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e319(66.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e109(68.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e50(31.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e159(33.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eConstipation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e223(78.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e61(21.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e284(59.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e135(69.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e58(31.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e194(40.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDiarrhea\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e178(75.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e58(24.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e236(49.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e180(74.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e62(25.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e242(50.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNausea and vomiting\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e98(73.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e36(26.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e134(28)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e260(75.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e84(24.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e344(72)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eInsomnia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e172(77)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e51(23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e223(46.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e186(72.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e69(27.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e255(53.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDyspnea\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e202(77.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e58(22.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e260(54.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e156(71.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e62(28.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e218(45.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAppetite loss\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e224(81.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e51(18.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e275(57.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e134(66)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e69(34)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e203(42.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFatigue\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e225(86.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e34(13.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e259(54.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e133(60.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e86(39.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e219(45.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFinancial difficulty\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e252(81.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e57(18.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e309(64.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e106(62.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e63(37.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e169(35.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eGlobal scale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e240(80)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e60(20)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e300(62.8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e118(66.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e60(33.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e178(37.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003e5.1.4 QOL of cancer patients on chemotherapy\u003c/b\u003e \u003c/p\u003e \u003cp\u003eThe quality of life was calculated after transforming the domain (functional scale, symptoms scale, and global health) to linear, and the sum of all domains was divided by three and finally categorized as good QOL for greater than or equal to 75 and poor QOL for less than 75.\u003c/p\u003e \u003cp\u003eThree-fourths of the patients receiving chemotherapy, 74.9% with 95% CI (70.99\u0026ndash;78.8) had poor QOL. \u003cb\u003e(See Fig.\u0026nbsp;3 below).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003e5.1.5 Factors associated with quality of life\u003c/b\u003e \u003c/p\u003e \u003cp\u003eFrom the total variables, in bivariable analysis ten variables were significantly associated with QOL at P value less than 0.25\u003cb\u003e(Table\u0026nbsp;7).\u003c/b\u003e\u003c/p\u003e \u003cp\u003eThe bivariable logistic regression analysis shows, age, educational status, occupational status, BMI, cycles of chemotherapy, stage of cancer, co morbidity, side effects of chemotherapy, anxiety, and depression were associated with QOL at p\u0026thinsp;\u0026lt;\u0026thinsp;.0.25 and entered for multivariable analysis. In the multivariable analysis.\u003c/p\u003e \u003cp\u003eAfter adjusting for potential confounders in the multivariable binary logistic regression analysis, only five variables showed an overall significant effect on quality of life at the 5% level of significance. College and above were 64%[AOR\u0026thinsp;=\u0026thinsp;0.36,95%CI (0.16\u0026ndash;0.83)]less likely to have poor QOL as compared with those who were unable to read and write. The odds of being under weight were about 3 times [(AOR\u0026thinsp;=\u0026thinsp;3, 95% CI (1.28\u0026ndash;7.47)] more likely to have poor quality of life than those who were overweight. The odds of having anxiety had about 2.7 times [AOR\u0026thinsp;=\u0026thinsp;2.7, 95% CI (1.29\u0026ndash;5.7)]more likely to have poor quality of life than those who had no anxiety. Cancer patients with five and above chemotherapy cycles were 57%[AOR\u0026thinsp;=\u0026thinsp;0.43,95%CI(0.19\u0026ndash;0.95)] less likely to have poor QOL as compared with those who had a second chemotherapy cycle. The odds of having stage four cancer patients were about 2.5 times [AOR\u0026thinsp;=\u0026thinsp;2.5, 95% CI (1.06,-6.38)] more likely to have poor quality of life than those who had stage one cancer patients was statically significant at p value\u0026thinsp;\u0026lt;\u0026thinsp;0.05. The enter method regression was used. \u003cb\u003e(Table\u0026nbsp;6 below).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab6\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 6\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eAssociation between associated factors of quality of life among cancer patients receiving chemotherapy at ACSH and AKUCSH Tigray, Ethiopia 2024/2025.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVariables\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePoor QOL%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eGood QOL%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eCOR\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAOR\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eP-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e18\u0026ndash;40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e78(72.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29(27.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e41\u0026ndash;49\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e91(72.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34(27.20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.99(0.55\u0026ndash;1.78\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1(0.54\u0026ndash;2.28)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.79\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e50\u0026ndash;59\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e90(70.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e37(29.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.9(0.5\u0026ndash;1.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.84(0.4\u0026ndash;1.77)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.71\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026gt;=60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e99(83.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e20(16.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.8(0.97\u0026ndash;3.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.3(0.53-3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.5\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOccupation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHousewife\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e128(73.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e46(26.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePrivate empl\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e34(73.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e12(26.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1(0.5\u0026ndash;2.13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1(0.4\u0026ndash;2.58)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.93\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGovt employ\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e39(76.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e12(23.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.2(0.56\u0026ndash;2.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.5(0.5\u0026ndash;3.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.39\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMerchant\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e32(64)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18(26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.64(0.33\u0026ndash;1.25)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.52(0.22\u0026ndash;1.24)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.14\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFarmer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e74(78.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e20(21.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.33(0.73\u0026ndash;2.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.92(0.48\u0026ndash;1.96)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.81\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDaily worker\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e37(84.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7(15.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.9(0.79\u0026ndash;4.56)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.7(0.95\u0026ndash;7.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.055\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOthers\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e14(73.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5(26.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1(0.34\u0026ndash;2.94)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.62(0.15\u0026ndash;2.54)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.51\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEducation\u003c/p\u003e \u003cp\u003eUnable to read \u0026amp;write\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e155(80.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e38(19.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAble to read \u0026amp;write\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e63(71.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25(28.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.61(0.34\u0026ndash;1.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.88(0.43\u0026ndash;1.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.73\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePrimary school\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e65(73.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23(26.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.69(0.38\u0026ndash;1.25)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1(0.48\u0026ndash;2.37)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.82\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSecondary school\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e20(66.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10(33.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.49(0.2\u0026ndash;1.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.57(0.12\u0026ndash;1.63)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.29\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCollege and above\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003e55(69.6)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e24(30.4)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e0.56(0.3-1)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.36(0.16\u0026ndash;0.83)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.017*\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBMI\u003c/p\u003e \u003cp\u003eUnderweight\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003e198(84.6)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e36(15.4)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e4.4(2.08\u0026ndash;9.28)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e3(1.28\u0026ndash;7.47)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.012*\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003cp\u003eOverweight\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e140(67.3)\u003c/p\u003e \u003cp\u003e20(55.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e68(32.7)\u003c/p\u003e \u003cp\u003e16(44.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.65(0.8\u0026ndash;3.38)\u003c/p\u003e \u003cp\u003e\u003cb\u003e1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.35(0.62\u0026ndash;3.01)\u003c/p\u003e \u003cp\u003e\u003cb\u003e1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.46\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStage of cancer\u003c/p\u003e \u003cp\u003eStage 1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e27(61.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e17(38.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStageII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e74(60.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e48(39.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.97(0.47\u0026ndash;1.96)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.58(0.7\u0026ndash;3.87)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.28\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStageIII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e113(77.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33(22.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.15(1.04\u0026ndash;4.43)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.3(0.99\u0026ndash;5.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.052\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStage IV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003e144(86.7)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e22(13.3)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e4.12(1.93\u0026ndash;8.78)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e2.5(1.06\u0026ndash;6.38)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.047*\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComorbidity\u003c/p\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e126(86.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19(13.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.88(1.68\u0026ndash;4.93)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.6(0.85\u0026ndash;3.14)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.13\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e232(69.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e101(30.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAnxiety\u003c/p\u003e \u003cp\u003eNo anxiety\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e140(62.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e83(37.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBorder line\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e55(78.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e15(21.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.2(1.15-4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.75(0.79\u0026ndash;3.85)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.16\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAnxiety\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003e163(88.1)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e22(11.9)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e4.4(2.6\u0026ndash;7.4)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e2.7(1.29\u0026ndash;5.7)*\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.008*\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDepression\u003c/p\u003e \u003cp\u003eNo depression\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e128(64)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e72(36)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBorder\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e73(73)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e27(27)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.5(0.89\u0026ndash;2.57)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1(0.5\u0026ndash;2.16)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.69\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDepression\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e157(88.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21(11.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.2(2.4\u0026ndash;7.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.4(0.6\u0026ndash;2.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.28\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCycle of chemotherapy\u003c/p\u003e \u003cp\u003eSecond cycle\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e73(86.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e11(13.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eThird cycle\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e101(82.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21(17.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.72(0.33\u0026ndash;1.59)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.82(0.3\u0026ndash;1.87)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.67\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFourth cycle\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e59(76.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18(23.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.49(0.22\u0026ndash;1.13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.81(0.32\u0026ndash;2.25)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.67\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFive \u0026amp; above\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003e125(64.1)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e70(35.9)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e0.27(0.13\u0026ndash;0.54)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.43(0.19\u0026ndash;0.95) *\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.037*\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSide effects of chemotherapy\u003c/p\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e214(78.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e58(21.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.58(1.04\u0026ndash;2.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.6(0.98\u0026ndash;2.67)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.072\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e144(69.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e62(30.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eNote:1.00\u0026thinsp;=\u0026thinsp;Reference, *statistically significant, Hosmer and Lemeshow test (P-value\u0026thinsp;=\u0026thinsp;0.82)\u003c/p\u003e\u003cp\u003e \u003cb\u003e5.2 Qualitative study results\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003e5.2.1 Demographic Characteristics of the In-depth Interview (IDI\u003c/b\u003e)\u003c/p\u003e\u003cp\u003eA total of 11 adult cancer patients receiving chemotherapy treatment participated in the in-depth interview. The age of patients ranged from 35 to 70 years, with a mean age of 53 years.\u003c/p\u003e \u003cp\u003eThe majority, 7 (66.34%), of the patients were diagnosed at cancer stage III and IV. \u003cb\u003e(See Table\u0026nbsp;7 below).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab7\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 7\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eDescription of the Socio-demographic, clinical, and chemotherapy-related factors of adult cancer patients receiving chemotherapy treatment at AKUCSH(n\u0026thinsp;=\u0026thinsp;11)\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"9\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003ecode\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSex\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eEducational level\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eType of Ca\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eStage of Ca\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eOccupation\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003eCycle of chemo\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c9\"\u003e \u003cp\u003eHospital\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eP1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eCollege\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eRectal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eTeacher\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e3th\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eAKUCSH\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eP2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIlliterate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eCervical\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eIV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eHousewife\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e5th\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eAKUCSH\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eP3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIlliterate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eBreast\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eIV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eHousewife\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e5th\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eAKUCSH\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eP4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIlliterate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eGastric\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eIII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eWidowed\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e7th\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eAKUCSH\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eP5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e57\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eElementary\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eColonic\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eIV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eHousewife\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e6th\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eAKUCSH\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eP6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eHigh school\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eColonic\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eMerchant\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e9th\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eAKUCSH\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eP7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIlliterate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAppendiceal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eIII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eFarmer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e4th\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eAKUCSH\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eP8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIlliterate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eLung\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eIV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eFarmer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e5th\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eAKUCSH\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eP9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ehigh school\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eBreast\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eHousewife\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eSecond\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eAKUCSH\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eP10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIlliterate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMyeloma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eIV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eWidowed\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eSecond\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eAKUCSH\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eP11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eDegree\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eRectal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eGov\u0026rsquo;t employee\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e6th\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eAKUCSH\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cdiv id=\"Sec25\" class=\"Section3\"\u003e \u003ch2\u003eThematic findings\u003c/h2\u003e \u003cp\u003eThe findings that are found from the analysis of in-depth interviews were presented as themes and subthemes. The two main themes and subthemes were arranged by analysis through Atlas.ti version 7..5.8 The major themes were the experience of patients with the cancer and chemotherapy, and Barriers affect quality-of-life cancer patients receiving chemotherapy.\u003c/p\u003e \u003cp\u003e5.2.2. Theme 1. Experience of patients with cancer under chemotherapy\u003c/p\u003e \u003cp\u003epositive experiences\u003c/p\u003e \u003cp\u003eSeven participants reported that they were terrified of dying after heard about their illness; nevertheless, chemotherapy, despite having a positive effect, provides them hope for survival and positive health progress.\u003c/p\u003e \u003cp\u003eThe following participants expressed.\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;After I begin chemotherapy treatment, after fourth round of the treatment I have seen a good progress thanks to God and chemotherapy treatment\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 5(F),57, stageII).\u003c/b\u003e\u003c/p\u003e \u003cp\u003eThis was supported by the following quote taken from in-depth interview:\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;My pain began to subside after fourth chemotherapy rounds, and I was able to move a little more easily. I feel more at ease knowing that the treatment is having some effect\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 6(M),45, stage II).\u003c/b\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec26\" class=\"Section3\"\u003e \u003ch2\u003eNegative experiences\u003c/h2\u003e \u003cp\u003eEvery participant in this study had some level of chemo-related adverse symptoms, including nausea, vomiting, hair loss, and low appetite. The patient's quality of life is impacted by these side effects of chemotherapy.\u003c/p\u003e \u003cp\u003e\u0026rsquo;The following participant expressed;\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;Symptoms like nausea, vomiting, appetite loss, and hair loss are all present after received the treatment. Although I am bothered by the hair loss, the nurses told me that it will return once the treatment is complete\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 3 (F),60, stage IV)\u003c/b\u003e \u003c/p\u003e \u003cp\u003eThis was supported by the following quote taken from in-depth interview:\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;I'm constantly exhausted and nauseous after chemotherapy. I'm unable to eat or sleep, and the treatment seems worse than the cancer itself. All I want is for it to stop\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 10 (F),70, stage IV).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;Chemotherapy made me fatigued and lose my hair. I look like a ghost and feel so weak. Being this ill makes it difficult for me\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 9 (F),36, stage II).\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003e5.2.3 Theme2.Barriersand facilitators affect QOL in cancer patients receiving chemotherapy\u003c/b\u003e \u003c/p\u003e \u003cp\u003e(\u003cb\u003esee Fig.\u0026nbsp;4 below)\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec27\" class=\"Section3\"\u003e \u003ch2\u003eSocio-demographic related barriers\u003c/h2\u003e \u003cdiv id=\"Sec28\" class=\"Section4\"\u003e \u003ch2\u003eInadequate patient education\u003c/h2\u003e \u003cp\u003eMost of the participants six (6) had a lack of knowledge and experience about the disease and chemotherapy treatment. The following participant expressed; The quality of life for cancer patients receiving chemotherapy is greatly impacted by a lack of understanding and living in a remote area. The following participant expressed,\u003c/p\u003e \u003cp\u003e \u003cem\u003e\"I didn't understand what the medications were doing or why I required so many chemotherapy sessions. Because I felt so ill, I thought I was getting worse, and I stopped my treatment\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 9 (F),36, stage II).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\"Most of the time, I have no idea what the physicians are saying. They speak in difficult words, and I'm too embarrassed to ask again. I'm feeling terrible about the treatment, and I'm not even sure whether it's helping\"\u003cb\u003e(participant 2 (F),40 stage IV).\u003c/b\u003e\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec29\" class=\"Section2\"\u003e \u003ch2\u003ePoverty\u003c/h2\u003e \u003cp\u003eThe majority of the patients' economic status was low, and they couldn\u0026rsquo;t afford the medical costs and the cost of transportation.\u003c/p\u003e \u003cp\u003eThe following participant expressed.\u003c/p\u003e \u003cp\u003e \u003cb\u003e\u0026lsquo;\u0026rsquo;\u003c/b\u003e \u003cem\u003eI had to sell my animals to cover the high cost of the chemotherapy medications. My family is now poor, and I feel bad every day. I find it difficult to concentrate on improving while I'm worried about money.\u003c/em\u003e\u0026rsquo; \u003cb\u003e(participant 9 (F),36, stage II).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cb\u003e\u0026ldquo;\u003c/b\u003e \u003cem\u003eEvery time, I\u0026rsquo;m thinking about my poverty, and I skipped my treatment because I had to choose between feeding my kids\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 4 (F),40, stage III).\u003c/b\u003e \u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eSocio-demographic related facilitators\u003c/h3\u003e\n\u003cdiv id=\"Sec31\" class=\"Section2\"\u003e \u003ch2\u003eAdequate patient education\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe health providers told me about hair loss and other side effects of the chemotherapy before I started the treatment, so I could prepare myself for that risk. I know it is hard, but I haven\u0026rsquo;t another opportunity.\u003c/p\u003e \u003cp\u003e\u0026rsquo;I have a bachelor's degree and am searching for information about my disease condition and the side effects of the chemotherapy beyond of the health professionals told me. I think this helps me manage my problems.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec32\" class=\"Section2\"\u003e \u003ch2\u003eClinical and symptom-related\u003c/h2\u003e \u003cdiv id=\"Sec33\" class=\"Section3\"\u003e \u003ch2\u003eClinical and symptom-related barriers\u003c/h2\u003e \u003cdiv id=\"Sec34\" class=\"Section4\"\u003e \u003ch2\u003eSeverity of the disease\u003c/h2\u003e \u003cp\u003eSeven (7) participants discussed the disease's status as an incurable condition and stated that it is fatal. The primary grounds for categorizing the illness as serious were its symptoms and indicators, which they described. Additionally, the participants described the causes of the disease, including the combination of chemotherapy treatment and its adverse effects, which make it dangerous.\u003c/p\u003e \u003cp\u003eThe following participant expressed,\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;Because of the effect of chemotherapy and metastasis of the disease to part of our body, food is always fed by my family. I am always in bed because I have severe fatigue due to those reasons and am abstaining from any daily and social activities\u0026rsquo;\u0026rsquo;\u003c/em\u003e(\u003cb\u003eparticipant 5 (F),57, stage IV).\u003c/b\u003e\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e\n\u003ch3\u003eSevere side effects\u003c/h3\u003e\n\u003cp\u003ePatients frequently reported debilitating side effects such as nausea, vomiting, fatigue, and pain, which severely disrupted their daily lives.\u003c/p\u003e \u003cp\u003eThe following participant expressed;\u003c/p\u003e \u003cp\u003e\u0026lsquo;\u003cem\u003e\u0026rsquo;Because of the effect of chemotherapy and metastasis of the disease to part of our body, food is always provided by my family. I am always in bed because I have severe fatigue due to those reasons,and I abstain from any daily and social activities\u003c/em\u003e \u003cb\u003e(participant 4 (F),40, stage III).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;After treatment, I have severe weakness, and my appetite disappears for five to seven days. due to this, my weight decreased by 20 kilograms, nausea is persistent, and I'm exhausted. I feel as though my body is collapsing, and I am unable to eat or sleep normally. I don't know how to continue in this manner.\u0026rsquo;\u0026rsquo;\u003c/em\u003e (\u003cb\u003eparticipant 1 (M),55, stage II\u003c/b\u003e\u003c/p\u003e\n\u003ch3\u003emobility and self-care limitations\u003c/h3\u003e\n\u003cp\u003ePhysical weakness and fatigue restricted patients\u0026rsquo; ability to perform basic activities like walking or self-care.This was supported by the following quote taken from an in-depth interview:\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;I used to work part-time, but now I can't even get out of bed most days because my body feels so weak from chemotherapy that I can't walk normally. I feel like I'm not just myself anymore\u003c/em\u003e\u0026rsquo;\u0026rsquo; (\u003cb\u003eparticipant 2 (F),40, stage IV).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;I'm too weak from chemotherapy to take a shower or put on clothes. I feel like a child because my husband cares for me. It deprives me of my dignity and is degrading. This demonstrates how restrictions in self-care affect quality of life\u003c/em\u003e \u003cb\u003e(participant 9 (F),36, stage II).\u003c/b\u003e \u003c/p\u003e \u003cdiv id=\"Sec37\" class=\"Section2\"\u003e \u003ch2\u003eWeight loss\u003c/h2\u003e \u003cp\u003eThe majority of the participants from the in-depth interview had impaired weight due to the severity of the disease and side effects of the chemotherapy.The following quote is taken from an in-depth interview.\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;My weight has fallen as you can see because I have no hunger and can only gently attempt fluids like milk instead of solid things like injera. The drug has its side effects like general weakness, appetite loss, nausea, and vomiting, especially in the early phase of treatment \u0026lsquo;\u0026rsquo;\u003c/em\u003e (\u003cb\u003eparticipant 11, (F),55, stage IV).\u003c/b\u003e\u003c/p\u003e \u003cdiv id=\"Sec38\" class=\"Section3\"\u003e \u003ch2\u003eClinical and symptom-relatedfacilitators\u003c/h2\u003e \u003c/div\u003e \u003cdiv id=\"Sec39\" class=\"Section3\"\u003e \u003ch2\u003eEarly diagnosis\u003c/h2\u003e \u003cp\u003eParticipants mentioned that early diagnosis and removal of the tumor by operation was it makes easier for the treatment and follow-ups.The following quote is taken from an in-depth interview\u003c/p\u003e \u003cp\u003e \u003cem\u003efollow-up for nurses. \u0026lsquo;\u0026rsquo;I was diagnosed earlier, and an operation was done for the tumor,and the disease did not metastasize to other parts of my body, and this helped me more.\u0026rsquo;\u0026rsquo;(\u003c/em\u003e \u003cb\u003eparticipant 9(F),36, stage II).\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eEarly diagnosis of my illness allowed me to begin chemotherapy earlier and with less physical strain on my body. I still considered myself quite lucky.\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 6 (M),45 stage III)\u003c/b\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec40\" class=\"Section3\"\u003e \u003ch2\u003eLate cycle of chemotherapy\u003c/h2\u003e \u003cp\u003e \u003cem\u003eThe majority of the respondents taken more cycles of chemotherapy expressedgood quality of life.\u003c/em\u003eThe following quote is taken from an in-depth interview;\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;I took the chemotherapy for nine rounds, and at the first three to four cycles,it was difficult; now, thanks to God and chemotherapy, my general health condition hasimproved. \u0026lsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 5 (F),57, stage II)\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eDuring my earlier chemotherapy treatment,it was difficult to remember the tough time. but after taking more than five rounds, the side effects of chemotherapy were decreased.\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant\u003c/b\u003e \u003cb\u003e10, (F),70, stageIV).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cb\u003ePsychological and care-related\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003ePsychological and care-related barriers\u003c/b\u003e \u003c/p\u003e \u003cp\u003eAnxiety and fear of treatment\u003c/p\u003e \u003cp\u003eMost of the participants experienced a wide range of psychological impacts as a result of the disease condition and the chemotherapy. They reported that negative feelings, fear, and anxiety were the most common psychological problems of cancer patients.\u003c/p\u003e \u003cp\u003eThe following participant stated the same thing as;\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;Because I had heard that chemotherapy causes hair loss and has other side effects, I was afraid of it. I tremble during every session, and it's difficult for me to remain hopeful when I'm so terrified. This demonstrates how worry about adverse outcomes increases anxiety and lowers quality of life\u0026rsquo;\u0026rsquo;\u003c/em\u003e (\u003cb\u003eparticipant 7(M),50, stage\u003c/b\u003eIII).\u003c/p\u003e \u003cp\u003eThis was supported by the following quote taken from an in-depth interview:\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;I always fear that the cancer may spread because the chemotherapy isn't working. because of this so nervous before every treatment. This illustrates how treatment efficacy anxiety affects quality of life\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 9(F),36, stage II).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cb\u003eDepressive symptoms\u003c/b\u003e \u003c/p\u003e \u003cp\u003eSome participants became emotionally unstable and started to suffer from loss of independence and autonomy, and this in turn increased their levels of depression.\u003c/p\u003e \u003cp\u003eThe following participant stated the same thing as;\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;After being diagnosed with cancer and losing everything we had, I separated from my wife, and now I am at my parents\u0026rsquo; house. I am not living a happy life with them because I feel like a dependent on them, and I have anxiety and depression when I remember those things\u003c/em\u003e\u0026rsquo;\u0026rsquo;\u003cb\u003e(participant 1, male, age45).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;Due to my inability to work and dependence on my family, I have no hope for the future. makes me feel depressed at all\u003c/em\u003e.\u0026rsquo;\u0026rsquo;\u003cb\u003e(participant 11, (M),40, stageII).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cb\u003eFear of death\u003c/b\u003e \u003c/p\u003e \u003cp\u003eThe majority of respondents seven(7) had a fear of death, hopelessness due to the severity of the disease, and side effects of the treatment. The following participant stated the same thing as;\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;\u0026rsquo;My nausea from chemotherapy makes me feel as though I will never recover. I consider passing away and leaving my kids behind, which makes me cry every day. This illustrates how the depression symptoms caused by chemotherapy worsen and lower quality of life\u003c/em\u003e \u003cb\u003e(participant\u003c/b\u003e \u003cb\u003e10, (F),70, stageIV).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;I keep thinking about dying when I'm lying in bed after chemotherapy. I am afraid of what lies ahead as I watch my body deteriorate. Everyone urges me to keep strong, yet I want to talk about this fear. It's weighty, and death is always on my mind.\u003c/em\u003e\"\u003cb\u003e(participant 2 (F),40 stage IV).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cb\u003ePsychological and care-related facilitators\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eHope\u003c/b\u003e \u003c/p\u003e \u003cp\u003eSome of the respondents had hope and trust in the chemotherapy treatment,The following participant stated the same thing as;\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026rsquo;I believe that God will cure me of this illness, and I have faith in Him to do so.\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 4 (F),40, stage III).\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;I no longer feel negatively about the illness. I am getting better, thank God.I'm hopeful that God will heal me.\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 5 (F),57, stage II)\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003ecompletelywell; therefore, I\u0026rsquo;m not concerned about today's\u003c/em\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eHealthcare provides support\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;The eighth follow-up is this one. and they reassured me when I questioned them about the illness. They gave me an injection and told me not to worry too much. and they have a great deal of compassion\u003c/em\u003e.\u003cb\u003e\u0026rsquo;\u0026rsquo;\u003c/b\u003e\u003cb\u003e((participant 3, (F),60, stageIV).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;They gave me a warm welcome when I came back for a follow-up appointment. They take the time to inform me about the state of my health, offer suggestions for prescription drugs, and counsel us on healthy eating practices.\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e((participant 10, (F),70, stage IV).\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eCounseling\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;I was terrified of the side effects of chemotherapy when I first started, including hair loss and constant nausea. the nurses' advice, which gave me courage to keep going, and that's made me stronger.\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 6 (M),45 stage III).\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;I was discomfort during my chemotherapy treatment due to side effects and other financial issues, The health providers encouraged me to keep going, and that's made me stronger.\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e((participant 3, (F),60, stage IV).\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eSocial related\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eSocial-related barriers\u003c/b\u003e \u003c/p\u003e \u003cp\u003eInterrupt Social Life\u003c/p\u003e \u003cp\u003eThe disease condition and chemotherapy impacted the participant's social life, which affects the participant's involvement in daily activities. Due to this, some of the participants, especially at the early cycles of chemotherapy, don\u0026rsquo;t want to be seen by anyone while they get chemotherapy services because they think it will affect their family and social relationships.\u003c/p\u003e \u003cp\u003eThe following participant stated the same thing as;\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;Our community has a lack of awareness about the cancer, because of how thin I was, people understood it spreads from person to person, I feel ashamed and don\u0026rsquo;t mix much with people\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e((participant 10, (F),70, stage IV).\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;I'm too weak from treatment to attend community events anymore. People's perceptions of me vary, and I feel quite isolated. This illustrates how the physical side effects and social stigma of chemotherapy cause social isolation and lower quality of life.\u0026rsquo;\u0026rsquo;\u003c/em\u003e(\u003cb\u003eparticipant 7(M),50, stage\u003c/b\u003eIII\u003cb\u003e)\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cb\u003eInterrupt family life\u003c/b\u003e \u003c/p\u003e \u003cp\u003eThe participants had participated in family activities, but they decreased their involvement once an illness issue affected their lives, which affected their family life. Furthermore, the community believes they are unable to engage in social activities. Such a condition impacts their social lives and makes living with the illness difficult. The following research participants support this:\u003c/p\u003e \u003cp\u003e\u0026lsquo;\u003cem\u003e\u0026rsquo;After being diagnosed with cancer and losing everything we had, I separated from my wife, and now I am at my parents\u0026rsquo; house. I am not living a happy life with them because I feel like a dependent on them, and I have anxiety and depression when I remember those things\u0026rsquo;\u0026rsquo;\u003c/em\u003e\u003cb\u003e(participant 1, male, age45).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u0026lsquo;\u003cem\u003e\u0026rsquo;My inability to work while undergoing treatment is causing hardship for my family. My husband is often upset. This demonstrates how family interactions are impacted by the financial disturbances caused by chemotherapy, which lowers quality of life\u003c/em\u003e\u003cb\u003e\u0026rsquo;\u0026rsquo;\u003c/b\u003e\u003cb\u003e(participant 9(F),36, stage II).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cb\u003eSocially related facilitators\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eFamily and social support\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eThe relationship between family and society had positive impact on the quality of life the cancer patients on chemotherapy.\u003c/em\u003e The following research participants support this\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;Since I was diagnosed with cancer, my family has not left my side. We have a wonderful bond, and I want to thank them. The good life I am living now would be unimaginable without them.\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 6 (M),40, stage II)\u003c/b\u003e \u003c/p\u003e \u003cp\u003e\u0026lsquo;\u0026rsquo;I usually get support from my friends and family both during and after the chemotherapy treatment, which helps me feel strong and normal.\u0026rsquo;\u0026rsquo;\u003cb\u003e(participant 1, male, age45).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cb\u003eSystemic and access-related\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eSystemic and access-related barriers\u003c/b\u003e \u003c/p\u003e \u003cp\u003eLimited access to medication and treatment\u003c/p\u003e \u003cp\u003eAll eleven(11) respondents stated that the unavailability of cancer medications in government hospitals and the high cost of private are the main challenges during chemotherapy treatment.\u003c/p\u003e \u003cp\u003eThe following research participants support this:\u003c/p\u003e \u003cp\u003e \u003cem\u003emost of the time, cancer patients\u0026rsquo; medications are not easily available in governmental hospitals. Even when they are available, their high cost adds to our worries, as lack of access to these medications concern us more than the disease itself. Radiation Is not found completely in Tigray\u003c/em\u003e. \u003cb\u003e(participant 2 (F),40 stage IV).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;I frequently have to wait weeks when the hospital runs out of chemotherapy medications. I am left with no choice except to lie in bed as my discomfort worsens. My inability to receive the medication on time makes me feel as though the illness is winning. Drug shortages have a direct influence on quality of life by delaying therapy and exacerbating physical symptoms\u0026rsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 5 (F),57, stage II)\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eLate diagnosis and treatment delays\u003c/b\u003e \u003c/p\u003e \u003cp\u003eLate diagnosis was a significant issue including to advanced disease stages and weekend physical states. Majority respondents prolonged illness before diagnosis.The following research participants support this,\u003c/p\u003e \u003cp\u003e\u0026ldquo;\u003cem\u003eWhen I was told I have cancer, it was difficult. I was shocked because it was already in a bad stage. If they had found it earlier, maybe I wouldn\u0026rsquo;t feel this weak and hopeless now.\u0026rdquo;\u003c/em\u003e \u003cb\u003e(participant 8 (M),65, stage IV)).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;Although I had swelling, I didn't think it was dangerous. Nobody instructed me to check it. When I arrived at the hospital, they informed me that it was stage four, and as a result of the treatment, I'm constantly exhausted and in agony.\u0026rsquo;\u003c/em\u003e \u003cb\u003e(participant 2 (F),40 stage IV).\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eCost of treatment\u003c/b\u003e \u003c/p\u003e \u003cp\u003eMost of the participants participated in this study stated cost of the treatment was so expensive. Some cancer drugs are not available in government hospitals. Most of the time, the treatment drugs came from private clinics, and some were also not widely available in the town. These produce psychological disturbance in the family and interrupt the treatment schedule. The following participant stated the same thing as;\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;The cost of the chemotherapy and other laboratory investigations is expensive; it is not the illness the poor can afford. Until now, people they helped me because I am poor\u0026rsquo;\u0026rsquo;\u003c/em\u003e (\u003cb\u003eparticipant 7(M),50, stage\u003c/b\u003eIII\u003cb\u003e).\u003c/b\u003e\u003c/p\u003e \u003cp\u003eThis was supported by the following quote taken from an in-depth interview:\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026rsquo;\u0026rsquo;I was first unable to pay for the costly chemotherapy medications. By the time I received the medications, my condition had gotten worse, and I was too weak to even walk, so I had to borrow money. This demonstrates how financial limitations impair quality of life during treatment by delaying access to medication\u003c/em\u003e. \u003cb\u003e\u0026lsquo;\u0026rsquo;(participant 6 (M),40,stage II).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cb\u003eCost of Transport\u003c/b\u003e \u003c/p\u003e \u003cp\u003eThe majority of nine (9) participants reported that the cost of the transport from the home to the treatment center was too expensive. The majority of the participants said \u003cem\u003e\u0026lsquo;\u0026rsquo;Due to the absence of fuel, we paid double the normal tariff of transportation and it is difficult to follow our treatment, mostly every three weeks\u0026rsquo;\u003c/em\u003e.\u003c/p\u003e \u003cp\u003eThe following participant expressed.\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;I come from tselemti wereda and it is far away from the treatment center, Aksum and the Transport costs are very expensive due to fuel shortage\u0026rdquo;\u003c/em\u003e (\u003cb\u003eParticipant 4, (F),35, stage III).\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cem\u003eI have to travel far for chemotherapy, and the cost of transportation is difficult due to the shortage of fuel. My discomfort worsens when I neglect my treatment due to the cost of transportation\u003c/em\u003e \u003cb\u003e(participant 11, (M),40, stage II).\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eSystemic and access-related facilitators\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eDistance to the hospital\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eSome of the respondents said their home is close to the hospital and benefits from different directions.\u003c/em\u003e The following research participants support this;\u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;My home is nearest to the hospital, and I don\u0026rsquo;t feel tired after chemotherapy, I can rest at home sooner \u0026lsquo;\u0026rsquo;\u003c/em\u003e \u003cb\u003e\u0026rsquo;(participant 6 (M),40,stage II).\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003e\u0026lsquo;\u0026rsquo;The transport is cheap from the town to the treatment center. so I don\u0026rsquo;t stress about the expenses of transport, also going to the hospital without care caregiver\u003c/em\u003e.\u003cb\u003e\u0026rsquo;\u0026rsquo;\u003c/b\u003e\u003cb\u003e(participant 7(M),50, stage\u003c/b\u003eII)\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis explanatory sequential mixed-method study aimed to assess quality of life, associated factors, and explore perceived barriers among cancer patients receiving chemotherapy at Tigray,Ethiopia, 2024/25.\u003c/p\u003e \u003cp\u003eThis study showed that the poor quality of life among cancer patients receiving chemotherapy was \u003cb\u003e74.9%\u003c/b\u003e with 95% CI(\u003cb\u003e70.99–78.8).\u003c/b\u003eThe finding of this study is higher than the results of the studies conducted in Amhara regional state on breast cancer, DessieComprehensive SpecializedHospital,Tikur AnbesaComprehensive SpecializedHospital,Amhara regional state 68.4,64.3,57.28,55.68[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e].The possible explanation might be due to the tool used to measure the quality of life,and the current situation of Tigray, conflict and the related issues(war crisis),may be due to my study including various cancer types, which could encompass more advanced stages or cancers with greater symptom burdens[\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eFactors associated among cancer patients receiving chemotherapy treatment were: college and above educational status,stage four cancer,five or abovechemotherapy cycles,underweight, and anxiety.Statistically significant at p-value less than \u003cb\u003e0.05.\u003c/b\u003e\u003c/p\u003e \u003cp\u003eThis study showed that cancer patients with college and above were 64%{AOR = 0.36,95%CI(0.16–0.83)}less likely to have poor QOL as compared with those who had unable to read and write.This was similar to a cross-sectional study conducted cross sectional study in the Amhara regional state, Tikur Anbesacomprehensive specialized hospital,Ethiopia,in Gaza,Palestine, and in Nairobi,Kenya[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan additionalcitationids=\"CR17\" citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e–\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]Thiscould be due to lower education levels correlating with poorer self-reported health[\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e].\u003cem\u003eThis is supported by qualitative data showing thatthe quality of life for cancer patients receiving chemotherapy is greatly impacted by a lack of understanding and Inadequate patient education.\u003c/em\u003e\u003c/p\u003e \u003cp\u003eThe odds of beingunderweightwere3 times (AOR = 3, 95% CI (1.28–7.47)} more likely to have poor quality of life than those who wereoverweight.This finding was supported bycross-sectionalstudies conducted in Amhara National Regional State,Ethiopia,Brazil, and Malawi [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e].This could be due to malnutrition is linked to a decline in functional ability, an increase in the number and duration of hospital admissions, the experienceof worse symptoms, anxiety, and depression; all of which can lead to poor QOL[\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e].\u003cem\u003eThis is supported by qualitative data showing that Loss of appetite,nausea, and vomiting lead to weight loss were the most frequently reported impairments affecting the quality of life by the interviewee participants.\u003c/em\u003e\u003c/p\u003e \u003cp\u003eThe odds of having anxiety were about 2.7times {AOR = 2.7, 95% CI (1.29–5.7)}more likely to have poor quality of life than those who had no anxiety.This was supported by studies conducted in selected comprehensive and specialized hospitals in the Amhara region, Ethiopia,Jordan, and Malawi.[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e].This may be due to adverse drug reactions, prognostic uncertainty, the utilization of mostly disease-centered treatment modalities, and the significant compromise of patients' mental well-being[\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e].\u003cem\u003eThe qualitative findings support this; the majority of the participants experienced a wide range of psychological impacts as a result of the disease condition and the chemotherapy. They reported that negative feelings, fear, anxiety, and depression were the most common psychological and emotional problems of cancer patients receiving chemotherapy as a result affected the quality of life..\u003c/em\u003e\u003c/p\u003e \u003cp\u003eThisstudy also showed that cancer patients with five and above chemotherapy cycle were 57% {AOR = 0.43,95%CI(0.19–0.95)} less likely to have poor QoL as compared with those who hada second chemotherapy cycle.This was similar study conducted a cross sectional study in the Amhara region, Tikur AnbesaComprehensive SpecializedHospital, Ethiopia,Egypt,Iran[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e].This could be due to This might be because chemotherapy frequently causes acute side effects that worsen patients' quality of life after they occur, usually at the end of the first cycle. Later, when their health improves and their symptoms lessen, their quality of life improves[\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e] \u003cb\u003e.\u003c/b\u003e\u003cem\u003eThis qualitative study also strengthened this which stated that;majority of the respondents subside from the side effects of chemothrapy on the late cycle of chemothrapy and gave thanks for chemothrapy treatment\u003c/em\u003e.\u003cem\u003eThis implies that finishing more cycles—including late ones—is linked to improved quality of life, either as a result of adaptation or successful treatment results.\u003c/em\u003e\u003c/p\u003e \u003cp\u003eThe odds of having stage four cancer patients had about 2.5 times {\u003cb\u003eAOR = 2.5, 95% CI (1.06,-\u003c/b\u003e6.38)} more likely to have poor quality of life than those who had stage one cancer patients.This was similar to a cross-sectional study conducted cross sectional study in the Amhara region, Tikur Anbesacomprehensive specialized hospitals,Ethiopia,Dessie comprehensive specialized hospitals, Ethiopia. Kenya[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e].This could be due toas the illness worsens, patients will have more excruciating symptoms, physical functioning impairment, and increased stress, anxiety, and depression, all of which are likely to have an impact on their quality of life[\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e].The qualitative findings support this:the \u003cem\u003emajority of cancer patients,stage 4 patients, frequently report severe physical symptoms such as pain, fatigue, nausea, and loss of appetite,fear of death.The qualitativeinterviews reveal these symptoms significantly disrupt daily activities, emotional well-being, and social interactions, unlike stage 1 patients who often experience milder symptoms and less aggressive treatments.\u003c/em\u003e\u003c/p\u003e \u003cp\u003eLimitation of the study\u003c/p\u003e \u003cp\u003eThe study was performed only once, and QOL may differ during different cycles of chemotherapy\u003c/p\u003e \u003cp\u003eThere was no comprehensive nutritional assessment because BMI is only used to determine nutritional status and has its limitations.\u003c/p\u003e \u003cp\u003eSome drug-related variables (e.g., chemotherapy medication) were not assessed well in my study\u003c/p\u003e \u003cp\u003eThe study was performed only once, and QOL may differ during different cycles of chemotherapy.\u003c/p\u003e \u003cp\u003eThe information was gathered using a face-to-face interviewing method. Because of this, the respondents may respond in favor of those who are either overreporting or underreporting due to the severity of their condition.\u003c/p\u003e \u003cp\u003e \u003cb\u003eConclusion and Recommendation\u003c/b\u003e \u003c/p\u003e \u003cp\u003eAccording to this study overall quality of life cancer patients receiving chemotherapy at tigray Comprehensive SpecializedHospitals three-fourth of the patients was poor quality of life..college and above educational status,underweight,stage four of cancer,five and above cycle of chemotherapy and patients with anxiety was significant factors associated with the poor quality of life.\u003c/p\u003e \u003cp\u003eMobility and self-care limitations,side effects of the chemotherapy,anxiety, and fear of treatment.depression symptoms,interrupt social life,interrupt family life,expensive cost of the chemotherapy and transportation,late diagnosis and treatment delays,limited access to medication and treatment,were barriersaffectingthe quality of life of patients on chemotherapy.\u003c/p\u003e \u003cp\u003eBased on the findings of this study, the following recommendations are forwarded:\u003c/p\u003e \u003cp\u003eHealth care providers should focus on addressing the side effects of therapy and on palliative care to improve quality of life.\u003c/p\u003e \u003cp\u003ePromote healthcare and educational services, outreach initiatives, and mobile clinics to help cancer patients live better lives\u003c/p\u003e \u003cp\u003eThe administrators of hospitals and Tigray regional health bureaus advocate to nongovernmental organizations to cover the cost of treatment and other laboratory investigations.\u003c/p\u003e \u003cp\u003eCancer patients should be supported and encouraged to participate in economic activities and capacity development initiatives, either individually or in groups. Health advocates should also insist on financial assistance for cancer patients undergoing chemotherapy.\u003c/p\u003e \u003cp\u003eA longitudinal study for future researchers to assess the quality of life of cancer patients receiving chemotherapy.\u003c/p\u003e \u003cp\u003eHealth care providers should focus on counseling services to minimize emotional challenges like anxiety and depression.\u003c/p\u003e \u003cp\u003eThe administrators of hospitals and Tigray regional health bureaus advocate to nongovernmental organizations to cover the cost of treatment and other laboratory investigations.\u003c/p\u003e "},{"header":"ABREVIATIONS","content":"\u003cdiv class=\"gridtable\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003ctable float=\"No\" id=\"Tabd\" border=\"1\"\u003e\u003ccolgroup cols=\"2\"\u003e\u003c/colgroup\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eACSH\u003c/p\u003e \u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAyder Comprehensive Specialized Hospital\u003c/p\u003e \u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAKUCSH\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAksum Comprehensive Specialized Hospital\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAOR\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAdjusted Odd Ratio\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBMI\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBody Mass Index\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBSc\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBachelor of Science\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCA\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCancer\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCI\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eConfidence Interval\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCOR\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCrude Odd Ratio\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCSH\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eComprehensive specialized hospital\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDC\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eData Collector\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEORTC QLQ C30\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eEuropean Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHADS\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHospital Anxiety DepressionScale\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHRQOL\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHealth Related Quality of Life\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMSc\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMaster Of Science\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePI\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePrincipal Investigator\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eQOL\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eQuality of Life\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSPSS\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eStatistical Package for Social Science Software\u003c/p\u003e \u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/table\u003e\u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e \u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e \u003cp\u003e An official IRC letter (082/2024) has been obtained from the ethical review board of Aksum University College of Health Sciences. The letter was handed over to the comprehensive specialty hospitals of Aksum and Ayder universities. in accordance with the ethical principles of the Declaration of Helsinki (1964) and its later amendments, as well as the National Research Ethics Review Guidelines of Ethiopia. After informing them, the respondents gave their verbal agreement. Every respondent's freedom to decline or discontinue participation in the interview was fully respected, and all information submitted was kept private by encoding each questionnaire and not disclosing any patient's personal information to outside parties..\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eConsent for publication\u003c/strong\u003e \u003cp\u003eNot applicable\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eCompeting interest\u003c/strong\u003e \u003cp\u003eThe authors declare no competing interest.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eHailseslasie Hailemariam designed this study, and all authors participated in the analysis. This manuscript is written by Hailseslasie Hailemariam, and the authors read and approved the manuscript.\u003c/p\u003e\u003ch2\u003eACKNOWLEDGMENT\u003c/h2\u003e \u003cp\u003eFirst of all, I would like to thank my advisors, Tekleweyni Mariye and Abrha Hailay, for guiding and supervising my thesis. Also, I would like to thank to study participants and data collectors who helped me to collect my data.Finally, I would like to thank Aksum University, which gave me this opportunity to attend my MSc program.\u003c/p\u003e\u003ch2\u003eData Availability\u003c/h2\u003e\u003cp\u003eAll data supporting this finding are presented in the manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eFerlay J, et al. Global cancer observatory: cancer today. Lyon: International agency for research on cancer; 2020. p. 20182020.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIslami F et al. \u003cem\u003eAmerican Cancer Society's report on the status of cancer disparities in the United States, 2021.\u003c/em\u003e CA: a cancer journal for clinicians, 2022. 72(2): pp. 112\u0026ndash;43.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTadele N. Evaluation of quality of life of adult cancer patients attending Tikur Anbessa specialized referral hospital, Addis Ababa Ethiopia. Ethiop J health Sci. 2015;25(1):53\u0026ndash;62.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLewandowska A, et al. Quality of life of cancer patients treated with chemotherapy. Int J Environ Res Public Health. 2020;17(19):6938.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGebregziabher M, et al. Geographical distribution of the health crisis of war in the Tigray region of Ethiopia. BMJ global health. 2022;7(4):e008475.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTuem KB, et al. Adequacy of Cancer-Related Pain Treatments and Factors Affecting Proper Management in Ayder Comprehensive Specialized Hospital, Mekelle, Ethiopia. J Oncol. 2020;2020(1):2903542.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAbegaz TM, Ayele AA, Gebresillassie BM. Health Relat Qual life cancer patients Ethiopia J Oncol. 2018;2018(1):1467595.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMuhamed AN, Bogale SK, Netere HB. \u003cem\u003eQuality of life and associated factors among adult cancer patients undergoing chemotherapy treatment at Amhara National, Regional State, Ethiopia\u003c/em\u003e, 2021. SAGE Open Nursing, 2023. 9: p. 23779608231174866.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBayked EM, et al. Quality of life and associated factors among patients with cancer receiving chemotherapy at Dessie Comprehensive Specialized Hospital, North-East Ethiopia: a cross-sectional study. Front Oncol. 2024;13:1288166.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFayers P et al. \u003cem\u003eThe EORTC QLQ-C30 scoring manual, Brussels, Belgium: European Organization for Research and Treatment of Cancer 2001\u003c/em\u003e. 2021.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHassen AM, et al. Quality of life and associated factors among patients with breast cancer under chemotherapy at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. PLoS ONE. 2019;14(9):e0222629.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAraya LT, et al. Health-related quality of life and associated factors among cervical cancer patients at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. Volume 18. Health and quality of life outcomes; 2020. pp. 1\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRhee CK et al. \u003cem\u003eCOMPARISON OF WORLD HEALTH ORGANIZATION AND ASIA-PACIFIC BODY MASS INDEX CLASSIFICATIONS IN COPD PATIENT.\u003c/em\u003e Respirology, 2017. 22: pp. 4\u0026ndash;4.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlem T, et al. Quality of life of breast cancer patients in Amhara region, Ethiopia: A cross-sectional study. PLoS ONE. 2024;19(6):e0305263.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTeka H, et al. The impact of armed conflict on maternal morbidity and mortality at a teaching hospital in the Tigray region of Ethiopia: a pre-war and wartime comparative analysis. BMC Pregnancy Childbirth. 2025;25(1):1\u0026ndash;12.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAbraha A. \u003cem\u003eAssessment of Breast Cancer Patients\u0026rsquo; Quality of Life under Chemotherapy treatment at Tikur Anbessa Specialized Hospital, in Addis Ababa, Ethiopia\u003c/em\u003e, 2018. 2018.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eElMokhallalati Y, et al. The symptom burden and quality of life in cancer patients in the Gaza strip, Palestine: a cross-sectional study. PLoS ONE. 2022;17(1):e0262512.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKung\u0026rsquo;u M, Onsongo L, Ogutu JO. Factors influencing quality of life among cancer survivors in Kenya. Afr Health Sci. 2022;22(4):87\u0026ndash;95.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOECD. An OECD learning framework 2030. Springer; 2019.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoreira DP, et al. Quality of life of patients with cancer undergoing chemotherapy in hospitals in Belo Horizonte, Minas Gerais State, Brazil: does individual characteristics matter? Volume 37. Cadernos de Sa\u0026uacute;de P\u0026uacute;blica; 2021. p. e00002220. 8.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBanda JC, et al. Quality of life among cancer patients at Queen Elizabeth and Kamuzu Central Hospitals in Malawi: a cross-sectional double-center study. Afr Health Sci. 2022;22(3):222\u0026ndash;32.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMaia FdCP, et al. Malnutrition is associated with poor health-related quality of life in surgical patients with gastrointestinal cancer. Nutrition. 2020;75:110769.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMosleh SM. Health-related quality of life and associated factors in Jordanian cancer patients: A cross‐sectional study. Eur J Cancer Care. 2018;27(5):e12866.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAmrein AC. Exploring the integration of evidence-based medicine, quality of life considerations and health economics for rare diseases. University of Southern Queensland; 2020.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBayumi H, Mohamed HS. Factors affecting quality of life among cancer patients with chemotherapy at Qena university hospital in upper Egypt. IOSR J Nurs Health Sci. 2016;5:168\u0026ndash;73.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHeydarnejad MS, Hassanpour DA, Solati DK. Factors affecting quality of life in cancer patients undergoing chemotherapy. Afr Health Sci, 2011. 11(2).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAkhtari-Zavare M, et al. Determinants of quality of life among Malaysian cancer patients: a cross-sectional study. Health Qual Life Outcomes. 2018;16:1\u0026ndash;17.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRamasubbu R, et al. Long versus short pulse width subcallosal cingulate stimulation for treatment-resistant depression: a randomised, double-blind, crossover trial. Lancet Psychiatry. 2020;7(1):29\u0026ndash;40.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Cancer, Chemotherapy, quality of life, Tigray, Ethiopia","lastPublishedDoi":"10.21203/rs.3.rs-8010679/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8010679/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eCancer is the main cause of morbidity and mortality in every part of the world, regardless of human development. Globally, there were 10.0\u0026nbsp;million recorded deaths and 19.3\u0026nbsp;million new cases of cancer in 2020.\u003c/p\u003e\u003ch2\u003eObjectives\u003c/h2\u003e \u003cp\u003eThis study aimed to assess quality of life and associated factors among cancer patients receiving chemotherapy at the comprehensive specialized hospitals of Tigray, Ethiopia, 2024/25.\u003c/p\u003e\u003ch2\u003eMethod and Materials:\u003c/h2\u003e \u003cp\u003eA hospital-based mixed study design was conducted from December-January 2024 GC for quantitative and from 1 April to 21 April for qualitative data on patients (492) at comprehensive specialized hospitals Tigray region, Ethiopia. A systematic sampling method was used to select study participants for the quantitative part, and a purposive sample method was used for the qualitative. For the Quantitative data, EpiData version 4.6 was used for entry, and Statistical Package for the Social Sciences version 27 was used for analysis.Bivariate and multivariable logistic regression analysis was done, and variables having a p-value of \u0026lt;\u0026thinsp;0.25 were considered candidates for multivariable logistic regression. P-value of \u0026lt;\u0026thinsp;0.05 was used as the criterion for statistical significance, and the qualitative data were analyzed by thematic analysis using the software Archive of Technology Life world and Language Text Interpretation (ATLAS.TI) version 7.5.8 software.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eFrom 478 patients included in this study, 74.9%,95% CI (70.8\u0026ndash;79.9%) of cancer patients on chemotherapy had poor quality of life, College and above [AOR\u0026thinsp;=\u0026thinsp;0.36,95%CI (0.16\u0026ndash;0.83)] underweight(AOR\u0026thinsp;=\u0026thinsp;3, 95% CI (1.28\u0026ndash;7.47),anxiety[AOR\u0026thinsp;=\u0026thinsp;2.7, 95% CI (1.29\u0026ndash;5.7)],five and above chemotherapy cycle were 57% [AOR\u0026thinsp;=\u0026thinsp;0.43,95%CI(0.19\u0026ndash;0.95)] and stage 4 cancer (AOR\u0026thinsp;=\u0026thinsp;2.5, 95% CI (1.06,-6.38) were significantly associated with quality of life.\u003c/p\u003e\u003ch2\u003eConclusion and recommendation:\u003c/h2\u003e \u003cp\u003eThree-fourths of the patients with cancer had a poor quality of life. Healthcare providers should also focus on addressing the side effects of therapy and providing palliative care to improve quality of life.\u003c/p\u003e","manuscriptTitle":"Quality of Life and Associated Factors Among Adult Cancer Patients Receiving Chemotherapy at Tigray, Ethiopia 2024/25: A Mixed Study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-01-16 06:29:50","doi":"10.21203/rs.3.rs-8010679/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"88c69dfe-c32e-44e7-acb0-97e7fd32ea8a","owner":[],"postedDate":"January 16th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2026-04-16T10:27:06+00:00","versionOfRecord":[],"versionCreatedAt":"2026-01-16 06:29:50","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8010679","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8010679","identity":"rs-8010679","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}